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ABSTRACT 
THE ROLE OF RUNX1 N-TERMINAL SPLICE ISOFORMS IN 
HEMATOPOIETIC DEVELOPMENT 
 
FEBRUARY 2010 
 
EMMETT E. HEDBLOM, B.S., UNIVERSITY OF VERMONT 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Janice C. Telfer 
 
 Runx1/AML1 transcription factor expression in hematopoietic cell lineages is 
differentially regulated via usage of two distinct promoters. The 5' UTR and a 19 amino 
acid encoding sequence transcribed from the distal promoter is inserted via alternative 
splicing into the 5' end of the mRNA transcript, replacing the 5' UTR and a 5 amino acid 
encoding sequence usually transcribed from the proximal promoter. Expression of 
proximal Runx1 in 32Dcl.3 cells delays G-CSF induced neutrophil terminal 
differentiation by increasing viability compared to distal Runx1. We utilized Runx1 N-
terminal deletion and point mutants of three evolutionarily conserved residues to describe 
dual N-terminal isoform motifs that promote two distinct differentiation phenotypes as 
regulatory elements in hematopoietic cell differentiation.  Runx1 isoforms were evaluated 
in established hematopoietic in vitro and ex vivo differentiation systems. Deletion of 
vii 
amino acids 3’-14’ (Δ3-14) or 3’-19’ (Δ3-19) of the distal Runx1 N-terminus delayed 
terminal differentiation of the 32Dcl.3 myeloid cell line, indicating a regulatory motif in 
distal Runx1 abrogates the delay of terminal differentiation induced by proximal Runx1. 
Deletion of amino acids 3’-8’ (Δ3-8) or mutation of amino acids serine 3’, serine 5’ and 
phenylalanine 7’ of the distal Runx1 N-terminus reduce Runx1 expression in the 32Dcl.3 
cell line.  The N-terminus motif, runt domain and nuclear matrix-targeting sequence of 
Runx1 modulated Ets1 activity on the KIR3DL1 bidirectional promoter element.  The 
transcription factor YY1 promotes both forward and reverse activation of the KIR3DL1 
bidirectional promoter element dominantly in the presence of Runx1, and additively with 
Ets1.  Distinct Runx1 proximal and distal N-termini induced phenotypes were observed 
in myeloid and thymocyte differentiation, but not with the KIR3DL1 luciferase assay 
system. This work identifies a previously unknown N-terminal regulatory motif that acts 
with spatio-temporal and gene target specificity to add another level of control over 
Runx1 activity during hematopoiesis. 
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CHAPTER 1 
INTRODUCTION 
Runx Discovery and Characterization 
 
 The Runx family of transcription factors is named after the Drosophila mutant in 
whom the runt domain was first described (1).  The runt domain is a highly conserved 
128 amino acid region common to all known runt homologs (2).  The runt gene was first 
identified as causing a defect in the development, patterning and segmentation of the 
Drosophila embryo.  Products of Runx genes were localized to the nucleus and later 
experiments in mammalian cells confirmed Runx genes encode transcription factors (3).  
 The first mammalian Runx family member was cloned from the chromosomal 
translocation t(8;21) found in 18% of patients diagnosed with acute myelogenous 
leukemia subtype M-2 (AML-M2), and was thus named AML1 (4).  This chromosomal 
translocation results in the fusion of the transcriptional repressor ETO and a truncated 
Runx1 containing the N-terminus, DNA-binding runt domain and nuclear localization 
sequence (NLS), and has been shown to have a high correspondence with the 
development of acute myeloid leukemia.  Thus, in humans, Runx genes are referred to as 
AML (4).  Later experiments identified two more human genes containing the 
characteristic runt domain, which were identified as AML2 and AML3 (5).  The Runx 
family of genes in mice was originally referred to as core-binding factors (CBFα1, 
CBFα2, CBFα3) or polyoma enhancer binding proteins (PEBP2αA, PEBP2αB, and 
PEBP2αC) based on their binding of viral regulatory sequences (3, 6).  The three mouse 
genes were later renamed Runx1, Runx2, and Runx3, corresponding to the human 
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AML1, AML3, and AML2 genes, respectively.  Mouse knockout studies were performed 
for each of the Runx family members; Runx1 (AML1) (7), Runx2 (AML3) (8), and 
Runx3 (AML2) (9). The names of all Runx genes were codified in 1999 by the Human 
Genome Organization (HUGO) and will be used throughout this dissertation (10). 
 
Runx Promoter Structure and Transcriptional Regulation 
 
 The Runx family members, Runx1, Runx2, and Runx3, are regulated from two 
promoters designated either P1 and P2, or distal and proximal, based on their distance 
upstream of the respective genes (11-13).  Splicing of the alternatively transcribed 
mRNA transcripts results in two different 5’ end sequences (Figure 1) (14).  Initiation 
from the proximal promoter results in a transcript with a long 5’ untranslated region 
(UTR) and a short 15 base pair coding sequence that is translated into the N-terminal five 
amino acid sequence.  Initiation from the distal promoter results in a short 5’ untranslated 
region in the transcript and a unique 57 base pair sequence that is spliced to replace the 
proximal promoter initiated 5’ coding sequence (Figure 1).  Translation of the spliced 
distal promoter initiated transcript results in a nineteen amino acid N-terminus. 
 There is evidence that the transcription of mammalian Runx genes can be 
controlled by promoter usage (15-17).  The two Runx promoters have distinct features 
that play important roles in their expression patterns.  The proximal promoter is situated 
within a large evolutionarily conserved CpG island that may contribute to silencing or 
tissue specific expression according to the methylation status of the chromatin (18).  The 
long proximal 5’ UTR contains an internal ribosome entry site (IRES) and mediates 
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relatively inefficient cap-independent translation, while the short distal 5’ UTR is 
regulated by cap-dependent translation (15).  
 The six promoters regulating the expression of the three Runx family members all 
contain multiple Runx binding sites, indicating a role for self-regulation of expression 
(19).  Occupation of one of the three Runx binding sites in the distal promoter region of 
Runx2 is sufficient for transcriptional auto-suppression (20).  Runx3 was identified in a 
microarray study as a target for the Epstein-Barr virus (EBV) EBNA-2 in human B-cell 
lymphoma cell lines that normally expressed Runx1. Induction of Runx3 expression was 
correlated with a concomitant decrease in Runx1 expression (21).  Direct evidence of 
Runx family cross-regulation was demonstrated by Runx1 repression in B-cell lymphoma 
lines, mediated by Runx3 binding to the distal Runx1 promoter (22) in association with a 
TLE co-repressor (23).  However, due to the high sequence homology of the runt 
homology domain (RHD), it is unclear how promiscuous the Runt family members are in 
regulating themselves and other family members.  The study of Runx2 expression during 
bone formation has given insight into some of the factors involved in Runx gene 
expression.  The NF1-A protein isoform binds to a Runx2 enhancer region to repress 
transcription in non-bone lineage cells.  The FosB transcription factor is able to bind the 
Runx2 enhancer and activate expression at specific stages of bone lineage development 
(24).  Retinoic acid (Vitamin A) is a drug used in classical experiments for induction of 
myeloid differentiation and has been shown to increase expression of Runx1 in vitro (25).  
The spatio-temporal regulation of Runx family member expression is a complex interplay 
of many factors and promoters that have not been exhaustively defined. 
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 Temporal regulation of Runx1 expression is essential for hematopoietic 
development.  The timing of Runx expression in thymic development has been 
demonstrated by disruption of the proximal promoter with a neomycin gene that created a 
hypomorphic allele, which had significantly attenuated proximal promoter activity.  
Attenuation of proximal promoter activity impairs the development of early embryonic 
hematopoiesis and abrogates thymic development.  A switch to the distal promoter 
immediately prior to birth limits this impairment, though this switch is insufficient to 
provide viable offspring (16).  The dual promoter structure of the Runx genes promotes 
cell-type specific temporal expression of two N-terminal isoforms throughout 
hematopoiesis, in that specific cell types have been shown to express different ratios of 
distal versus proximal Runx1 isoforms (14, 17).  These studies imply that the two N-
terminal isoforms provide independent functions during hematopoiesis, and that 
switching promoter usage is an essential component of the regulation of Runx spatio-
temporal expression (Figure 2). 
 
Protein Structure and Domains 
 
 Humans and mice both have three members of the Runx family that share several 
highly conserved domains, (Table 1, Figure 3).  Runx proteins bind DNA as a 
heterodimer with CBFβ, a co-factor that increases DNA binding affinity (26).  The runt 
domain simultaneously binds a consensus PyGPyGGTPy DNA sequence as well as 
modulating the interaction with CBFβ (27).  The C-terminus of Runx is a region of 
recruitment for co-factors that are required for the function of Runx as a transcriptional 
5 
activator or repressor.  The nuclear matrix-targeting site (NMTS) is required for the 
transport to and localization within the nucleus.  Lack of the NMTS in Runx1, as 
evidenced by natural C-terminal splice isoforms and some chromosomal translocations, 
results in a block to myeloid differentiation (28).  Point mutations of arginine 398 and 
tyrosine 428, located within the NMTS of Runx2, impair sub-nuclear targeting and 
activity of Runx2 in breast cancer cells (29).  Runx proteins can act as both activators and 
suppressors of transcription for target genes in a manner that is often spatially and 
temporally regulated.  The C-terminal amino acid residues of Runx proteins are VWRPY, 
a known binding motif for the transcriptional co-repressor Groucho/TLE (30, 31).  The 
co-repressor mSin3A associates with Runx1 independently of the TLE binding motif to 
repress Runx1 target genes (32).  Runx2 is required for bone growth and development as 
a target of TGFβ and BMP-smad pathways for the induction of bone specific genes. (33).  
The transcription factors Ets, Myb, C/EBP and co-activators p300, ALY, and YAP 
interact with Runx1 to induce genes essential for differentiation programs in lymphoid 
and myeloid cell types (34-39).  In developmental pathways, Runx proteins act as the 
nucleating center of a transcription complex that recruits different sets of co-factors in a 
context dependent manner to several unique binding sites. 
 The transcriptional activity of Runx1 is regulated by intramolecular interactions 
between the N-terminus and the C-terminus.  The C-terminal region directly adjacent to 
the Runt domain contains an auto-inhibition domain, also known as the negative 
regulatory region of DNA binding (NRDB), which negatively regulates DNA binding of 
Runx1 alone (40).  Physical interaction with CBFβ or the transcriptional co-factor Ets-1 
releases the Runx1 auto-inhibition and enhances Runx1 DNA binding affinity (41).  The 
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release of auto-inhibition via binding Ets-1 is reciprocal as the interaction of the auto-
inhibitory domains stabilizes both molecules in the open conformation required for DNA 
binding (42, 43).  Intermolecular interaction of the N-terminus of Runx1 from amino 
acids 1-41 with the NRDB is necessary for maintaining the auto-inhibition of Runx1, 
though there is some weak DNA binding ability of Runx1 alone, suggesting an 
equilibrium state between the open and closed conformations.  Ets1 interactions with the 
Runx1 N-terminus and the C-terminal NRDB are sufficient for DNA binding, and the 
addition of CBFβ greatly increases the DNA binding affinity (41, 43). 
 There are two distinct N-terminal motifs of Runx1 resulting from alternative 
splicing of transcripts from a proximal or distal promoter.  Previous work suggests a role 
for distal Runx1 in differentiation and proximal Runx1 in proliferation during the 
myeloid differentiation pathway (14).  Distal Runx1 protein has a higher DNA-binding 
affinity than proximal Runx1 protein; however, proximal, but not distal, Runx1 promotes 
proliferation and delays terminal differentiation during the differentiation of a myeloid 
cell line (14). Crystal structures for the Runx1 and Runx family DNA binding runt 
domain have been solved (44), but the N-terminus in these structures has not due to their 
mobile nature in solution.  The five proximal N-terminal residues, excluding the initiating 
methionine, are the hydrophobic residues valine and isoleucine, proline (frequently found 
in turns), and the polar hydrophilic arginine.  In sum, the proximal Runx1 N-terminus 
appears ideally suited for tucking into the main mass of the Runx1 protein and does not 
contain any obvious sites of structural significance such as sites of phosphorylation.  The 
region encompassing amino acids 3’-8’ of the distal N-terminus contains aspartic acid 
and glutamic acid residues whose polar character play important roles in ionic bonding 
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and solubility in aqueous solutions.  In addition, serine residues at positions 3’ and 5’ as 
well as phenylalanine at position 7’ are 100% conserved across species from human, 
mouse, chicken, skate, frog, zebra fish, cow, bony fish, and cartilaginous fish.  A second 
region between amino acids 9’-14’ is generally polar and contains another phenylalanine 
residue as well as two serine residues and a tyrosine residue important for 
phosphorylation sites in proteins.  Finally, the third region of the N-terminus between 
amino acids 15’-19’ is generally hydrophobic and contains one cysteine residue with the 
potential for creating disulfide linkages.  Current data suggests the structure of the 
alternative Runx N-termini are able to regulate differential function of Runx proteins as a 
target site for modification affecting Runx DNA binding or recruitment of co-factors. 
 
Post-Translation Regulation of Runx 
 
 Runx proteins are regulated by phosphorylation, acetylation, and ubiquitination.  
It is widely thought that the chromosomal translocations involved in acute myelogenous 
leukemias prevent the proper regulation of Runx activity (45).  Putative PKA mediated 
phosphorylation of serine/threonine residues in the N-terminus has been identified as 
possible regulators of Runx activity (45, 46).  Pim-1, a serine/threonine kinase member of 
the calcium/calmodulin regulated kinase (CAMK) family involved in cytokine-dependent 
signaling, has been shown to specifically interact with Runx via yeast 2-hybrid and co-
immunoprecipitation assays.  Pim-1 phosphorylates Runx1 C-terminal residues and 
increases Runx1 transactivation of a β-galactosidase reporter in a Pim-1 dose dependent 
fashion, though whether Pim-1 interacts with the N-terminus was not evaluated (47).  The 
8 
unique 19 amino acids of the Runx1 distal N-terminus do not contain any known kinase 
targeted motifs as determined by predictive algorithms, despite the high degree of 
evolutionary conservation of potentially targeted serine residues.  Acetylation of two N-
terminal lysine residues by the acetyltransferase p300 in vitro enhances the ability of 
Runx1 to bind DNA and increase transcription of target genes during myeloid 
differentiation (48).  Acetylation by p300 of Runx family members protects from 
ubiquitination and degradation of the protein (49).  The N-terminus of Runx1 proteins 
contains serine, threonine, and lysine residues that have been identified as targets for 
post-translational modification, though the global function of the N-terminal motif in the 
regulation of activity is still unclear. 
 
Runx and Cell Cycle 
 
 Hematopoiesis and development require tight regulation of the cell cycle 
throughout the program of differentiation.  The characteristics of each cell lineage are in 
part determined by their cell cycle status; stem cells cycle slowly or are dormant in order 
to maintain the property of self-renewal, progenitor cells cycle quickly during expansion 
of specific lineages, and mature, terminally differentiated cells cease cycling altogether 
(50).  In particular, the G1-S transition is of great importance to hematopoiesis as this is 
the checkpoint that controls the transcription machinery for chromosome replication, 
which is required for proliferation during a program of differentiation.  Cyclin proteins, 
cyclin-dependent kinases (Cdks), and Cdk inhibitors tightly regulate the cell cycle via 
control of the cellular transcriptional machinery (51).  Cyclin B, cdk2, and p21 are some 
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of the factors that increase in expression, allowing entry into S phase and promoting 
active cycling (52).  Cyclin D3 and Cdk2 are involved in lineage specific cell cycle 
increases, in particular with megakaryocytes (53).  Cyclin D proteins complex with Cdk4 
and Cdk6 to promote phosphorylation of retinoblastoma (Rb).  The phosphorylation of 
Rb in turn frees the E2F family of proteins to activate the transcription of genes necessary 
for entry into S-phase (51).  
 Runx1 modulates the G1-S transition in order to regulate the proliferation and 
differentiation status of hematopoietic cells. The AML1-ETO chromosomal translocation 
oncoprotein, which does not have the C-terminal domains following the Runt domain, is 
found in many cases of acute myelogenous leukemia and has been shown to slow the 
progression of the cell cycle (54, 55).  This is consistent with over expression studies of 
Runx1 that show increased progression through G1-S (56).  Deletion of Runx1 in adult 
HSCs decreased the production of lymphoid cells, inhibited platelet formation, and 
increased the proliferation of myeloid cell lineages (57, 58). 
 The effects of cell cycle regulatory Cyclins and Cdks have been classified based 
on their functions during hematopoiesis.  Runx1 actively represses the Cdk inhibitor 
p21waf1/cip1 in association with mSin3A, which permits entry into S-phase and active 
cycling (32).  In differentiating myeloid cells Runx1 levels increase during the G1-S 
transition and promote Cyclin D3 gene expression (59).  Yeast two-hybrid studies 
demonstrated a direct interaction between Runx1 and Cyclin D3.  In addition, Cyclin D3 
competes with CBFß for association with Runx1, decreasing Runx1 transactivation 
ability (60).  The transactivation of Cyclin D3 by Runx1 appears to initiates a negative 
feedback loop that regulates the levels of Runx1 within the cell.  Transactivation studies 
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in vitro indicate that Cyclin A/Cdk2 and Cyclin B/Cdk1 directly phosphorylate Runx1 
serine residues S276 and S303, thereby increasing degradation of Runx1 by the 
anaphase-promoting complex during M-phase (61).  An alternative model of Runx 
activity during the cell cycle showed that Cyclin B/Cdk1 and Cyclin D3/Cdk6 
phosphorylate additional serine residues, S58 and S424 respectively, increasing 
transactivation by Runx1 in vitro and stimulating cell proliferation (62).  In this respect, 
Runx may have an alternate function in specific cell lineages, where a continuous 
proliferative state is required. 
 Runx family members, notably Runx2 in osteoblast differentiation, can regulate 
Bcl2 activity thereby modulating cell survival (63).  Runx3 interactions with Bcl2 and its 
target Bim play an important role in the regulation of differentiation and proliferation in 
epithelial cells (64).  Runx family member interactions with several proteins, most 
notably cell cycle and survival regulators like Bcl2 in the hematopoietic system may aid 
in the regulation of increased neutrophil production in the bone marrow. 
 
Downstream Targets of Runx1 
 
 The Runx family of transcription factors binds to a consensus PyGPyGGTPy 
sequence, where Py represents either thymine or cytosine (65).  Runx by itself is not a 
strong activator or repressor by itself, rather it requires interaction with co-activators and 
co-repressors.  Runx1 binding sites are necessary, but not sufficient for transcriptional 
activation (66). 
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 Runx proteins interact with additional transcription factors to modify the 
expression of target genes involved in hematopoiesis (Table 2).  The transcription factor 
Ets1 binds cooperatively with Runx to the TCRβ enhancer region.  This binding is 
inhibited if either of the transcription factors is absent or the binding sites are mutated 
(67).  The mutual increase in DNA binding of AML1 and Ets1 occurs through the direct 
interaction of their auto-inhibitory regulatory domains (43).  The myeloid transcription 
factor MEF, a member of the ETS transcription factor family, can physically interact via 
protein-protein binding with both Runx1 or the AML1-ETO fusion on the IL-3 promoter.  
The interaction between Runx1 and MEF activates transcription of IL-3, while MEF 
interaction with AML1-ETO suppresses transcription of IL-3 in a t(8;21) positive 
myeloid leukemia cell line, indicating that the C-terminal half of Runx1 is required for 
transactivation of IL-3 (68).  The macrophage colony stimulating factor (M-CSF) 
receptor promoter contains binding sites for Runx1, PU.1, and C/EBPα.  Runx1 binds 
cooperatively with C/EBPα, but not PU.1, though all three factors physically interact and 
synergistically activate M-CSF receptor expression in vitro (35).  Runx1 physically 
interacts via the runt domain with the B-cell specific transcription factor Pax5 paired 
DNA binding domain to synergistically activate transcription of the B-cell specific 
tyrosine kinase Blk (69).  Runx1 physically interacts via the C-terminal transactivation 
domain with the MITF transcription factor in mast cells, a cell type involved in the 
allergic immune response (70).  MITF and Runx1 synergistically activate mast cell 
protease-6 gene expression (71).  These studies indicate that Runx1 often functions in a 
cell specific context to modify partner transcription factor activity within a transcriptional 
complex to alter overall transcriptional activity of specific promoters. 
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 Runx family members are capable of altering gene transcription through 
interactions between co-activators and co-repressors and the C-terminus of Runx (72).  
DNA accessibility can be modified through the acetylation state of histone tail lysine 
residues by histone acetyl transferases (HATs), which increase accessibility and 
transactivation potential, and histone deacetylases (HDACs), which decrease accessibility 
and contribute to repression (73, 74).  The activity of HAT and HDAC activity is 
regulated by numerous processes including transcriptional regulation, post-translational 
modification, and protein-protein interactions with transcription factors (75).  The HATs 
p300, CBP, and MOZ can be recruited to transcriptional complexes, such as those 
mediated by Runx1 and have the ability to both modify the chromatin around the 
promoter and also to modify specific residues of proteins (76). The transcriptional co-
activator p300 is a HAT that is recruited to Runx1 mediated transcriptional complexes 
during myeloid differentiation (37).  The homeodomain interacting protein kinase 2 
(HIPK2), recruited by an activated Runx1, phosphorylates p300 to allow for chromatin 
remodeling and activation of transcription (77).  The monocytic zinc-finger protein 
(MOZ) is a strong co-activator of Runx1 mediated transcription (78).  TLE1, the 
mammalian homologue of the Drosophila co-repressor Groucho, physically interacts 
with the ultimate C-terminal VWRPY sequence of Runx1 and represses Runx1 activity 
(79).  The ability of TLE family members, including TLE1 and TLE2, to repress 
transcriptional activity of Runx1 is cell-stage limited for regulation of specific cell 
processes such as repressing Wnt signaling required for T-cell receptor expression during 
lymphogenesis or osteocalcin gene expression during bone formation (30, 80). The 
interaction of the co-repressor mSin3A and the C-terminus of Runx1 is dependent on the 
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phosphorylation status of Runx1.  Phosphorylation of Runx1 releases the mSin3A-
induced repression of Runx1 activity, allowing Runx1 activity and proteosome-mediated 
degradation (81). It is interesting to note that despite the lack of the Runx1 C-terminal 
domains mSin3A was demonstrated to be a key factor in the aberrant activity of the 
AML1-ETO fusion protein during the progression of myelogenous leukemias due to the 
ability of mSin3A to bind to normal ETO and the ETO portion of the AML1-ETO fusion 
protein (82).  
 
Runx and Hematopoiesis 
 
 Hematopoiesis is the sequential process of formation and differentiation of red 
and white blood cells (Figure 4).  Mature blood is comprised of many distinct cell types, 
each with a specific function. Erythrocytes, commonly known as red blood cells (RBC), 
comprise the majority of the cells of the blood and are responsible for the transport of 
oxygen throughout the body.  Leukocytes, commonly known as white blood cells, are the 
primary effectors of the adaptive and innate immune response.  Leukocyte is a general 
term that refers to populations of many distinct unipotent cell types that have 
differentiated to fulfill a single specific function.  The process of differentiation is 
generally unidirectional; an individual cell will give rise to two daughter cells with equal 
or decreased potential. The hematopoietic stem cell (HSC) is a multipotent cell type 
capable of self-renewal and is able to give rise to all of the cells of the immune system, 
including granulocytes, monocytes, lymphocytes, mast cells, erythrocytes and 
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megakaryocytes (83) (Figure 4).  The property of self-renewal allows HSCs to maintain a 
constant population level during hematopoiesis. 
 
Definitive Hematopoiesis 
 
 Runx1, but not Runx2 or Runx3, is required for the definitive hematopoiesis that 
occurs during embryonic development.  HSCs are derived during embryogenesis from 
yolk sac pluripotent embryonic stem (ES) cells.  The relationship between early primitive 
HSCs, prior to E11, and later definitive HSCs, post E12, is unclear. Primitive HSCs are 
unable to reconstitute the blood of lethally irradiated mice, whereas definitive HSCs can 
(84-87). The first definitive HSCs arise from the dorsal aorta-of the gonad-mesonephros 
(AGM) region (85).  Runx1 knockout mice are non-viable, the embryos die at 
approximately embryonic day 12.5, the same time frame that definitive hematopoiesis 
occurs (7, 88).  Subsequent studies confirmed the expression pattern of Runx1 was 
limited to the AGM embryonic region early in development that later give rise to HSCs 
(89-91).  Runx1 was shown to be required for the development of HSCs from definitive 
hemangioblasts, the precursors of endothelial cells and HSCs. (92). A conditional Runx1 
knockout mouse model has demonstrated Runx1 is required for the transition of 
endothelial cells to HSC (93)  Companion studies, both in vivo and in vitro, showed that 
disruption of CBFβ, the Runx1 heterodimeric partner, produces similar defects of 
hematopoiesis (94, 95). 
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Adult Hematopoiesis 
 
 The differentiation of HSCs, and thus hematopoiesis, is localized to the bone 
marrow following birth.  The subsets of cells derived from HSCs migrate from the bone 
marrow to primary organs of the immune system, such as the thymus and spleen, to 
continue their differentiation and maturation within specific microenvironments. 
Expression pattern analysis during the differentiation of leukocyte subsets reveals that the 
presence of Runx1 is variable between subsets (96-98). A definitive panel of cell surface 
markers delineating the HSC population has not been established so the most accurate 
way to describe and identify these cells is through functional assays.  The hallmark of an 
HSC is the ability to repopulate all of the erythroid and leukocyte lineages in long-term in 
vivo repopulation assays.  All of the identified long-term repopulating cells are positive 
for Runx1 expression. 
 The myeloid lineage, excluding erythrocytes, expresses Runx1 throughout 
development.  As cells of the erythroid lineage develop to their mature state, the number 
of cells expressing Runx1 is dramatically reduced (99). The majority of myeloid 
progenitor cells express Runx1.  This expression is increased in the developing 
granulocytes and continued during the terminal differentiation of neutrophils. Monocytes 
and derived macrophages also express Runx1 at a higher level than their progenitor cells 
(97-99). 
 The lymphoid lineage, including T-cells, B-cells, and NK cells, is marked by 
dramatic changes in the expression level of Runx1 between discrete developmental 
stages.  The majority of the earliest B-cell progenitors express Runx1 at a level that 
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slowly declines until the pre-B cell stage (99).  Runx1 is strongly expressed in mature 
peripheral circulating B-cells (100).  Runx1 is expressed in the majority of NK cells and 
developing T-cells up to the DN3 stage of development (96, 98).  The DN4 stage has a 
dramatically reduced percentage of cells with Runx1 expression (96).  The majority of 
single positive T-cells express Runx1, though CD4+ cells express more Runx1 than 
CD8+ cells (96, 98, 101). The role of Runx in thymopoeisis will be discussed in more 
detail in a following section. 
 
Neutrophils 
 
 Neutrophils function as front line defense in the innate immune system by 
monitoring and reacting to changes within their environment.  Approximately 1.6x1011 
neutrophils are produced in human bone marrow on a daily basis, a number that can 
increase 10 fold during infection (102). Circulating neutrophils respond to inflammatory 
cytokine signals and undergo a process of extravasation out of circulation and into the 
infected tissue area.  Neutrophils at the site of infection release cytotoxic granules in a 
non-specific manner to destroy invading pathogens.  The rapid response to infection is 
crucial for the effectiveness of the innate immune system and is a result of molecular 
regulation of myeloid development. Neutrophils develop from HSCs through a series of 
morphologic changes that are accompanied by a progressive change in cell surface 
proteins that allow for their change in function (Table 3).  Neutrophil development from 
HSC into the mature polymorphonuclear (PMN) stage occurs within the bone marrow 
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and subsequently the PMN move into the blood where they comprise the majority of 
circulating leukocytes. 
 The morphologic stages of neutrophil development within the bone marrow 
include immature myeloblasts, promyelocytes, myelocytes and metamyelocytes, and 
mature bands and PMN neutrophils (Figure 5).  The development of cytotoxic granules 
occurs progressively, with azurophils developing first in the promyelocyte stage, 
followed by specific granules, which may contain alkaline phosphotase, lactoferrin, 
lysozyme, and NADPH oxidase, in the myelocyte stage.  The metamyelocyte stage is 
characterized by a condensation of chromatin, rendering the neutrophils non-proliferative 
in successive stages of development.  The nucleus continues to condense into the 
characteristic band morphology before separating into the distinct multi-lobed PMN 
phenotype observed in mature neutrophils (103). 
 The morphologic developmental stages characteristic of neutrophil development 
are related to concomitant changes in cell surface antigen expression. Panels of 
antibodies specific for CD16, CD35, CD64, and CD87 have been used to delineate stages 
of neutrophil development with correlation of accompanying morphologic changes (104). 
The expression level of cell surface protein markers makes the correlation between 
surface markers and morphologic stages difficult; often a marker is present at low or 
intermediate levels leading to subjective analysis.  Mature PMN neutrophils however, 
may be sorted to high levels of purity with the cell surface markers CD11b and Gr1 
(Ly6G) (Table 3).  CD11b, also known as complement receptor 3 or Mac-1, is first 
expressed on intermediate mature myelocytes and is not expressed at earlier blast stages. 
CD11b resides within an intracellular storage pool and surface expression increases 
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through the mature stages of myeloid development as assessed by flow cytometry (105). 
CD11b is also expressed on other cell types including macrophages, monocytes, subsets 
of NK cells, and activated peripheral lymphocytes. Gr1, also known as granulocyte 
differentiation antigen 1 or Ly6G, is highly expressed on mature band and PMN stage 
neutrophils and transiently expressed during early monocyte development (106). Mature 
PMN neutrophils can be reliably identified by the level of co-expression of CD11b and 
Gr1 on an individual cell. 
 Runx1 plays an integral role in the regulation of genes required for neutrophil 
development.  Transcription factor profile studies of developing myeloid cells have 
shown strong expression of Runx1 in the immature myeloblast/ promyelocyte stages with 
a gradual reduction of expression through the mature band/ PMN stages of development 
(107).  This agrees with earlier studies that indicate Runx1 promotes cell proliferation via 
repression of the cdk inhibitor p21waf1/cip1, therefore a reduction in Runx1 levels is 
necessary during the transition to mature non-proliferative stages of myeloid 
differentiation (32).  Myeloperoxidase (MPO), a peroxidase enzyme, and neutrophil 
elastase, a serine protease, are two important components of azurophilic granules 
developed during the immature promyelocyte stage of neutrophil maturation. The 
promoter regions for both MPO and neutrophil elastase contain Runx1 binding sites that 
are required for expression of these genes in immature stages of G-CSF stimulated 
myeloid 32Dcl.3 cell line differentiation (27). 
 Neutrophil development has been studied in several in vitro systems that allow for 
examination of the role of Runx1 during myelopoiesis.  Early studies relied on the in 
vitro differentiation of whole bone marrow derived cells into neutrophils.  This system 
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however, resulted in a heterogeneous population of bone marrow derived cells and the 
assessment of the contribution of individual growth factors to neutrophil development 
was very complex (108).  Newer studies of neutrophil development rely on two systems; 
immortalized myeloid cell lines such as mouse 32Dcl.3 and human HL-60, and in vitro 
culture of stem cells.  The 32Dcl.3 cell line is a promyelocyte stage cell line immortalized 
with the Friend murine leukemia virus and is dependent on IL3 for long-term survival 
(109).  In the presence of purified granulocyte colony-stimulating factor (G-CSF), and 
absence of IL3, the 32Dcl.3 cell line can be induced to differentiate into cells bearing all 
of the morphologic characteristics and surface markers indicative of mature PMN 
neutrophils (110).  Distinct subsets of the 32Dcl.3 cell line, expressing cell surface 
receptors at low levels, can be selected after stimulation to proliferate in response to Epo, 
and GM-CSF in the absence of IL3.  The 32Dcl.3 cell line in these studies yielded no 
clones that proliferated in response to G-CSF stimulation. The isolated GM-CSF lines 
displayed myeloblast morphology, while G-CSF stimulated cells were mostly myelocytes 
and metamyelocytes indicating the early-uncommitted nature of this cell line similar to in 
vivo myeloid precursors, which can be pushed with specific cytokines to develop into 
different myeloid cell types (111).  As discussed previously, Runx1 plays an essential 
role in the regulation of the cell cycle during hematopoiesis in a cell type specific 
manner. Deletion of Runx1 during adult mouse hematopoiesis decreases proliferation of 
lymphoid cells and platelet production, but also results in a myeloproliferative phenotype 
(57). Differentiation of 32Dcl.3 cells in response to G-CSF stimulation can be blocked by 
the expression of the AML1-ETO fusion, which is a dominant negative for Runx1 C-
terminal functions (112). Exogenous expression of Bcl2 delays the onset of terminal 
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differentiation of 32Dcl.3 cells, though this activity is independent of the up-regulation of 
Bcl2 by the AML1-ETO fusion protein (112). The Runx1 mediated regulation of 32Dcl.3 
differentiation can be abrogated by the ectopic expression of Ear-2, a nuclear hormone 
receptor that binds directly to Runx1 (113). More recently, several in vitro systems for 
the differentiation of stem cells into the various lineages of the hematopoietic system, 
including neutrophils, have been developed.  Embryonic stem (ES) cells are the least 
derived and most pluripotent cell type, having the potential to develop into any cell 
lineage. The differentiation of ES cells into hematopoietic cell types requires a substrate 
to support differentiation such as an OP9 cell monolayer or commercially available cell 
matrix substrates. ES cells are grown as embryoid bodies in suspension culture.  These 
embryoid bodies are then seeded onto an OP9 monolayer substrate with appropriate 
growth factors to initiate differentiation through the earliest cell stages.  Neutrophil 
specific differentiation is achieved with the addition of myeloid specific differentiation 
factors, G-CSF, GM-CSF, and IL6 (102). The methods for in vitro differentiation of 
neutrophils used in this dissertation utilize whole bone marrow containing myeloid 
precursors.  In this case, fewer growth factors are required for the survival of the myeloid 
precursors and by supplying stem cell factor (SCF) and G-CSF the myeloid precursors 
can be induced to differentiate into neutrophils during five days in culture. 
 
Thymocytes 
 
 Thymocytes develop from the common lymphoid progenitor (CLP) in a series of 
discrete stages that can be characterized by the expression of cell surface proteins (Figure 
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6).  Each of the stages of thymocyte development is a checkpoint that regulates the proper 
expression of regulatory molecules that define the activity of the mature T-cell.  
Thymocytes in the earliest stages of development lack the hallmark surface CD4 and 
CD8 T-cell receptor (TCR) accessory proteins that define the two main groups of mature 
T-cells and are thus defined as double negative (DN).  DN thymocytes can be further 
defined by the expression pattern of CD44, an adhesion molecule involved in homing, 
and CD25, the α-chain of the IL-2 cytokine receptor (Figure 6). The thymocytes cease 
proliferation and down-regulate expression of CD44 during the DN2-DN3 transition, at 
which point the RAG family of genes is turned on and begin to re-arrange the TCRβ 
chain genes. The first major checkpoint of thymocyte development is a process called 
beta selection that regulates the DN-DP transition.  An expressed TCRβ chain on the 
surface of the cell pairs with a pre-TCRα chain and with CD3 signal transduction 
complex to provide signals for proliferation, suppression of further TCRβ chain 
rearrangement, activation of TCRα chain rearrangement, and progression to the CD4-
CD8 double positive (DP) developmental stage. It is important to note that DN4 stage 
thymocytes express CD2, a co-stimulatory adhesion molecule expressed after beta 
selection during a period of proliferation. 
 The DP thymocytes then undergo the processes of positive and negative selection.  
In positive selection, a DP thymocyte whose TCR binds an MHC antigen presenting 
molecule will survive. A DP thymocyte that does not receive any signal undergoes 
apoptosis via death by neglect (114). Negative selection then occurs for those thymocytes 
that express a high affinity for self-MHC or self-MHC and self-antigen, thereby 
eliminating potential auto-reactive T-cells.  DP thymocytes that pass the positive and 
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negative selection are then further delineated into single positive (SP) CD4+ or CD8+ 
thymocytes commonly known as T-helper and cytotoxic T-cells respectively. 
 Runx1 is expressed throughout thymocyte development and plays an essential 
role in the differentiation and maintenance of single positive T-cell lineages.  The vast 
majority of DN1-DN3 developing thymocytes strongly express Runx1, though the 
percentage of Runx1 expressing cells dramatically drops at the DN4 post-beta selection 
stage.  Approximately half of DP thymocytes and the majority of both CD4 and CD8 SP 
cells strongly express Runx1 (96). These data support the idea that Runx1 serves to 
silence CD4 expression through the DN3 stage, at which point the level of Runx1 is 
reduced in the DN4 stage in preparation for the transition to the CD4+/CD8+ DP stage.  
Several enhancers, a promoter, and a single 434 bp silencer regulate CD4 expression.  
The CD4 silencer contains five consensus Runx1 binding sites as well as binding sites for 
the co-repressors Hes-1, c-myb, and repressive transcription factor ZEB, though the 
timing of when these co-repressors come into play during the SP transition is a matter of 
debate as the cell lines used in these studies are immortalized post-beta selection and may 
already be committed to an SP lineage (115, 116).  Recently, a pair of studies 
demonstrated that the process of positive selection and the single positive lineage 
transition are two distinct events.  A mouse mutant was characterized where MHC class 
II thymocytes were aberrantly directed towards the CD8 SP lineage.  The cause of this 
phenotype was determined to be a single point mutation of the Th-POK transcription 
factor also known as cKrox (117). Constitutive expression of cKrox impairs the 
development of CD8+ cells as MHC class I restricted thymocytes are differentiated into 
CD4+ cells (118). Th-POK (cKrox) expression is inhibited by a Runx-dependent silencer, 
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which allows for CD8+ cell differentiation (119) Runx1 and Runx3 are expressed 
throughout thymocyte development and are required, along with Runx binding sites, for 
repression of the CD4 locus during DN and CD8+ thymocyte stages respectively (101) 
Runx1 was shown to be able to partially substitute for a lack of Runx3 in the thymocyte 
development of a Runx3 knockout mouse, indicating overlapping functions for Runx 
family members (120)  Runx1 and Runx3 are both active in the silencing of CD4 
expression, an activity that is dependent on the presence of the Runx NMTS domain and 
independent of TLE co-repressor activity (121).  Runx1 and Runx3 may share some 
overlapping functions, but primarily Runx3 initiates epigenetic CD4 locus silencing in 
mature CD8 SP thymocytes post positive selection, while Runx1 is required for CD4 
silencing in DN thymocytes (101).  
 
Natural Killer Cells 
 
 Natural killer (NK) cells play a vital role in the effectiveness of the innate 
immune response. NK cells help to control viral infections during the early stages of the 
lag period before an adaptive T-cell mediated response can be mounted. NK cells differ 
from T-cells in that they do not express antigen specific receptors and do not have the 
capacity of immunologic memory.  Lacking the structure of the T-cell receptor, NK cells 
monitor surroundings and mediate the killing response through the use of inhibitory and 
activating classes of cell surface receptors, the majority of which recognize HLA 
subtypes (122).  In the opposing signal model, NK cell activating and inhibitory receptor 
pairs share specificity for specific HLA on a target cell, but have opposite intracellular 
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signaling potentials (Figure 7).  Inhibitory KIR receptors bind strongly to cognate HLA 
antigens to transduce a signal that will result in no killing, even in the presence of the 
weakly binding activating KIR.  In the case of a non-self or virus-infected cell, down-
regulation or expression of abnormal MHC class I, and therefore only activation signal 
transduction in the NK cell, will result in killing (Reviewed in (123)).  Recent studies of 
patients with rheumatoid and psoriatic arthritis suggest that expression of activating KIR 
receptors in an individual lacking the appropriate HLA specific KIR inhibitory receptors 
can lead to predisposition for autoimmune disorders (124, 125).   
 In humans, the KIR gene locus encodes a variable number of KIR that appears in 
variable combination throughout the population.  The KIR locus is arranged with several 
invariant framework loci flanking variable regions that encode different numbers of KIR 
genes.  The number and subsets of KIR genes in an individual are a function of gene 
duplication and possible gene conversion events via exon exchange (126).  KIR contain 
two (KIR2D) or three (KIR3D) extracellular Ig like domains and either a long (L) 
intracellular tail containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
required for inhibitory function, or a short (S) intracellular domain that allows NK cell 
activation (127). Specificity of NK cells is determined in part by clonally maintained KIR 
expression within specific NK cell subsets. Inhibitory KIR can be further divided into 
sub-groups that display an affinity for particular HLA subsets of MHC class I (128, 129). 
The paired expressions of inhibitory and activating KIR contribute to the broad repertoire 
of NK cells necessary for NK cell activity and specificity for the accurate determination 
of self and non-self. 
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 The selection of a subset of KIR for clonal expression appears to be a stochastic 
process regulated by a combination of transcription factors and unique promoter regions. 
Three functionally different types of promoters have been described that regulate the 
expression of classes of KIR genes that are clonally expressed, constitutively active 
(KIR2DL4), or weakly expressed (KIR3DL3). In these studies, Runx3 was shown to 
occupy the majority of Runx binding sites in the KIR promoters, and acted as a repressor 
of KIR expression in mature NK cells (130).  A bidirectional promoter has been 
identified that may provide a mechanism for a probabilistic switch leading to the 
stochastic expression of the inhibitory KIR3DL1 gene (131).  AML2 and AML3 have 
been shown to bind some KIR promoter fragments by EMSA (130, 132). Specific 
deletion of both AML and ETS binding sites in in-vitro promoter assays reduces activity 
of some KIR promoter regions by approximately 40% (131, 133, 134). In contrast, 
mutation of an AML binding site alone can reduce expression of specific KIR genes such 
as KIR2DL5.2, KIR2DL4, and KIR3DL1 (128, 135).  The establishment of a diverse 
repertoire of NK cells is dependent on the molecular regulation of NK cell recognition 
receptors such as the KIR family of paired receptors.  The presence and importance of 
Runx consensus binding sites has been established in many different in vitro promoter 
assays, but the actual function and activity of Runx1 in regard to the developing and 
mature NK cells has not been established. 
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Figure 1 Runx1 Genomic Structure 
 
Alternative promoter usage generates two distinct Runx1 N-termini. The black boxes 
represent 5’ UTR, and the white boxes are N-terminal coding regions. The transcript 
from the proximal promoter includes a 1.5 kb 5’ UTR and a 5 amino acid encoding 
sequence. The distal promoter lies approximately 150 kb upstream from the proximal 
promoter.  The transcript from the distal promoter includes a spliced 5’ UTR, and a 19 
amino acid encoding sequence that replaces the 5 amino acids encoding proximal N-
terminus. (14) 
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Figure 2 Differential Runx1 Promoter Expressions 
 
Runx1 is transcribed from either a proximal or distal promoter, resulting in two distinct 
N-termini.  The various hematopoietic cell lineages express Runx1 from either promoter 
equally or preferentially in a defined spatio-temporal manner. The significance of 
‘switching’ promoter usage is a process that has not yet been fully characterized yet 
appears to play an essential role in the proliferation or differentiation checkpoints during 
hematopoietic development. (14). 
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Figure 3 Domain Structure of Runx1 
 
The Runx1 transcription factor, shown here with all exons, is comprised of many 
domains. Table 1 lists some of the important features of the protein relevant to the 
regions noted here. All of the amino acid numbering of Runx1 downstream of the 
alternatively spliced N-terminus used in this thesis corresponds with the proximal 
isoform. The unique distal N-terminus is noted as (1’-19’).  N-terminus (dark blue); Runt 
domain (red); C-terminus (yellow) 
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Table 1 Domain Structure of Runx1 
 
Amino Acid 
Region 
(Numbering of the 
Proximal Isoform) 
Putative Function References 
N-terminal Splice 
Variants 
1-5 
(Proximal Isoform) 
1’-19’  
(Distal Isoform) 
Unknown (14) 
N-terminus 1-50 Transactivation (136) 
Runt Domain 50-177 DNA Binding CBFβ Dimerization (137) 
Nuclear 
Localization 
Signal 
177-181 Trafficking to the Nucleus (121) 
Negative 
Regulatory 
Region of DNA 
Binding 
177-291 Auto-inhibitory Domain (40, 41, 43) 
Nuclear Matrix 
Targeting 
Sequence (NMTS) 
320-360 Sub-nuclear localization (138, 139) 
Transactivation 
Domain 181-451 
The transactivation 
domain contains multiple 
sites of interaction with 
co-activator and co-
repressor binding partners 
Ear-2    (113) 
ALY      (38) 
ETS-1    (43) 
P300      (37) 
HES-1  (140) 
PU.1      (35) 
C/EBP   (36) 
TLE Domain 446-451 VWRPY 
Groucho/ TLE Co-
repressor binding site (79) 
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Table 2 Selected Target Genes of Runx1 in Hematopoietic Tissues 
 
Lineage Gene Cell Type 
Runx1 Effect 
on 
Expression of 
Target 
References 
TCR α, β, γ, δ 
chains T-cells Increased (141) 
IL-3 T-cells Increased (68) 
Granzyme B T-cells Increased (142) 
CD3 T-cells Increased (143) 
GM-CSF T-cells Increased (144) 
Blk B-cells Increased (69) 
Lymphoid 
G-protein g3 T-Cells Decreased (145) 
M-CSF Receptor Monocytes Increased (146) 
MPO Immature myeloid Increased (27) 
p21Waf1/Cip1 Multiple Cell Lineages Increased (147) 
Complement 
Receptor 1 
Hematopoietic 
Lineage Increased (148) 
Neutrophil 
Elastase Immature myeloid Increased (27) 
Myeloid 
PKCβ Myeloid Lineage Increased (149) 
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Figure 4 Hematopoiesis 
 
All of the cell types of the immune system are derived from a multipotent, self-renewing 
hematopoietic stem cell. Hematopoiesis is a stepwise unidirectional process in which cell 
fate is gradually restricted, leading to a unipotential terminally differentiated cell type. 
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Figure 5 Neutrophil Differentiations 
 
Neutrophil development proceeds through several morphologically distinct stages of 
development that can be followed by changes of cell surface protein expression.  The 
immature mitotic blast stages are defined by the ability to proliferate and two discrete 
secretory promyelocyte and myelocyte stages that produce azurophils (filled circles) and 
specific granules (open circles) essential to the cytotoxic activity of mature neutrophils.  
The mature post-mitotic stages of development are characterized by a cessation of 
proliferation due to the gradual condensation of chromatin ultimately leading to a highly 
condensed segmented nucleus. 
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Table 3 Granulocyte Differentiation Markers 
 
 CD11b Gr1 (Ly6G) 
Hematopoietic Stem Cell - - 
Myeloblast - - 
Promyelocyte - - 
Myelocyte ++ + 
Metamyelocyte +++ + 
Band +++ ++ 
Polymorphonuclear +++ +++ 
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Figure 6 Stages of T-Cell Development 
 
Hematopoietic stem cells (HSC) give rise to common lymphoid precursors (CLP) that 
migrate from the bone marrow to the thymus where environmental cues from the thymic 
architecture induce the rearrangement of the T-cell receptor and expression of co-
stimulatory cell surface molecules. The double negative (DN) thymocyte stage, which is 
characterized by a lack of CD4 and CD8 expression, can be further delineated by the cell 
surface expression of CD44 and CD25. The TCR beta chain (black oval) is paired with a 
surrogate alpha chain (empty oval) prior to beta selection.  After the pre-TCR has been 
expressed and signaling initiated, the thymocytes lose CD25 expression and enter the 
CD8+ immature single positive (ISP) stage. The double positive (DP) stage, 
characterized by expression of both CD4 and CD8 in conjunction with the TCR alpha 
chain (gray oval), undergoes positive and negative selection prior to the single positive 
(SP) CD4+ and CD8+ stages. 
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Figure 7 Opposing Signal Model of NK Receptor Mediated Killing 
 
KIR activation and inhibitory receptor pairs recognize specific HLA class I antigens and 
regulate NK cell activity via the use of opposing signals.  KIR3DL and KIR2DL 
receptors (red) have a long cytoplasmic tail (white box) with a single or tandem 
immunoreceptor tyrosine-based inhibitory motif (ITIM) motifs (black bars) that 
potentiates an inhibitory signal when bound to self-MHC. KIR2DS receptors (green) 
have a short cytoplasmic tail that lacks an ITIM motif, but these receptors can associate 
with the DAP family of signaling adaptor molecules (gray box) which contain an 
immunoreceptor tyrosine-based activation motif (ITAM) motif (black bar), thereby 
potentiating an activation signal when bound to MHC. NK cells express a repertoire of 
KIR, and the balance of positive and negative signaling determines whether there will be 
a killing response. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Generation of mutant runx1 constructs 
 
  Runx1 mutant constructs were created via PCR primer directed mutagenesis from 
full-length distal (466 amino acids) and proximal (452 amino acids) Runx1 templates. 
The two isoforms were identical except for the sequence encoding the proximal 5 amino 
acids or distal 19 amino acids N-termini. Mutant PCR products were cloned into the Bgl 
II and Xho I sites of the retroviral plasmid MSCV-HA-IRES-GFP in frame with a C-
terminal HA-tag and confirmed by sequencing (Genewiz, South Plainfield, NJ).  
 
Retrovirus generation and transduction 
 
  293T cells were co-transfected with Fugene HD (Roche, Indianapolis, IN) 1 µg 
MSCV vectors encoding mutant Runx constructs and 1 µg pECL-Eco ecotropic retroviral 
packaging vector. Retroviral supernatants collected at 48 and 72 hours were used in spin 
infections of the 32Dcl.3 cell line and sorted for GFP expression on a FACS Vantage cell 
sorter (BD Biosciences, San Diego, CA).  All 32Dcl.3 cells were maintained in DMEM 
(Invitrogen, Carlsbad, CA) with 10% FBS (Hyclone, Logan, Utah), 10% conditioned 
media from the IL-3 producing WEHI-3B cell line, 10 mM HEPES, 1 mM sodium 
pyruvate, 0.1 mM MEM non-essential amino acids, 50 µg/mL gentamicin, and 50U/mL 
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penicillin/50 µg/mL streptomycin (P/S) (Invitrogen). The 293T and WEHI-3B cell lines 
were maintained in IMDM (Invitrogen) with 10% FBS (Hyclone), 10 mM hepes, 1 mM 
sodium pyruvate, 0.1 mM MEM non-essential amino acids, 50 µg /mL gentamicin, and 
50U/mL penicillin/50 µg/mL streptomycin (P/S) (Invitrogen).  
 
Intracellular staining for microscopy and flow cytometry 
 
 Transduced 32Dcl.3 cells maintained in IL-3 containing media were harvested, 
fixed with 4% methanol-free formaldehyde (Ted Pella Inc., Redding, CA), and 
permeabilized in methanol. 
 Microscopy samples were stained with α-HA (Cell Signaling, Danvers, MA), 
goat anti-mouse IgG-Texas Red (Jackson Immunoresearch Lab Inc., West Grove, PA) 
and DAPI (Molecular Probes, Eugene, OR). Slides were mounted using Vectashield 
(Vector Laboratories, Burlingame, CA) and imaged using a Zeiss Axiovert 200M 
inverted microscope equipped with a Ludl XY-stage control and a Hamamatsu Orca 
camera. Images were taken using the ApoTome structured light illumination system 
(Zeiss Thornwood, NY) and the AxioVision software (Zeiss). 
Flow cytometry samples were stained with α-HA (Cell Signaling, Danvers, MA) 
and goat anti-mouse IgG APC (Jackson Immunoresearch Lab Inc., West Grove, PA). The 
cells were re-suspended in CBE (PBS pH 7.4, 0.2% BSA, 1 mM EDTA) and analyzed on 
a BD LSR II flow cytometer. 
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Cell Counting/ Proliferation Assay   
 
 32Dcl.3 cells were harvested, washed twice with 32Dcl.3 media without IL-3 and 
counted. An aliquot of 1x105 cells were plated in 96-well round bottom plates (Corning, 
Corning, NY) in 200 µL of 32Dcl.3 IL-3 free media with 500U/mL G-CSF (Biosource, 
Camarillo, CA). 
 For the proliferation assays, the wells were pulsed with 1 µCi/ well 3H-thymidine 
(GE Health Care Life Sciences, Piscataway, NJ) at 0, 24, or 48 hours and harvested after 
24 hours of thymidine incorporation at 24, 48 and 72 hours.  The level of thymidine 
incorporation was assayed with liquid scintillation fluid. 
 For the cell counting assay, the cells were harvested at 24, 48, and 72 hours. An 
aliquot was mixed with the trypan blue viability dye, added to a hemacytometer and 
manually counted with a light microscope. 
 
Bone Marrow Culture 
 
 Hematopoietic progenitor cells were obtained from 3-6 month old AML 
heterozygous mice.  Whole bone marrow was collected by excising femurs, tibia, and 
fibula and flushing with CBE (PBS pH 7.4, 0.2% BSA, 1 mM EDTA).  The collected 
bone marrow cells were incubated in RBC lysis buffer (17 mM Tris, 144 mM ammonium 
chloride) to remove erythrocytes. Cells were cultured 48 hours in DMEM supplemented 
with 10% FBS, 10% stem cell factor-containing supernatant from the BHK/MKL cell 
line, 20 ng/mL IL-3 (PeproTech, Rocky Hill, NJ), and 50 ng/mL IL-6 (PeproTech).  Cells 
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were transduced with a 1 mL aliquot of the Runx1 construct retroviral supernatant 
supplemented with 6 µL Lipofectamine (Invitrogen) and centrifuged at 600 xg, 30°C, for 
one hour.  The media was changed to DMEM with 10% FBS, 10% SCF, 10 mM Hepes, 1 
mM sodium pyruvate, 0.1 mM MEM non-essential amino acids, 50 µg /mL gentamicin, 
50U/mL penicillin/50 µg/mL streptomycin (Invitrogen) and 500 U/mL G-CSF 
(Biosource) for five days.  The cells were then harvested and analyzed on a BD LSR II 
flow cytometer (BD Biosciences) for expression of 7-AAD vitality dye exclusion 
(Calbiochem, San Diego, CA), GFP, and surface expression of CD11b and Gr-1 (Ly6G 
isoform only) (eBioscience, San Diego, CA). Data was prepared using FlowJo analysis 
software (Treestar Inc., Ashland, OR).  
 
Thymocyte Co-Culture 
 
 Thymocytes were obtained from thymi of 3-6 month old Bcl-2 mice (The Jackson 
Laboratory, Bar Harbor, ME). Thymocytes were re-suspended in CBE (PBS pH 7.4, 
0.2% BSA, 1 mM EDTA) and labeled with magnetic bead conjugated antibodies for 
CD4, CD8 and CD2 (Miltenyi Biotech, Auburn, CA). A negative selection was 
performed with MACS columns (Miltenyi Biotech) to obtain double negative stage 2 
thymocytes.  Thymocytes were cultured in DMEM (Invitrogen) with 10% charcoal 
stripped FBS (Hyclone), 10 mM Hepes (pH 7.4) (Invitrogen), 50U/mL penicillin/50 
µg/mL streptomycin (P/S) (Invitrogen), and 0.05 mM β-mercaptoethanol (EMD 
Biosciences, La Jolla, CA).  The cells were transduced with the Runx1 constructs via spin 
infection as described previously and rested for 24 hours.  The thymocytes were then 
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induced to differentiate for 5 days on a monolayer of the OP9 DL1 stromal cell line, 
kindly donated by Juan Carlos Zúñiga-Pflücker.  The differentiated thymocytes were 
removed from the adherent monolayer and analyzed on a BD LSR II flow cytometer (BD 
Biosciences) for GFP and fluorescent immuno-staining of cell surface CD4 (PE 
conjugated), CD8 (PerCP conjugated) and TCRβ (APC conjugated) (eBioscience, San 
Diego, CA). 
 
Luciferase Assay 
 
 The 293T cell line was transfected with mutant Runx1 constructs using Fugene 
HD (Roche) A total of 5x105 cells were co-transfected with three plasmids: 0.1 µg pRL-
SV40 Renilla loading control, 0.9 µg forward or reverse KIR promoter pGL3-luciferase 
reporter, and 1 µg of either MSCV-HA-IRES-GFP runx1 mutants, Ets1, or YY1. The 
luciferase, renilla, and KIR promoter plasmids were all kindly donated by Steve 
Anderson. The 293T cells were plated in 6 cm plates and cultured for 48 hours in RPMI 
(Invitrogen) with 10% FBS (Hyclone), 10 mM Hepes, 1 mM sodium pyruvate, 0.1 mM 
MEM non-essential amino acids, 20 µg /mL gentamicin, and 20U/mL penicillin/20 
µg/mL streptomycin (Invitrogen). The Dual-Luciferase® Reporter Assay System 
(Promega) was used according to manufacturer’s instructions to assay the activity of 
Runx1 N-terminal mutants on the activity of the forward and reverse KIR promoters. The 
luciferase activity of the KIR3DL1 promoter constructs with runx1 mutants was corrected 
for transfection efficiency to the activity of the Renilla luciferase activity, and normalized 
to the activity of the forward or reverse KIR3DL1 promoter constructs alone. 
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Animals 
 
 All of the procedures on animals contained in this thesis were performed 
according to NIH guidelines for the treatment of animals and the University of 
Massachusetts Amherst Institutional Animal Care and Use Committee (IACUC) 
approved protocols.  The AML mice referenced in these studies are C57BL6/6J with a 
heterozygous deletion of one Runx1 allele.  Crossing a Runx1 +/+ wild type with a 
Runx1 +/- heterozygous mouse generated a mixed litter of wild type and heterozygous 
mice as the Runx1 -/- mutation is embryonic lethal at embryonic day 12.5. The Bcl-2 
mice referenced in this study are from the Eµ-bcl-2-25 line of transgenic mice, which 
have T-cell lineage restricted expression of the human Bcl2 transgene. The genotype of 
all mice was determined by PCR amplification of extracted genomic DNA. 
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CHAPTER 3 
RUNX1 N-TERMINUS 
 
Construction of Runx1 N-terminal Isoform Deletions and Mutants 
 
 The N-terminal sequences unique to both distal and proximal Runx1 are highly 
conserved across the three Runx family members and across species including human, 
mouse, chicken, skate, frog, zebra fish, cow, bony fish, and cartilaginous fish. The five 
amino acids unique to proximal Runx isoforms thus far identified are 100% conserved. 
The distal N-termini identified have a higher degree of variability in both sequence and 
length, though residues from position 1’ to 3’, serine at position 5’, hydrophobic residues 
at position 6’ and 17’ and phenylalanine at position 7’ are 100% conserved across all 
species identified (Figure 8A).  The conservation of the distal and proximal N-termini 
suggests that these motifs are required for the function of the distal and proximal Runx1 
isoforms.  To test the hypothesis that distal or proximal-specific amino acids determine 
the differential function of distal and proximal Runx1 isoforms, we generated constructs 
encoding full-length Runx1 (proximal FL and distal FL), and distal mutants with internal 
deletions of amino acids 3’ to 8’ (Δ3-8), amino acids 3’ to 14’ (Δ3-14), amino acids 3’ to 
19’ (Δ3-19) and point mutations of the conserved serines and phenylalanine to alanine 
(F7A, S3A/S5A, and S3A/S5A/F7A) (Figure 8B). The sequences downstream of the 
distal and proximal-specific N-terminal sequences are identical, including the sequence 
upstream of the runt domain, the DNA-binding runt domain itself and the C-terminus. 
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 Runx1 proteins contain a nuclear localization sequence (NLS) and are normally 
translocated to the nucleus in conjunction with CBFβ (49). Further, Runx1 proteins are 
known to occupy distinct sub-nuclear foci, a phenomenon dependent on the presence of 
the nuclear matrix targeting sequence (NMTS) (150). This sub-nuclear localization of 
Runx is critical to Runx1 function, as a point mutation of a single tyrosine residue in the 
NMTS is sufficient to block differentiation of myeloid precursors (151). Deletion of the 
NMTS ablates the ability of Runx1 to silence the CD4 gene in thymocytes (16).  
 Accordingly, we first tested whether the mutant Runx1 molecules would be 
expressed and localized appropriately in 32Dcl.3 cells.  The 32Dcl.3 cells were 
transduced with a retroviral bicistronic vector expressing HA-tagged Runx1 constructs 
and sorted for GFP expression by flow cytometry (Figure 9).  GFP expression levels of 
the Runx1 proteins varied among cells of a sorted population and between different 
Runx1 mutants, with the S3A/S5A mutant consistently displaying the lowest GFP 
expression levels (Figure 9).  We also examined the localization and expression of HA-
tagged Runx1 with fluorescent microscopy (Figure 10).  Over-expressed Runx1 proteins 
were all present in the cytoplasm of the 32Dcl.3 cells and to varying degrees in the 
nucleus.  The myeloid precursor 32Dcl.3 cell line stained with the nuclear dye DAPI 
showed the large distinctly irregular nucleus characteristic of this cell type.  Within the 
nucleus, Runx1 wild type and mutant constructs were localized to specific foci within the 
nuclei, indicating that the nuclear matrix targeting sequence in these mutants is 
functional. There is no difference between the sub-nuclear localization of the proximal 
FL and distal FL isoforms (Figure 10). 
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 Mutation or deletion of the N-terminus of Runx1 alters protein expression of 
retrovirally transduced bulk sorted cell populations.  A bicistronic vector such as MSCV 
is designed with an internal ribosome entry site (IRES) that allows equal expression of a 
visible marker, GFP, as well as our gene of interest, Runx1.  We observed that the 
expression of GFP, representing global expression from the MSCV construct, was not 
consistent with the level of expression of HA-tagged Runx1 proteins (Figure 11).  The 
proximal FL, distal FL, (Δ3-14), (Δ3-19), and F7A constructs are all expressed in the 
32Dcl.3 cells.  The (Δ3-8), S3A/S5A, and S3A/S5A/F7A mutants had a very low 
percentage of HA+ cells in the live GFP+ population, indicating decreased protein 
expression. 
 
Deletion of Conserved Regions in the Distal Runx1 N-terminus Promotes the 
Prolonged Proliferation Phenotype Observed in Proximal Runx1 Transduced 
32Dcl.3 Cell Populations 
 
 The 32Dcl.3 cell line is a bone marrow derived IL-3 dependent lymphoblast cell 
line. In the presence of IL-3 the cells maintain blast characteristics and proliferate (111). 
Addition of G-CSF in concert with the removal of IL-3 induces differentiation of the cell 
line into polymorphonuclear neutrophils. 32Dcl.3 cells transiently transfected with the 
proximal Runx1 isoform continue to proliferate after the removal of IL-3 and addition of 
G-CSF (14). Transfection with the distal isoform immediately led to cessation of 
proliferation, the cells having become committed to a program of terminal differentiation 
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and death.  This difference in phenotype is attributable to the activity of the N-terminal 
residues, as the rest of the Runx sequences were identical.   
 Proliferation assays were performed to assess whether the previously observed 
increase in cell numbers conferred by the proximal isoform was due to increased 
proliferation (14).  All of the transduced cell populations maintained in IL-3 containing 
media grew normally and maintained expression of GFP.  Upon removal of IL-3 and 
addition of G-CSF the transduced cells showed reduced proliferation ability and 
phenotypic markers of neutrophil differentiation, including characteristic band and 
polymorphic nuclear condensation.  Increased viable cell number and proliferation index 
of the proximal full-length transduced cells was evident at 24 hours and became more 
pronounced over 72 hours as compared to the distal full-length and 32Dcl.3 negative 
control (Figure 12, Figure 13).  The (Δ3-14) deletion and (Δ3-19) deletion also displayed 
increased cell number and proliferation over 72 hours, which may support either the 
hypothesis that the distal N-terminus contains a regulatory motif for the abrogation of 
proliferation or the distal N-terminus helps to promote differentiation. The (Δ3-8) 
deletion, S3A/S5A/F7A and S3A/S5A point mutants were all poorly expressed and 
showed no difference in proliferation compared to 32Dcl.3 control over 72 hours despite 
the similarity in cell number with distal full length transduced cells.  The F7A population 
exhibits a slight trend downward at 72 hours in both cell number and proliferation index, 
but does not significantly decrease over the time course compared to distal full length.  
Deletion of the region containing the highly conserved serine and phenylalanine residues 
appears to be detrimental to the activity of distal Runx1.  These results indicate that the 
proximal N-terminus itself is unnecessary for the proliferation phenotype in the presence 
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of G-CSF and that deletion of the (Δ3-14) distal N-terminus amino acid region is 
sufficient to induce a proximal phenotype. 
 
Proximal Runx1 Increases Expression of Neutrophil Markers of Differentiation on 
Transduced Myeloid Precursors as Compared to Distal Runx1 
 
 In order to further analyze the differential activities of proximal and distal Runx1 
in hematopoiesis an ex vivo bone marrow culture system was utilized. Myeloid lineage 
precursors residing in the bone marrow can give rise to neutrophils under appropriate 
differentiating conditions.  Whole bone marrow was harvested and retrovirally 
transduced with wild type Runx1 and Runx1 N-terminal mutants. Stimulation with stem 
cell factor (SCF) and G-CSF promotes the differentiation of monocytes and neutrophils, 
this differentiation can be tracked by flow cytometry analysis of the up-regulation of cell 
surface markers CD11b and Gr1 (LY6G). Developing myelocytes first up-regulate 
CD11b, a marker common to monocytes and neutrophils. Mature neutrophils are 
characterized further by additional expression of Gr1. 
 Retrovirally transduced cells were harvested and analyzed with flow cytometry 
first for viability and GFP expression, and then for markers of differentiation CD11b and 
Gr1 (LY6G) (Figure 14).  The Gr1+ population was significantly increased as a 
proportion of live/GFP+/CD11b+ cells when transduced with proximal FL Runx1 as 
compared to distal FL transduced cells. In contrast, the (Δ3-14) deletion mutant showed a 
significant decrease of the live/GFP+/CD11b+/Gr1+ population as compared to distal FL 
transduced cells.  The (Δ3-19) deletion mutant and the point mutants S3A/S5A, and 
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S3A/S5A/F7A all showed an increased proportion of CD11b+/Gr1+ cells as compared to 
distal full-length though this was not statistically significant. The (Δ3-8) deletion mutant 
showed a decreased percentage of CD11b+/Gr1+ cells as compared to distal full-length, 
though this decrease was not statistically significant. 
 Experimental variability due to infection efficiency, long term cell culture, and 
flow cytometry analysis prevented significant experimental analysis. Individual 
experiments each displayed a similar pattern of increased proportion of neutrophils in the 
proximal compared to the distal transduced populations. The percentage of the 
live/GFP+/CD11b+/ Gr1+ population of proximal Runx1 transduced cells compared to 
distal Runx1 transduced cells across independent experiments was significantly higher, 
ranging between 2% to 13%. The percentage of the live/GFP+/CD11b+/ Gr1+ population 
of (Δ3-8) and (Δ3-14) transduced cells compared to distal Runx1 transduced cells across 
independent experiments was lower, ranging between -2% to 10% and -3% to 7% 
respectively.  The S3A/S5A and S3A/S5A/F7A point mutants and the (Δ3-19) deletion 
mutant produced a trend towards a proximal like phenotype across experiments; however 
the percentage of these live/GFP+/CD11b+/Gr1+ populations compared to distal FL 
within experiments was not consistently higher or lower, ranging between -21.7% to 
+22.5%, -3% to +6%, and -12% to +33% respectively.  The experimental variation of the 
percentage of live/GFP+/CD11b+/Gr1+ cells was an obstacle to a significant correlation 
between the results from the 32Dcl.3 experiments and the bone marrow ex vivo 
experiments.  
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Discussion 
 
 The requirement for Runx during definitive hematopoiesis was demonstrated in 
mouse knockout experiments where the phenotype was lethal at embryonic day 12.5 (88). 
Adult hematopoiesis has been examined with reversible knockout systems and a Runx1 
knock-in mouse where the expression of Runx1 can be followed with a GFP marker (98, 
152).  Perturbations of Runx DNA binding activity or its association with other 
regulatory proteins are correlated with leukemia, immuno-suppression, and a deficiency 
in platelets (153).  These systems have illuminated the importance of spatial-temporal 
expression of Runx in myeloid and lymphoid precursors but do not address the function 
of Runx N-terminal isoform activity during these stages of development. 
 Expression and regulation of Runx1 activity is a complex and tightly controlled 
program essential to the differentiation of all hematopoietic cell lineages (45). This study 
examined the relatively short N-terminus that contributes to subtle differences in the 
progression of hematopoietic differentiation. Deletion and mutation of conserved residues 
within the distal Runx1 N-terminus led us to conclude that the distal N-terminus contains 
a negative regulatory motif that functions to abrogate the default differentiation program 
supported by the proximal N-terminus. Removal of amino acids (Δ3-14) is sufficient to 
mimic a proximal Runx1 phenotype in the 32Dcl.3 cell line 
 Runx1 is critical for the developmental regulation of myeloid differentiation via 
expression of differentiation specific granule proteins, and proliferation by inhibiting 
p21CIP1 (27, 32). The 32Dcl.3 cell line is a well-established in vitro system for the study 
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of myelopoiesis due to its state of being poised on the brink of differentiation. The initial 
observation of a difference in proximal and distal activities was first demonstrated in 
these cells (14). Distal Runx1 binds DNA with a higher affinity, though in the 32Dcl.3 
neutrophil precursor cell line the proximal isoform shows a greater effect. 
 Here, we recapitulated the proximal phenotype of delayed terminal differentiation 
and continued proliferation by deletion of amino acids (Δ3-14) or the entire distal N-
terminus (Δ3-19).  Furthermore, in this cell line we found deletion of amino acids (Δ3-8) 
or mutation of serines 3 and 5 in the S3A/S5A and S3A/S5A/F7A point mutants 
significantly decreases the expression of Runx1.  Point mutations of key residues in the 
distal N-terminus had an opposite effect to the gross deletion of sections of the N-
terminus, indicating that the distal N-terminus may be regulated via more than one 
mechanism. 
 Over-expression of Runx increases the rate of differentiation in the in vitro 
systems used here (154). The majority of the GFP+ cells examined in primary bone 
marrow in vitro cultures have reached a mature stage of development as determined by 
CD11b cell surface marker.  The proportion of mature neutrophils is increased by 
expression of the proximal Runx1 N-terminal isoform in each of the systems assayed in 
this study. The enforced expression of proximal Runx1 in the committed 32Dcl.3 
myeloid cell line clearly delays the terminal differentiation of the immortalized cell line, 
whereas in primary cells the phenotype is subtle.  The point mutations of evolutionarily 
conserved residues S3A/S5A or S3A/S5A/F7A showed intermediate statistically 
insignificant phenotypes in vivo or low protein expression in vitro.  The F7A mutant did 
57 
not affect viability or proliferation index in 32Dcl.3 cells and was only used in one bone 
marrow infection experiment and could not be statistically analyzed. 
 The whole bone marrow used in the ex vivo culture system contain less derived 
neutrophil progenitors cells than the myelocyte stage represented by the 32Dcl.3 cell line, 
which suggests that the role of Runx1 N-terminal isoform activity in myeloid 
differentiation is stage specific.  Runx1 expression studies in transgenic mice have shown 
that enforced expression of Runx1 in HSCs and progenitor cells does not increase the 
cellularity of the population.  However, enforced expression of Runx1 in the late stages 
of granulocytic differentiation did produce a significant increase in cellularity (96). 
 In the bulk sorted long-term culture of stably transfected 32Dcl.3 cells, the 
deletion of (Δ3-8), or mutation of the serines in the S3A/S5A and S3A/S5A/F7A mutants 
resulted in very low expression of HA-tagged Runx1 in the GFP+ population (Figure 11).  
The impaired expression of proteins is a cumulative result of transcription, translation 
efficiency, co-translational modifications and post-translation stability. 
 All of the Runx1 constructs used in these experiments are expressed from the 
MSCV-IRES-GFP vector.  Transcription from this vector creates a single mRNA 
transcript encoding two proteins.  The presence of GFP translated from mRNA 
downstream of Runx1 in all of the cell lines indicates that transcriptional efficiency from 
this vector is not the root cause of the differences seen in protein expression.  This 
conclusion should be tested experimentally by Northern blot or RT-PCR to detect the 
presence of Runx1 mRNA. 
 Translational efficiency is mediated by sequence specificity and mRNA 
secondary structure.  The Runx1 constructs cloned into the MSCV-IRES-GFP vector 
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contain a consensus GCCRCCaugG Kozaks sequence flanking the initiating AUG start 
codon that supports efficient translation in eukaryotes (155). Mutations to this consensus 
sequence, in particular the purine at -3 upstream of the AUG start codon or the G at +4 
downstream of the AUG start codon, can reduce translation up to 20 fold (156).  The 
distal Runx1 deletion and mutation constructs all maintain +4 position by retaining the 
Met-Ala encoding 5’ATG GCT sequence (Figure 8).  It has been hypothesized that the 
increased translational efficiency provided by the 5’ Kozaks sequence is due to a physical 
interaction with the ribosome that slows scanning of the mRNA, an effect that could also 
be caused by the secondary structure of the mRNA (157).  A hairpin structure 
approximately 15 bp downstream of the start codon, approximately the footprint of the 
ribosome, has been shown in mutation experiments to promote efficient translation (158). 
The distal FL construct used in these experiments has no predicted secondary structure in 
the first 10 bp, but does include a hairpin at approximately 10-15 bp and would be 
efficiently translated according to this model (Figure 15 A).  The (Δ3-8), S3A/S5A and 
S3A/S5A/F7A mutants all contain secondary hairpin base pairing within the first 15 bp, 
which may pose a hindrance to initiation of translation (Figure 15 B-D). 
 Several studies have identified differences in translation of two genes from 
bicistronic vectors such as MSCV-IRES-GFP.  In general, the gene under IRES mediated 
cap-independent control is translated less efficiently than the cap-dependent gene (159). 
A second AUG codon downstream of the true start codon can also inhibit efficient 
translation from a bicistronic vector (160).  However, both of these detriments to efficient 
translation do not appear applicable to the expression of Runx1 from MSCV-IRES-GFP 
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as the GFP transcript is under translational control from the IRES sequence and the 
Runx1 constructs do not possess the specific second downstream methionine. 
 In eukaryotes there are several protein modifications to proteins that occur co-
translationally that modulate post-translational protein stability.  N-terminal methionine 
excision occurs as the nascent protein emerges from the ribosome and is dependent on the 
radius of gyration, or size, of the penultimate amino acid residue.  Alanine is the most 
common indicator of methionine excision, but other residues including serine, glycine, 
cysteine, threonine, proline, and valine also permit methionine cleavage.  Recent 
proteomics studies have indicated that residues at the P1’, P2’, and P3’ positions, 
methionine being P1, also influence whether methionine is efficiently cleaved by 
methionine aminopeptidase (MAP).  Residues at the P2’ and P3’ positions, including 
isoleucine, proline, aspartic acid and glutamine, inhibit efficient cleavage of the N-
terminal methionine by MAP (161).  Acetylation of the N-terminus by N-terminal 
acetyltransferases (NATs) is a second co-translational modification that also affects the 
stability of proteins that commonly occurs after methionine excision when 15-20 amino 
acid residues have exited the ribosome.  The most commonly acetylated N-terminal 
residues are alanine and serine, though methionine, glycine and threonine residues can 
also be acetylated (162). N-terminal acetylation is context specific, where the acetylation 
of a specific amino acid motif is not guaranteed and may either promote protein stability 
or ubiquitin mediated degradation (163, 164).  
 The N-end rule pathway is an ubiquitin dependent proteolytic pathway for the 
targeted degradation of proteins containing a destabilizing N-degron sequence.  The three 
main components of the ubiquitin pathway are the ubiquitin activating enzyme (E1), 
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ubiquitin conjugating enzyme (E2), and the component that confers substrate specificity, 
ubiquitin ligase (E3). Specific residues in the N-terminus of specifically short-lived 
proteins act as a signal for degradation known as an N-degron. The destabilizing N-
degron may be present in the nascent peptide or created by N-terminal modification such 
as cleavage of the N-terminal methionine revealing an N-degron (165). The primary 
destabilizing residues of N-degrons are divided into two classes; Type 1 residues include 
basic arginine, lysine and histidine; Type 2 residues include hydrophobic phenylalanine, 
tyrosine, tryptophan, leucine and isoleucine (Figure 15 E).  There is also an alternative 
pathway of arginylation where an arginine residue is added to an aspartic acid or glutamic 
acid residue to form a Type 1 N-degron.  The initial methionine cleavage event is protein 
N-terminal methionine excision that is regulated by two methionine aminopeptidases, 
MAP1 and MAP2.  The specificity of MAP1 and MAP2 is known to be determined by 
the initiating methionine (P1) and the following three amino acids P1’, P2’ and P3’.  
Alanine, serine and phenylalanine residues mediate highly efficient cleavage of the N-
terminus while other residues such as aspartic acid, isoleucine, proline, and glutamine 
confer resistance to cleavage (161).   
 The proximal Runx1 N-terminal isoform contains an arginine at position P1’, 
indicating a low probability of methionine cleavage, though there is the possibility of 
acetylation of the N-terminal methionine (Figure 15 E).  Distal Runx1 and all of the 
associated mutants contain an alanine at position P1’ which indicates a high probability 
of methionine cleavage.  However, the low expression of some of these constructs 
suggests a role for the residues at positions P2’ and P3’ in the regulation of methionine 
cleavage.  If the methionine is cleaved from the distal constructs, the exposed alanine is 
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also a high probability target for acetylation of all of these constructs.  An analysis of the 
N-terminal sequences of the (Δ3-8), S3A/S5A and S3A/S5A/F7A constructs provide 
clues about potential reasons why these constructs are poorly expressed.  The (Δ3-8) 
region contains the evolutionarily highly conserved residues serine 3’, serine 5’, and 
phenylalanine 7’ which may serve to stabilize the full length Distal isoform activity via 
phosphorylation (45).  The (Δ3-8) deletion results in three residues that promote highly 
efficient methionine cleavage and possible degradation of the protein. Serine residue 
mutation at positions 3’ and 5’ resulted in a pair of efficiently catalyzed alanine residues 
at both position P1’ and P2’.  Deletion of amino acids (Δ3-14) and (Δ3-19) both contain 
stabilizing residues at position P2’ while the F7A mutant, proximal FL and distal FL 
contain stabilizing residues at position P3’ (Figure 15 E).  The results of proteomic 
analysis of sequences susceptible to N-end rule degradation varies widely between 
species and cell types (166).  It is possible that the long-term cultures in the neutrophil 
environment of the 32Dcl.3 cell line are particularly conducive to the degradation of 
proteins by the ubiquitin and MAP regulated pathways. 
 In conclusion, it is likely a combination of inhibited translational efficiency and 
altered protein modification of the (Δ3-8), S3A/S5A, and S3A/S5A/F7A N-terminal 
mutants that contributes to low protein expression in the 32Dcl.3 cell line (Figure 11).  
Further experiments utilizing protease inhibitors during the propagation and 
differentiation of the 32Dcl.3 cell line should be performed to elucidate whether protein 
stability is a factor in the low protein expression of the (Δ3-8), S3A/S5A, and 
S3A/S5A/F7A N-terminal mutants. 
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 The cells transduced with the proximal Runx1 isoform display increased 
proliferation and viability that is abrogated by the presence of amino acids 3’ to 14’ of the 
distal N-terminus (Figure 12, Figure 13). The ex vivo differentiation of neutrophils 
consistently display a pattern similar to the 32Dcl.3 cell lines increased neutrophil 
expression induced by the proximal Runx1 isoform and distal mutant constructs, but the 
differences in the percentage of live/GFP+/CD11b+/Gr1+ cells are slight for the proximal 
and deletion mutant transduced cells, and not statistically significant for the point mutants 
that were evaluated (Figure 14). 
 This study supports the idea that Runx1 isoforms play specific roles at key stages 
of hematopoietic development.  These data further elucidate the role of the proximal and 
distal isoforms in regulating various stages of hematopoiesis. Expression of the proximal 
Runx1 isoform in a situation of immunologic challenge in both the myeloid cell 
compartments could lead to an enhanced cellular response due to increased proliferation 
and survival of neutrophils. 
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Figure 8 Runx1 N-terminal evolutionary conservation, deletion, and point mutant 
constructs 
 
(A) The distal and Proximal N-terminal Runx1 sequences are highly conserved across 
species. Top Panel: Gray box indicates 100% identity of known proximal Runx1 paralogs 
and orthologs. Bottom Panel: The three residues in bold, serine 3’, serine 5’, and 
phenylalanine 7’, are conserved across all known distal Runx1 paralogs and orthologs. 
Mus musculus – mouse (Runx1: distal - NP_001104491, proximal - NP_001104493) 
(Runx2: distal - NP_001139510, Proximal - NP_001139392) (Runx3: distal – 
NP_062706, proximal - AL731718); Homo sapiens – human; (distal - NP_001745, 
proximal - NP_001001890); Raja eglanteria – skate (proximal - AAR11381); Xenopus 
laevis – frog (distal – NP_001079966); Gallus gallus – chicken (distal - NP_990558); 
Danio rerio – zebra fish (distal - NP_998023), Bos taurus – cow (distal - XP_870864); 
Scyliorhinus canicula – dogfish (distal - ABL68113); Takifugu rubripes -  pufferfish 
(distal - NP_00109212) (B) Serial nested deletions and point mutations of conserved 
residues in the distal N-terminus were created via PCR mutagenesis. The residues in bold 
represent deletions (Δ3-8), (Δ3-14), and (Δ3-19) or mutations to alanine (S3A/S5A/F7A, 
S3A/S5A, and F7A). 
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Figure 9 Bulk sorted 32Dcl.3 populations express GFP as determined by FACS 
analysis. 
 
32Dcl.3 cells were transduced with a GFP bicistronic retroviral vector encoding the 
indicated proximal or distal constructs, and sorted by flow cytometry to >94% GFP+. 
32Dcl.3 populations were subsequently analyzed individually for bulk GFP expression. 
67
68
69 
 
Figure 10 Bulk sorted 32Dcl.3 populations express HA-tagged Runx1 mutants as 
visualized by fluorescence microscopy 
 
32Dcl.3 cells express Runx1 mutants. 32Dcl.3 cells were transduced with a GFP 
bicistronic retroviral vector encoding the indicated constructs and sorted by flow 
cytometry. (A) Proximal FL, distal FL, (Δ3-8), (Δ3-14), and (Δ3-19).  (B) F7A, 
S3A/S5A, S3A/S5A/F7A and non-transduced 32Dcl.3 cells were stained for a negative 
control. Cells were sorted for GFP expression, stained with nuclear dye DAPI, and anti-
HA Texas Red.  DAPI and anti HA images were merged (4). 
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Figure 11 Mutation or deletion of N-terminal residues altered Runx1 protein 
expression. 
 
Runx1 transduced bulk-sorted 32Dcl.3 populations were analyzed for levels of GFP 
expression and HA-tagged Runx1 expression via flow cytometry. The percentage of HA+ 
cells within the GFP+ population is a measure of Runx1 expressed from the bicistronic 
MSCV vector within individual transduced 32Dcl.3 populations. Cells were stained with 
anti-HA conjugated to APC. Asterisks indicate low expressing Runx1 mutants. Values 
represent the mean, and error bars the standard error of the mean for N=3 independent 
experiments.  
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Figure 12 Cell Counting Assay 
 
Stable retrovirally transduced GFP+ sorted 32Dcl.3 cell populations were treated with G-
CSF, harvested and live cells counted via trypan blue exclusion after 24, 48, and 72 
hours. Proximal FL, Distal FL, and 32Dcl.3 data are shown alone (A) in comparison with 
deletion mutants (Δ3-8), (Δ3-14), (Δ3-19) (B), and in comparison with point mutants 
F7A, S3A/S5A, S3A/S5A/F7A(C).  Values represent the mean, and error bars the 
standard error of the mean. N=3 per data point. 
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Figure 13 Deletion of (Δ3-14) and (Δ3-19) of the distal Runx1 N-terminus promotes 
the prolonged proliferation phenotype observed in proximal Runx1 transduced 
32Dcl.3 cell populations. 
 
Retrovirally transduced GFP+ sorted 32Dcl.3 cells were treated with G-CSF and pulsed 
with 1 µC/ well of 3H at 0, 24, or 48 hours and harvested after 24 hours of thymidine 
incorporation at 24 hours (A), 48 hours (B), and 72 hours (C). The horizontal bar 
represents mean. Significant decreases (24 and 48 hours) and increases (72 hours) 
compared to Distal FL are indicated with brackets. Significant values: p < .01 from a 
two-tailed t-test. The experiment was performed in triplicate with N=3, two experiments 
shown. 
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Figure 14 Bone marrow derived myeloid precursors transduced with Runx1 N-
terminal mutants differentiated ex vivo 
 
Whole bone marrow myeloid precursors stimulated with G-CSF proceed through 
successive differentiation stages into neutrophils characterized by surface markers as first 
CD11b and then Gr1 (LY6G) are expressed. FACS analysis of transduced AML +/- bone 
marrow differentiated in the presence of stem cell factor (SCF) and G-CSF for 5 days. 
The plots were gated sequentially for viability using 7AAD, Runx1 mutant expression via 
GFP from the bicistronic MSCV vector, and CD11b.  The bar graph values represent the 
mean, and error bars the standard error of the mean of live/GFP+/CD11b+/Gr1+ cells of 
the proximal FL, distal deletion mutants, and distal point mutants transduced cells minus 
the percentage of live/GFP+/CD11b+/Gr1+ cells of the distal full length transduced cells. 
Significant increase (Proximal FL) and decrease (Δ3-14) compared to Distal FL are 
indicated with brackets. Significant values: p < .05 from a two-tailed t-test. The FACS 
plots and bar graph are representative of N=3 experiments. 
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Figure 15 Secondary mRNA structure and N-end rule substrates 
 
Deletion of amino acids (Δ3-8) or mutation of serine 3’and serine 5’ alter potential N-
terminal secondary structure of Runx1 constructs. (A) Arrows in red indicate predicted 
hairpin structure 10 bases downstream of the initiating codon.  (B-D) Arrows in red 
indicate the 5’ start codon immediately upstream of the predicted hairpin structure. (E) N-
degron substrates may be created by an initiating methionine cleavage revealing a set of 
P1, P1’, P2’, and P3’ substrates. Residues highlighted in red confer increased 
susceptibility to methionine cleavage. Residues highlighted in blue confer resistance to 
cleavage. 
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CHAPTER 4 
RUNX1 MEDIATED TRANSCRIPTION COMPLEX 
KIR Bidirectional Promoter System 
 
 The promoter regions of the KIR genes include binding sites for many 
transcription factors. Despite the high sequence homology of the cis-acting elements of 
KIR gene promoters there are significant functional and structural differences that lead to 
variegated expression patterns (132). KIR2DL4 and KIR3DL1 promoters require distinct 
transcriptional co-factors for expression (128). This suggests a role for transcription 
factors in recruiting a specific repertoire for the activation and or suppression of 
expression. Binding sites for AML, Ets, SP1, CRE and STAT have all been identified to 
have varying degrees of redundancy and additive effects on the expression of individual 
KIR genes (133). The activity of KIR promoters is complicated by methylation status, 
transcription factor binding sites, and protein-protein interactions that ultimately regulate 
expression of specific KIR genes. These prior experiments focus on the deletion of Runx 
promoter binding sites, but do not specifically address the role of specific Runx family 
members in the regulation of this locus.   
 Transcription factors may be regulated via their ability to effectively bind DNA.  
In the case of the Runx transcription factors, heterodimerization with CBFβ co-factor 
increases DNA binding affinity 40-fold. The Ets-1 transcription factor can increase the 
DNA binding affinity of Runx, independent of CBFβ, 10-fold. This effect is reciprocal as 
the presence of Runx increases the DNA binding affinity of Ets-1 10-fold (41, 167). Ets1 
contains an auto-inhibitory domain that is normally in a ‘closed’ conformation and 
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prevents DNA binding. Structural studies of Ets1 bound to DNA show this Ets1 
inhibitory region to adopt an open conformation, indicating a requirement for a structural 
shift prior to DNA binding (42). The mutual increase in DNA binding of AML1 and Ets1 
occurs through the direct interaction of their auto-inhibitory regulatory domains (43). The 
interaction with the auto-inhibitory region of Ets1 is achieved via two Runx1 domains; 
one region is N-terminal to amino acid 41, and a second region between amino acids 190 
- 214. These interactions are independent of the heterodimerization with CBFβ (41, 43, 
167) Many of the KIR genes within the cluster contain both proximal and distal putative 
promoter elements. Some KIR genes, such as KIR3DL1, are regulated by a proximal 
bidirectional promoter system. The forward orientation produces functional transcripts 
found throughout differentiation of NK cells. Reverse transcripts are not found in mature 
NK cells, suggestive of a role for reverse transcription in blocking expression of KIR in 
immature NK precursors.  Minimal promoter regions containing an AML binding site 
display a bias towards the reverse promoter.  Deletion of ETS and AML together 
decrease promoter activity (131).  
 The transcription factor Yin Yang 1 (YY1) regulates the expression of many 
target genes during differentiation, in particular the globin genes during hematopoiesis 
(168).  YY1 knockout mice reveal an embryonic lethal phenotype due to defects in 
embryonic tissue development (169).  Retroviral insertion mutagenesis causing AML in 
mice is linked with disruption of the YY1 gene.  YY1 is highly expressed in the myeloid 
32D cell line during IL3 stimulated proliferation, but is reduced when the cells are 
induced by G-CSF to differentiate.  Interestingly, over-expression of YY1 delays 
terminal neutrophil differentiation of the 32D cell line, indicating a correlation with 
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Runx1 activity (170). The NK cell transcription factor milieu provides functional 
redundancy for the regulation of KIR expression by complex interactions between 
transcription factors including Runx1, Ets1, and YY1 (133). Though Runx1 and YY1 are 
expressed together in specific cellular contexts, the interactions between them are 
unclear.  
 The minimal promoter region is an overlapping site of initiation for sense 
(forward) and anti-sense (reverse) transcripts, which is the basis for a stochastic method 
for regulation of KIR3DL1 expression.  The promoter region contains consensus binding 
sites for Creb, Sp1, Ets, YY1, and AML/Runx transcription factors as confirmed by 
sequencing (Figure 16) and previous reports (131, 171). Previous experiments have 
focused on the definition of promoter sequences to indirectly identify the role for 
transcription factors in the regulation of gene expression. Here, we expressed 
transcription factors individually and in combination to directly assess their roles in 
regulation of KIR gene expression using a dual luciferase assay system. 
 The dual luciferase assay system was used in a series of experiments to further 
define the role of important functional domains within the distal Runx1 N-terminus and 
C-terminus in regulating KIR expression.  Triple transfections with a forward or reverse 
KIR3DL1 promoter luciferase construct, renilla transfection control, and wild type or 
mutant Runx1 MSCV construct were carried out with the 293T cell line.  Utilizing the 
adherent 293T cell rather than an NK cell line, such as the YT cell line, had the 
advantage of eliminating the confounding endogenous, stage specific milieu of 
transcription factors.  In this system, individual Runx1 isoforms and mutants, as well as 
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additional transcription factors YY1 and Ets1, may be expressed individually or in 
combination to assess activity on both the forward and reverse promoter. 
 
Runx1 proximal and distal Isoforms repress transcription of the forward KIR3DL1 
proximal bidirectional promoter 
 
 Transfection of Runx1 with the KIR promoter region globally displayed a bias 
towards transcripts in the reverse direction (Figure 17 B, C).  The primary activity of both 
wild-type proximal and distal Runx1 was to repress transcription from the forward 
promoter; transcription from the reverse promoter in the presence of Runx1 was 
negligible compared to empty vector control.  Disruption of the runt DNA binding 
domain by deletion (d.49), or mutation (K167A) eliminated repression by Runx1 on the 
forward promoter. Deletion or mutation of conserved residues within the distal N-
terminus did not affect the repressive activity of Runx1 alone on either the forward or 
reverse promoter and were not significant compared to the proximal Runx1 isoform 
(Figure 17 D, E). The domains necessary for the repressive activity of Runx1 on both the 
forward and reverse promoters were located in the C-terminus.  Deletion of the entire C-
terminus (d.190) permitted activity of both the forward and reverse promoters (Figure 17 
F, G). Specific disruption of the Runx1 region containing the C-terminal nuclear matrix 
targeting sequence (NMTS) (d.263-360) significantly reduced Runx1 repression of the 
forward promoter and allowed activation of the reverse promoter. The d.263-360 deletion 
showed greater specific function for the reverse promoter compared to the forward 
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promoter (Figure 17 G).  Deletion of the Groucho/TLE binding domain (d.446) had no 
effect on either the forward or reverse promoters (Figure 17 F, G).  
 
Runx1 mediated dominant repression of the KIR3DL1 promoter is reduced by Ets1 
 
 Transfection of Runx1 with Ets1 and the KIR promoter region globally displayed 
a reduction of Runx1 mediated repression of both forward and reverse transcripts (Figure 
18).  The bias towards transcription in the reverse was maintained in the presence of Ets1 
and Runx1 in combination.  Ets1 expressed alone strongly activated expression of both 
forward and reverse transcripts (Figure 19).  However, Runx1 appeared to be dominant to 
Ets1 despite the modest decrease in the repressive function of Runx1 in the presence of 
Ets1. 
 Three distinct Runx1 domains regulated the activity of Ets1: an N-terminal site of 
protein-protein interaction, the Runt DNA binding domain, and a C-terminal inhibitory 
domain.  Disruption of the DNA binding domain of Runx1 (d49 and K167A) was 
sufficient to reduce Ets1 activation of both forward and reverse transcripts (Figure 18 B, 
C). The d.49 fragment can neither bind to DNA nor dimerize with CBFβ, but was capable 
of significantly reducing Ets1 mediated activity of both the forward and reverse promoter 
transcripts. 
 Disruption of the distal N-terminus uncoupled the influence of Ets1 on KIR 
promoter activity. Deletions of the distal N-terminus, (∆3-14) or (∆3-19), enhanced 
repression of the forward KIR promoter (Figure 18 D) and in the case of (∆3-14) were 
independent of Ets1 (Figure 19 D). However, specific mutation of conserved N-terminal 
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residues did not significantly alter Runx1: Ets1 interactions, highlighting the importance 
of the N-terminus as a whole as opposed to specific residues. 
 The C-terminus of Runx1 was a negative regulator of Ets1 activity for both the 
forward and reverse directions. The d.190 mutant, encoding the runt DNA binding 
domain but no C-terminus, was unable to repress Ets1 mediated transcripts from either 
the forward or reverse KIR promoters (Figure 19 F, G).  The inhibitory domain for Ets1 
activity on the reverse promoter mapped to the C-terminal region spanning 212-360, 
where the two mutants, d.212-263 and d.263-360, displayed de-repressed forward 
promoter activity and no significant difference in activity compared to Ets1 on the 
reverse promoter (Figure 19 F, G). 
 
Runx1, Ets1, and YY1 
 
 Here, we continued the assessment of the KIR3DL1 proximal bidirectional 
promoter by examining the cumulative effects of three transcription factors in 
combination, Runx1, Ets1, and YY1. As mentioned previously, Ets1 by itself was a 
strong activator of both forward and reverse transcripts from the KIR3DL1 proximal 
bidirectional promoter (Figure 19).  YY1 alone as well was an equally strong activator of 
expression of forward and reverse transcripts, while in combination the two transcription 
factors displayed an additive increase (Figure 20 A, B).  YY1 acted dominantly and 
independently of the presence of Runx1, as the presence of Runx1 had no diminishing 
effect on activation of either forward or reverse transcripts (Figure 20 C, D). Therefore, 
Runx1-mediated repression activity on the KIR3DL1 promoter was a combination of Ets1 
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activation of forward and reverse transcript expression (Figure 20 E, F) and independent 
activation regulated by YY1 (Figure 20A, B). 
 
Discussion 
 
 In these experiments, we showed that Runx1 acted as a modulator of 
transcriptional activity of the KIR3DL1 proximal bidirectional promoter.  Our 
experiments further defined the relationship of Runx1 and Ets1. We showed that the bias 
towards reverse transcripts is a function of Runx1 repression of the forward promoter. In 
addition, the decrease in activity seen with deletion of Runx1 and Ets1 binding sites was 
the result of elimination of Ets1 activity, as Runx1 functioned as a repressor of transcript 
expression. 
 The DNA binding mutants shown in our experiments, d.49 and K167A, further 
support the idea that Runx1 and Ets1 have three important physical interactions (Figure 
21). The distal (∆3-14) deletion enhanced repression of the forward KIR promoter and 
was independent of Ets1 activity.  Deletion of the Runt DNA binding domain did not 
inhibit the ability of d.49 to repress Ets1 activity, indicating a role for the N-terminal 
motif in the structural shift required for Ets1 to bind DNA (Figure 21). The C-terminal 
region upstream of the NMTS (263-360) appeared to be necessary for the repression of 
Ets1 activity while bound to the promoter (Figure 21). 
 Our findings present a baseline of activity for Ets1, YY1, and Runx1 outside of 
the cellular milieu specific for sequential stages of differentiation (Figure 22). Reverse 
KIR transcripts are present in immature NK cells and absent in mature NK cells (131).  In 
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this context, we hypothesize a spatio-temporal model of KIR gene control where the 
expression of Runx1 acts to repress the expression of KIR genes in developing NK cells 
by global bias toward inactive reverse transcripts (Figure 22). Upon signaling for 
differentiation the NK precursor would up-regulate activators of expression such as Ets1 
and YY1 and down-regulate the expression of Runx1 (Figure 22).  The stochastic method 
of regulation of KIR proteins provides evidence of a mechanism for the expression of a 
repertoire of NK cells individually expressing a distinct sub-set of KIR receptors for the 
surveillance of MHC class I receptors. 
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Figure 16 Schematic of the KIR3DL1 proximal bidirectional promoter element 
 
A schematic of the KIR3DL1 bidirectional promoter element highlighting relative 
positions of binding sites for Stat, Ets, Creb, Sp1, YY1, and Runx transcription factors. 
Transcription can be initiated in the forward direction, creating transcripts of the 
KIR3DL1 gene, or the reverse direction, creating non-functional reverse transcripts as 
indicated by arrows. Transcription in the reverse direction inhibits KIR3DL1 expression 
in developing NK cells. The numbers on the ends of the promoter fragment indicate the 
distance upstream of the transcriptional start codon (131, 171). 
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Figure 17 DNA binding and C-terminal domains are required for Runx1 mediated 
activity of the KIR3DL1 promoter. 
 
The 293T cell line was transfected with Runx1 constructs (A), renilla, and KIR3DL1 
luciferase reporter and harvested at 48 hours. Runx1 full-length N-terminus and DNA 
binding mutants (B, C), N-terminal deletion and point mutants (D, E), and C-terminal 
deletion mutants (F, G) were tested for activity on the forward (B, D, F) and reverse (C, 
E, G) KIR3DL1 promoter fragment. The relative luciferase activity was corrected using a 
renilla transfection control and normalized to the activity of the KIR3DL1 promoter 
alone. Values represent the mean, and error bars the standard error of the mean. Columns 
marked with an asterisk indicate a p≤0.05 from a one-tailed t-test. 
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Figure 18 Runx1 repression opposes Ets1 transactivation of the KIR3DL1 forward 
and reverse promoters 
 
The 293T cell line was transfected with Runx1 constructs (A), renilla, Ets1, and 
KIR3DL1 luciferase reporter and harvested at 48 hours. Runx1 full-length N-terminus 
and DNA binding mutants (B, C), N-terminal deletion and point mutants (D, E), and C-
terminal deletion mutants (F, G) were tested for activity on the forward (B, D, F) and 
reverse (C, E, G) KIR3DL1 promoter fragment alone and in combination with Ets1. The 
relative luciferase activity was corrected using a renilla transfection control and 
normalized to the activity of the KIR3DL1 promoter alone. Values represent the mean, 
and error bars the standard error of the mean. Boxes indicate Runx1 constructs with 
insignificant change of normalized luciferase activity in combination with Ets1. Columns 
marked with an asterisk indicate a p≤0.05 from a one-tailed t-test. 
94
95 
 
Figure 19 Ets1 activates expression from the KIR3DL1 promoter and reduces 
expression mediated by Runx1 
 
The 293T cell line was transfected with Runx1 constructs (A), renilla, Ets1, and 
KIR3DL1 luciferase reporter and harvested at 48 hours. Runx1 full-length N-terminus 
and DNA binding mutants (B, C), N-terminal deletion and point mutants (D, E), and C-
terminal deletion mutants (F, G) were tested for activity on the forward (B, D, F) and 
reverse (C, E, G) KIR3DL1 promoter fragment in combination with Ets1. The relative 
luciferase activity was corrected using a renilla transfection control and normalized to the 
activity of the KIR3DL1 promoter alone. Values represent the mean, and error bars the 
standard error of the mean. Columns marked with an asterisk indicate a p≤0.05 from a 
one-tailed t-test. 
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Figure 20 Activation of the KIR3DL1 promoter by YY1 is additive with ETS, and 
independent of Runx1. 
 
The 293T cell line was transfected with the indicated transcription factors and harvested 
at 48 hours. Activity of the KIR3DL1 promoter in the presence of Ets1 and YY1 alone 
and in combination (A, B); Runx1 and YY1 (C, D); Runx1 and Ets1 (E, F) were tested 
for activity on the forward (A, C, E) and reverse (B, D, F) KIR3DL1 promoter fragment.  
The relative luciferase activity was corrected using a renilla transfection control and 
normalized to the activity of the KIR3DL1 promoter alone. Values represent the mean, 
and error bars the standard error of the mean. Columns marked with an asterisk indicate a 
p≤0.05 from a one-tailed t-test. 
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Figure 21 Runx1 and Ets1 interaction on the KIR3DL1 bidirectional promoter is 
regulated by three Runx1 domains 
 
The N-terminal motif  (N-TM) between amino acids 3’ to 14’, Runt DNA binding 
domain, and the nuclear matrix targeting sequence (NMTS) domain are necessary for 
Runx1-Ets1 interactions on the KIR3DL1 bidirectional promoter. Wild-type Runx1 
interaction with Ets1 is shown in the dark blue box. Light blue boxes indicate activities 
specific to Ets1, light green boxes indicate alterations of activity due to Runx1 mutants. 
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Figure 22 Model of transcription factor complex regulation of the proximal 
KIR3DL1 bidirectional promoter 
 
Full length Runx1 represses transcription of the forward KIR3DL1 transcript and has no 
effect on reverse transcription, leading to a global bias for repression of KIR3DL1 
expression. YY1 and Ets1 both activate forward and reverse transcription individually, 
and can additively increase activation in both directions. YY1 and Runx1 act 
independently from each other, while Runx1 may repress Ets1 activity via direct protein 
interactions. N-TM refers to the N-Terminal motif. 
102 
 
CHAPTER 5 
OP-9 THYMOCYTE CO-CULTURE PRELIMINARY DATA 
 
 The differentiation of T-cells is dependent on external signals provided by the 
unique environment where they are produced. The thymus consists of epithelial stromal 
cells, macrophages, and dendritic cells that are all crucial for the development, education 
and maturation of immature thymocytes.  Early in vitro studies of thymocyte 
differentiation and maturation relied on the technique of Fetal Thymic Organ Culture 
(FTOC) in which a fetal thymus is utilized as a platform with all of the necessary 
molecular signals required for normal thymocyte development (172).  The discovery of 
the role of Notch signaling in the early steps of T cell lineage commitment allowed for 
new in vitro methods to study T-cell development (173). Notch receptors on developing 
thymocytes bind to Jagged and Delta-like Notch ligand on neighboring stromal cells, thus 
inducing a program of differentiation for the T-cell lineage.  A stromal cell line 
ectopically expressing Delta-like Notch ligand is sufficient to signal and support the 
thymocyte program of differentiation leading to DP and SP T-cells (174). Notch1 and 
Runx1 are both essential for definitive hematopoiesis, though Runx1 has the ability to 
rescue Notch1 deficient thymocytes in an OP-9 stromal line co-culture (175). Runx1 may 
be a key downstream target of Notch1 signaling during early hematopoiesis and 
thymocyte development. The nature of the effect of Notch1 on Runx1 is unclear though 
suggestive of Notch1 regulation of both Runx1 expression and transcriptional activation. 
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 Runx1 mediated repression of CD4 in thymocytes is dependent on two C-terminal 
domains.  As discussed previously, the NMTS is a C-terminal domain of Runx proteins, 
localized between amino acids 263-360 of Runx1, which targets the transcription factor 
to specific sub-nuclear foci.  These foci are fixed in both nuclear position and number, 
providing evidence of the importance of Runx1 as a regulator of the nuclear environment 
as well as highlighting yet another level of control for the activity of Runx1 (176).  
Disruption of the Runx1 NMTS domain alleviated Runx1 mediated repression and 
permitting expression of CD4, evidence that the proper sub-nuclear localization of Runx1 
is critical for its function on the CD4 silencer (121).  The targeted deletion of another C-
terminal domain, located between amino acids 212-262, is also sufficient for the 
disruption of Runx1 mediated CD4 silencing.  The function of this region is unknown, 
though it is distinct from the NMTS, indicating that it may be a binding site for co-
repressors independent of Groucho/TLE, which has no effect on CD4 silencing in DP or 
SP thymocytes (121). 
 
Proximal Runx1 Increases Surface Expression of TCRβ  on Thymocytes 
Differentiated on an OP9-DL1 Stromal Cell Layer 
 
 The OP-9-DL1 cell line was used to study the differentiation of thymocytes in 
vitro by adding elements of the uniquely constructed environment of the thymus to mimic 
the education of T-cells in response to environmental cues (174). The OP9-DL1 cell line 
is an adherent stromal cell line stably expressing the protein delta-like1, which is a ligand 
for the signaling molecule Notch. Hematopoietic precursors cultured on an OP-9 
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monolayer will differentiate into double-positive (DP) and single-positive (SP) 
thymocytes. 
 Double negative thymocytes from BCL2 mice were sorted by negative selection 
using antibodies for CD4, CD8, and CD2, retrovirally transduced with Runx1 mutants 
and cultured on an OP-9-DL1 monolayer for 5 days. The BCL2 mice were utilized 
because of the enhanced survival ability during long-term tissue culture conditions.  In 5-
day culture DN thymocytes differentiated into DP and CD8 SP thymocytes, though the 
large number of cells in the DP compartment may be explained by the silencing of CD4 
SP thymocytes by Runx1. The population of CD4+ cells was diminished due to Runx1 
mediated silencing in cells transduced with either proximal FL or distal FL Runx1 in 
agreement with previous findings (121).  However, there was no apparent alteration of 
CD4 or CD8 expression attributable to only Proximal FL or Distal FL Runx1 expression. 
There was an up regulation of the mean fluorescence intensity of TCRβ on the proximal 
FL transduced thymocytes as compared to the Distal FL transduced thymocytes (Figure 
23).  
 The increase of relative TCRβ expression in the Proximal FL Runx1 transduced 
cells was attributable to the lack of a Distal FL Runx1 N-terminus.  Mutation of the 
conserved serine and phenylalanine residues partially abrogated the activity of the Distal 
N-terminus as evidenced by the intermediate phenotypes in the S3A/S5A and 
S3A/S5A/F7A mutants (Figure 24). The Distal N-terminus therefore appeared to act as a 
repressive element of Runx1 mediated TCRβ expression. These results demonstrated 
differential potential activities of the two N-terminal isoforms on a known Runx1 gene 
regulation target. 
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Discussion 
 
 The TCRβ enhancer contains consensus Runx and Ets binding sites and both 
transcription factors transactivate TCRβ expression (66).  In another study of thymocytes 
matured on an OP9 monolayer, truncation of Runx1 at amino acid 329 decreased the 
ability of Runx1 to transactivate TCRβ, though expression was not completely blocked, 
implying that other domains of Runx1 may participate in the transactivation activity 
(177).  The Distal N-terminal isoform is the dominantly expressed N-terminal variant in 
thymocytes, indicating that the Distal N-terminus may serve as a regulatory domain for 
the proper expression of TCRβ in response to extracellular development cues. 
 The Distal N-terminal Runx1 isoform is the more physiologically relevant Runx1 
variant in this system, however the expression of the Proximal N-terminal isoform 
allowed for the comparison and elucidation of activities expressly attributable to the 
Distal N-terminal isoform. The experiments presented in this chapter are preliminary 
studies designed for the purpose of establishing a system for the analysis of differential 
Runx1 N-terminal isoform activities.  Technical difficulties proved difficult to overcome 
in producing statistically significant values for TCRβ expression on the differentiated 
thymocytes. Future directions for this experimental system would rely on the refinement 
of the protocols for isolating the DN3 population and transduction of Runx1 N-terminal 
mutants. Flow cytometry sorting would reduce contaminating cell types and provide a 
more defined population for retroviral infection. In addition, the biological significance 
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of the up-regulation of TCRβ should be evaluated in T-cell response assays to determine 
whether the mature thymocytes derived from the OP-9 system are functional. 
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Figure 23 Runx1 N-terminal isoforms display distinct activities in the up-regulation 
of TCRβ  in the ex vivo OP-9 thymocyte co-culturing differentiation system. 
 
(A) FACS analysis of retrovirally transduced CD4/CD8 DN2 thymocytes co-cultured on 
the OP9-DL1 cell line for 5 days. Live thymocytes were first gated with FSC vs. SSC, 
and then for GFP expression. A representative CD4 vs. CD8 scatter plot and TCRβ 
histogram for the MSCV control are shown. (B) Histogram overlays of MSCV control 
(Red) and Runx1 transduced cells (blue) show an increase of TCRβ expression correlated 
with Proximal FL Runx1 N-terminal expression. Preliminary Data (N=1) 
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Figure 24 Mutation of Highly Conserved Residues of the Distal N-terminus Promote 
the Expression of TCRβ  
 
FACS analysis of retrovirally transduced CD4/CD8 DN2 thymocytes co-cultured on the 
OP9-DL1 cell line for 5 days. Live thymocytes were first gated with FSC vs. SSC, and 
then for GFP expression. Bars represent the mean and error bars the standard error of the 
mean. N=3  
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CHAPTER 6 
SUMMARY 
 
 The Runx family of transcription factors is integral for the establishment and 
maintenance of hematopoiesis that supports a functioning healthy immune system. The 
importance of proper expression and distribution of Runx1 throughout development is 
most clearly demonstrated in the several chromosomal translocations that contribute to 
M2 acute myelogenous leukemia (Runx1-ETO), chronic myelogenous leukemia (Runx1-
EAP, MSD1, or EV1), childhood acute lymphoblastic leukemia (Runx1-TEL), and 
therapy related myelodysplasia (178). Identifying Runx1 as a key player in hematopoietic 
maintenance logically led to the investigation of where and when Runx1 is expressed. 
Runx1 is expressed in a very specific spatio-temporal pattern that supports the 
development and maturation of many hematopoietic lineages beginning with the 
hematopoietic stem cell (96). The regulation of Runx1 expression is achieved via tight 
control during transcription, translation and post-translation in response to cell type 
specific and developmental stage specific stimuli (28). The expression pattern is tightly 
linked to the function of Runx1 at each of the stages of hematopoiesis.  Runx1 is the 
DNA binding center of a transcription complex that promotes a specific program of target 
gene expression or repression, and as such the protein itself is uniquely capable of several 
distinct activities based on the particular isoform being expressed. The Runx1 protein is 
comprised of modular functional domains that are present or absent in different isoforms 
(177). The runt DNA binding and CBFβ heterodimerization runt domain as well as the 
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NMTS are critical features of all Runx family members, while the C-terminus is 
alternatively spliced to produce several isoforms that permit binding of repressors or 
activators of Runx1 activity (31).  The N-terminus of Runx1 is a relatively small motif 
that is limited to two variants, Proximal and Distal, which can be coupled with all of the 
other C-terminal isoforms, but a function for the N-terminal motifs have not yet been 
established (179).  In these studies, we found that the two N-terminal isoforms of Runx1 
have both distinct and overlapping activities that contribute to the transcriptional 
regulation required for cell cycle control and cell surface protein expression at distinct 
stages during the differentiation of both myeloid and lymphoid hematopoietic cell 
lineages.  
 At the molecular level it is unlikely that the short Proximal N-terminus, in and of 
itself, is the functional motif responsible for the Proximal-Distal divergence of activity. 
Crystal structures for the Runx1 and Runx family DNA binding runt domain have been 
solved (44), but the N-terminus in these structures has not.  The five Proximal N-terminal 
residues, including the initiating methionine, are the hydrophobic residues valine and 
isoleucine, proline (frequently found in turns), and the polar hydrophilic arginine.  In 
sum, the Proximal Runx1 N-terminus appears ideally suited for tucking into the main 
mass of the Runx1 protein and does not contain any obvious sites of structural 
significance such as sites of phosphorylation.  The hypothesis that this work supports is 
that the Proximal N-terminus isoform of Runx1 regulates a default set of activities, 
whereas the Distal N-terminus allows additional regulation of the function of Runx1 in 
specific spatio-temporal cellular context. 
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 In the studies presented in this thesis, we have examined the function of the Distal 
Runx1 N-terminus utilizing two strategies, the first being dividing the Distal N-terminus 
into three regions and creating a series of nested deletions.  The three conserved residues 
that were mutated to alanine are located between amino acids 3’ to 8’ of the N-terminus, 
a region that also contains aspartic acid and glutamic acid residues whose polar character 
play important roles in ionic bonding and solubility in aqueous solutions.  The second 
region between amino acids 9’to 14’ is generally polar and contains another 
phenylalanine residue as well as two serine residues and a tyrosine residue important for 
phosphorylation sites in proteins.  Finally, the third region of the N-terminus between 
amino acids 15’ to 19’ is generally hydrophobic and contains one cysteine residue with 
the potential for creating disulfide linkages.  Overall, the in vivo conformation of the 
Distal N-terminus may be a modification site for interaction with activators or 
suppressors of Runx1 that is absent in the Proximal N-terminal isoform (Figure 8 B). 
 The second strategy for dissection of Runx1 N-terminus function involved 
targeted mutation of specific amino acid residues.  The Distal N-terminus contains three 
residues that are highly conserved across family members and evolutionarily conserved 
among all currently identified Runx1 species orthologs which suggests functional 
significance; two serines at positions 3’ and 5’ and a phenylalanine residue at position 7’. 
Structurally speaking, serine residues are small residues containing a hydroxyl group that 
can easily form hydrogen bonds with substrates.  Functionally, serine residues are 
frequently targets of phosphorylation by kinases in signal transduction pathways that 
modify protein behaviors.  Therefore, the conserved serine residues of the Distal N-
terminus could function as targets for the modification of Runx1 activity.  Phenylalanine 
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is an aromatic, hydrophobic residue that prefers to be buried within the structure of 
proteins. The conserved phenylalanine residue may therefore indicate a binding site for 
intramolecular interaction, intermolecular binding, or both. 
 The first demonstration of distinct functions for the N-terminal Runx1 isoforms 
utilized the 32Dcl.3 cell line.  32Dcl.3 cells are committed to the myeloid lineage, though 
the cells are transformed and dependent on IL-3 for routine maintenance and cell culture.  
A 32Dcl.3 population expressing the Proximal FL Runx1 isoform delayed terminal 
differentiation induced by G-CSF, as evidenced by an increased number of viable cells 
over a 72-hour culture period (Figure 12).  The Proximal FL Runx1 transduced cells also 
displayed a high proportion of cells with distinct blast morphology.  These results were in 
stark contrast to the population of Distal FL Runx1 transduced cells that did not increase 
in cell number, the majority of which were morphologically terminally differentiated, and 
died rapidly over 72 hours.  The only difference between the two Runx1 isoforms used in 
this initial study were the five amino acids of the Proximal isoform and the nineteen 
amino acids of the Distal isoform. 
 One of the greatest challenges encountered in this work was the expression of the 
N-terminal isoforms expressed in the 32Dcl.3 cell line. As outlined in the experiments in 
Chapter 3, the long-term expression of Runx1 N-terminal mutants can vary considerably.  
Targeted deletion of groups of N-terminal residues is useful for the gross identification of 
binding sites, though this may contribute to low expression of the proteins due to changes 
in secondary mRNA structure or alteration in protein stability.  We hypothesized that co-
translational modifications, including methionine excision and acetylation, may 
contribute to the targeted degradation of mutant proteins containing a destabilizing N-
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degron sequence created by N-terminal modification.  In the bulk sorted long-term 
culture of stably transfected 32Dcl.3 cells, the deletion of (Δ3-8) or mutation of S3A/S5A 
or S3A/S5A/F7A resulted in very low Runx1 expression whereas the deletion of amino 
acids (Δ3-14) or mutation of F7A does not affect protein expression. 
 The proliferation assay data from the 32Dcl.3 bulk sorted cell lines depicts a 
paradigm where the Proximal Runx1 isoform promotes proliferation and the distal 
isoform promotes differentiation (Figure 13).  The amino acid (Δ3-14) region, including 
the two highly conserved serines and single phenylalanine, negatively regulate the ability 
of Distal Runx1 to promote cellular proliferation. Our data shows that the Distal N-
terminus of Runx1 contains a functional motif that regulates the isoform specific activity 
of Runx1. 
 Runx1 N-terminal isoforms display differential activity throughout myeloid 
differentiation.  Enforced expression of either Proximal FL or Distal FL Runx1 isoforms 
in neutrophil progenitors promotes the myeloid lineage as evidenced by the increase of 
the CD11b+ granulocyte-monocyte progenitor population that gives rise to monocytes, 
macrophages, and neutrophils.  Proximal FL Runx1 increases the production of Gr1+ 
neutrophils as compared to distal FL Runx1. Proximal FL Runx1 may promote a default 
program of differentiation, including increased proliferation of precursor populations 
leading to increased neutrophil production as compared to the activity of the Distal FL N-
terminus (Figure 14). The Distal FL Runx1isoform favors the CD11b+/ Gr1- monocyte 
lineage, indicating a possible isoform switch at the lineage branching point of monocytes 
and neutrophils where the distal isoform could support monocyte development, while 
expression of the ‘default’ proximal isoform would promote increased production of 
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neutrophils.  The molecular dynamics of promoter usage at the monocyte/ neutrophil 
branching point have yet to be elucidated. 
 The ability of the immune system to adapt to antigenic incursion is the central 
tenet to the regulation of hematopoiesis. Approximately 1.6x1011 neutrophils are 
produced in human bone marrow on a daily basis, a number that can increase 10 fold 
during infection (102).  The work described in Chapter 3 strongly suggests a role for 
Runx1, a central molecular modulator of hematopoiesis, in the adaptation of the immune 
system to increase neutrophil production.  A molecular switch to the Proximal N-terminal 
isoform during myeloid differentiation, increasing the rate of proliferation and thereby 
production of neutrophils would greatly enhance the innate immune response.  
Alternatively, as has been seen in myelogenous leukemias, deregulation of myeloid 
proliferation can have catastrophic results, and the recognition of the alternative function 
of the splice isoforms of Runx1 may aid in the understanding and treatment of these 
diseases. 
 The significance of Runx1 in the development of the immune system has been 
well documented, but the specific role of Runx1 in the regulation of specific processes 
during cellular maturation is less clear (18).  In Chapter 4, we examined the functional 
aspects of specific Runx1 domains in the regulation of NK cell specific KIR gene 
expression.  In this specific context we found that there is no differential activity of the 
Runx1 N-terminal isoforms, which is in agreement with studies that did not find unique 
activities for the N-terminal isoforms. Previous studies have shown that Runx1 distal 
promoter use is sharply decreased in the NK lineage, leading to the primary use of the 
Runx1 proximal promoter (14). Our results support the idea that the proximal and distal 
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isoforms are relevant for the regulation of proliferation/ differentiation decisions during 
transition stages of hematopoietic development, possibly by the mechanism of ‘isoform 
switching’, but have overlapping roles in the regulation of specific transcription targets 
such as KIR genes. 
 The KIR3DL1 bidirectional promoter provides a mechanism for the stochastic 
regulation of KIR gene expression in NK cells.  Transcription from the forward promoter 
results in a functional transcript, and thus expression of the KIR3DL1 gene, whereas 
transcription from the reverse transcript results in a non-functional transcript and 
repression of the KIR3DL1 gene.  The bidirectional promoter contains potential binding 
sites for several transcription factors, including Runx1, Ets1, and YY1, which work 
together to regulate the stochastic expression of forward or reverse transcripts.  In this 
context, we have shown that Runx1 displays a global bias for the reverse transcripts and a 
general repression of transcription (Figure 17).  The N-terminal motif, runt DNA binding 
domain, and the region containing the NMTS domain are required for repressive Runx1 
activity.  These results strengthen the hypothesis that DNA binding function and sub-
nuclear localization of Runx1 are essential for the formation of a protein transcription 
holocomplex on the promoters of target genes. 
 The function of the Runx1 containing protein holocomplex is mediated by the 
activities of distinct regions of the Runx1 molecule. Runx1 dominantly reduces the 
ability of Ets1 to promote transcription in a manner that is dependent on Runx1 DNA 
binding.  There are two additional important domains of interaction with Ets1 on the 
Runx1 molecule; an N-terminal protein interaction motif and a C-terminal inhibitory 
domain located between amino acids 212-360 (Figure 18).  These studies were performed 
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with the longest isoform of Runx1 containing all of the genome encoded exons and 
therefore represents a default set of possible Runx1 activities on the KIR3DL1 promoter. 
The expression of alternate C-terminal splice isoforms of Runx1 provides a mechanism 
that would abrogate repression at the KIR3DL1 locus, thereby allowing expression of this 
particular KIR variant. 
 The luciferase assay system allowed for the examination of the dynamics of 
transcription factor interaction (Figure 20).  YY1 and Ets1 are both strong activators of 
transcription in both directions while Runx1 is a repressor of activation and shows a bias 
for the reverse transcript.  YY1 acts in an additive manner with Ets1, but is dominant and 
independent of Runx1 repression. Runx1 specifically represses Ets1 activation through 
defined domain interactions.  Runx1 chromosomal translocations and mutations are often 
associated with the development of cancer, leukemia, and dysplasia, so it follows that in 
the molecular context wild type Runx1 acts as a repressor, regulating the activity of 
partner molecules.  A single point mutation within the runt domain may have a high 
degree of correlation with cancer because of the many molecular co-activators and 
repressors that Runx1 is associated with. As the center of a transcription complex, a 
single mutation of Runx1 provides multiple hits to normal cellular processes such as cell 
cycle and the proliferation/ differentiation checkpoints, allowing further aberrant cellular 
behaviors.  The work in this thesis supports a dynamic stochastic model of KIR gene 
expression where multiple transcription factors, regulated by the modular activity of 
Runx1, provide a level of random gene expression for the production of a diverse 
repertoire of surface NK receptors.  This process is analogous to the repertoire created by 
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the RAG mediated re-arrangement of the TCR, except in NK cells there are multiple KIR 
receptors acting in concert to achieve diversity. 
 The preliminary data presented in Chapter 5 suggests that the Distal N-terminal 
splice isoform provides a means of regulation for the expression of TCRβ during 
thymocyte development. Distal FL Runx1 is the dominant isoform expressed during 
thymocyte development (14). We demonstrate that the serines 3 and 5, and phenylalanine 
7, comprise a regulatory motif for the repression of Distal FL Runx1 activity (Figure 24).  
Further studies examining the phosphorylation state of the Distal N-terminus at specific 
stages of DN thymocyte development will be required to elucidate the role of this motif 
in the regulation of gene targets such as TCRβ. 
 In this dissertation I have investigated the role of the alternatively spliced Runx1 
N-terminus in the process of hematopoiesis.  I have found that the Proximal N-terminus 
potentiates a default set of activities, and the Distal N-terminus contains a regulatory 
motif for the modification of Runx1 activity.  I have further demonstrated that the N-
terminal region encoding amino acids 3’ to 14’ is essential for two main functions: 
regulating the expression of the distal isoform and modulating the interactions of Runx1 
with other transcription factors. These data show that Runx1 is a complex, modular 
regulator of transcription complexes promoting a dynamic range of activities during adult 
hematopoiesis. 
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APPENDIX A 
THESIS EXPERIMENTS FILE INFORMATION 
Table 4 Experiments File Information 
Dates and Computer Files 
 Date(s) File(s) Experiment Type 
Figure 9 7/28/08 Bulk Sorted 32Dcl.3 FACS of Bulk 
Sorted 
Populations 
Figure 10 8/14/08 
8/15/08 
8/17/08 
8/29/08 
32Dcl.3 Figures (CD Media) 
Runx1 N-Terminal mutants (tif files) 
Runx1 N-Terminal mutants 
(Adobe Illustrator files) 
Microscopy 
Figure 11 10/8/08 
10/10/08 
10/13/08 
10/15/08 
10/08/08 HA Staining.jo 
10/10/08 HA Staining 1.jo 
10/13/08 HA Staining 1.jo 
10/15/08 HA Staining 1.jo 
HAstaining32D.xls 
HA Staining.pzf  
FACS 
Figure 12 7/21-7/24/08 Cell Counting Assay 07/21/08.xlsx 
32DCl3 Cell Counting Assay.pzf 
Cell Counting 
Figure 13 8/11-8/14/08 08/11/08-08/14/08 Tritium Assay.xls 
08/11/08-08/14/08 72 Hours Tritium 
Assay.pzf 
Tritium Assay 
Figure 14 1/19/04 
12/2/05 
5/11/06 
1/24/08 
BMI4.jo 
BMI8.jo 
BMI10.jo 
BMI12.jo 
BMI Analysis 2.pzf 
BMI Analysis 2.xlsx  
FACS  
Figure 17 
Figure 18 
Figure 19 
Figure 20 
12/13-12/15/08 
12/17-12/19/08 
1/2-1/4/09 
1/6-1/8/09 
1/10-1/12/09 
1/15-1/17/09 
1/20-1/22/09 
1/24-1/26/09 
1/26-1/28/09 
1/29-1/30/09 
2/5-2/7/09 
293T Luciferase Analysis Final 
Version.xls 
 
293T Luciferase Graphs 2.pzf 
Dual Luciferase 
Assay 
Figure 23 11/18-11/23/05 11.23/05.jo FACS  
Figure 24 11/18-11/23/05 OP9 Graph.pzf FACS  
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Localization of the Domains in Runx Transcription Factors
Required for the Repression of CD4 in Thymocytes1
Janice C. Telfer,2* Emmett E. Hedblom,* Michele K. Anderson,†‡ Micheline N. Laurent,† and
Ellen V. Rothenberg†
The runt family transcription factors Runx1 and Runx3 are expressed in developing murine thymocytes. We show that enforced
expression of full-length Runx1 in CD4!CD8! thymocytes results in a profound suppression of immature CD4/CD8 double-
positive thymocytes and mature CD4 single-positive thymocytes compared with controls. This effect arises from Runx1- or Runx3-
mediated repression of CD4 expression, and is independent of positively selecting signals. Runx1 is able to repress CD4 in
CD4/CD8 double-positive thymocytes, but not in mature splenic T cells. Runx-mediated CD4 repression is independent of asso-
ciation with the corepressors Groucho/TLE or Sin3. Two domains are required for complete Runx-mediated CD4 repression.
These are contained within Runx1 aa 212–262 and 263–360. The latter region contains the nuclear matrix targeting sequence,
which is highly conserved among runt family transcription factors across species. The presence of the nuclear matrix targeting
sequence is required for Runx-mediated CD4 repression, suggesting that Runx transcription factors are stabilized on the CD4
silencer via association with the nuclear matrix. The Journal of Immunology, 2004, 172: 4359–4370.
I
mmature CD4/CD8 double-negative (DN)3 thymocytes com-
mitted to the !" T cell lineage up-regulate expression of the
coreceptors CD4 and CD8 to become double-positive (DP)
thymocytes. It is at the DP stage and the intermediate CD4!
CD8low stage that the association between the CD4 or CD8 core-
ceptor, TCR!" specificity, and function is established. Cells ex-
pressing an TCR!" that recognizes the Ag presentation molecule
MHC class I down-regulate the expression of CD4, maturing to a
CD8! cytotoxic T cell. Conversely, cells expressing an TCR!"
that recognizes the Ag presentation molecule MHC class II fully
down-regulate the expression of CD8, maturing to a CD4! Th cell.
Therefore, the down-regulation of CD4 in DP thymocytes is an
integral part of the gene regulatory program leading to the pro-
duction of CD8! CTLs. The identity of the elements controlling
CD4 expression specifically in DP thymocytes is controversial. In
the CD4 locus, a combination of distal and proximal enhancers,
promoters, and a silencer directs expression of CD4 in CD4 single-
positive (SP) and DP thymocytes and silences expression of CD4
in DN and CD8 SP thymocytes (1–5). Several candidates have
been proposed for the trans-acting factors responsible for the si-
lencing of CD4 in DP thymocytes that have recently committed to
the CD8 T cell lineage. The transcriptional corepressor Hes-1 has
been shown to down-regulate the expression of CD4 through bind-
ing to the CD4 silencer in collaboration with c-myb (6, 7). How-
ever, these studies were done using a T cell clone (DH10) that has
already committed to the CD4! Th lineage. ZEB is another tran-
scription factor found to repress CD4 expression, but again only in
SP thymocytes, postpositive selection (8). The 434-bp CD4 si-
lencer (3, 4) contains a remarkable five consensus binding sites for
runt family transcription factors, making any runt family transcrip-
tion factors that are expressed in DP thymocytes strong candidates
for the factor responsible for down-regulation of CD4 in maturing
thymocytes. There are three known Runx family members in mice,
two of which, Runx1 and Runx3, are expressed at significant levels
in the thymus. A transgenic mouse expressing Runx1 under the
control of the CD2 promoter shows an increase in the number of
CD8 SP thymocytes, even when the thymocytes also express MHC
class II-restricted TCR (9). A transgenic mouse expressing the
osteoblast-specific runt family member Runx2 ectopically in thy-
mocytes also shows a skewing toward the development of CD8 SP
thymocytes (10). These effects have now been shown to result, at
least in part, from direct action of Runx proteins on the CD4 si-
lencer. Recent studies have shown that thymocytes with null mu-
tations in Runx1 and Runx3 are not able to silence CD4 appropri-
ately in T cell development (11, 12) and that silencing is dependent
upon the presence of runt family sites in the CD4 silencer (13).
These studies suggest that Runx1, Runx2, or Runx3 are equally
capable of repressing CD4 expression in DP thymocytes by a
mechanism that has been evolutionarily conserved since the du-
plication of the ancestral gene that generated the three mammalian
runt family members.
In this study, we focus on Runx1 to define the structural re-
quirements for this repressive activity. Runx1, also known as
PEBP2!B, CBF!2, or AML1, is the transcription factor of the runt
family (14) that is most highly expressed in hemopoietic stem cells
(15) and continues to be highly expressed in thymocytes through-
out their development (15, 16). The runt family is characterized by
the DNA-binding runt domain, which is highly conserved between
runt family molecules from Caenorhabditis elegans, sea urchins,
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Drosophila, chicken, mice, and humans. Besides the runt domain,
Runx1 also contains a C-terminal trans activation domain, a nu-
clear matrix targeting sequence (reviewed in Refs. 17 and 18), and
many sites of interaction with trans activators and corepressors
(19–28). Thus, it can serve as the nucleus of a trans-activating
complex of proteins, as well as part of a transcriptionally repres-
sive protein complex. It is not known what regulates the switch
between the assembly of a transcriptionally active or repressive
complex, but it could be influenced by the presence or absence of
Runx protein domains in the forms of Runx that predominate in a
given tissue. Different forms of Runx1 protein arise from alterna-
tive promoter use and alternative splicing. Runx1 is transcribed
from two promoters, the distal or proximal. The distal promoter is
particularly active in T-lineage cells and hemopoietic stem cells
(15). Two different N-terminal Runx1 isoforms (derived from dis-
tal and proximal promoters) and at least three C-terminal Runx1
isoforms ("5, "6, and full-length, derived from alternative splic-
ing) are expressed in the murine thymus. Distal Runx1 is the pre-
dominant N-terminal isoform expressed in the thymus; proximal
Runx1 is predominant in some myeloid cells. The distal and prox-
imal Runx1 isoforms have functionally different activities in my-
eloid commitment (15). In addition to promoter use isoforms, there
are myriad C-terminal splice isoforms that are expressed in the
same tissues that express full-length Runx proteins (15, 29–31).
The interaction sites for the two corepressors known to associate
with Runx1 map to these C-terminal regions (20, 25).
In this study, we confirm that enforced expression of either full-
length Runx1 or Runx3 represses CD4 expression in thymocytes,
but not in splenic T cells. We map the domains in these transcrip-
tion factors that are required for this repression. Our analysis
shows that this repressive activity is not dependent on the C-ter-
minal motif that binds the Groucho/TLE corepressor (20, 25, 32,
33). The domain most critical for Runx1-mediated CD4 repression
contains the nuclear matrix targeting sequence, which is conserved
between Runx1, 2, and 3. This suggests that the Runx-repressive
activity is dependent upon subnuclear localization. The conserva-
tion of the mechanism of Runx-mediated CD4 repression implies
that this mechanism is used in the regulation of other gene targets
potentially involved in the development of hemopoietic stem cells,
osteoblasts, or in oncogenesis. Thus, the elucidation of the mech-
anism of Runx-mediated CD4 repression has broader implications
than even the important problem of how CD4 expression is si-
lenced in developing thymocytes.
Materials and Methods
Fetal thymic organ culture (FTOC)
C57BL/6 # DBA F1 hybrids were mated overnight, with resulting fetuses
assessed to be 0 5 days postcoitus (d.p.c.). Fetuses were harvested at d.p.c.
14 5–15.5 for host thymic lobes and donor thymocytes and d.p.c. 12 5 for
fetal liver donors. Host thymic lobes were washed in DMEM-FTOC
medium (DMEM, 10% FCS, 2 mM L-glutamine, 100 #g/ml penicillin-
streptomycin, 50 #M 2-ME, 1# nonessential amino acids (Invitrogen Life
Technologies, Carlsbad, CA), 10 mM HEPES, pH 7) plus 1.35 mM deox-
yguanosine (Sigma-Aldrich, St. Louis, MO) before placing them on six-
well plate insert filters (Millipore (Bedford, MA) Millicell-CM PICM 030
50) underlaid by 1 ml of DMEM-FTOC plus 1.35 mM deoxyguanosine in
six-well plates. Host thymic lobes were then incubated in the deoxyguanosine-
containing medium for 72 h, with one to two medium changes. Host lobes
were washed in DMEM-FTOC before being dissociated with 0.05% trypsin-
EDTA for 30 min to use as stromal cells for fetal thymic reaggregations or
being placed whole in Terasaki plates in hanging drop cultures.
Donor thymocytes were dissociated by a 2-h, 37°C treatment with 2
mg/ml collagenase type IV (Invitrogen Life Technologies) in RPMI 1640
medium plus 20 mM HEPES, pH 7 5. Centrifuging an equivalent number
of stromal cells and donor thymocytes in a 1 5-ml centrifuge tube generated
reaggregates. All supernatant was removed, and the cell pellet was resus-
pended in a final volume of 0.5 #l/lobe, 5 # 105 cells/lobe. Reaggregates
were spotted onto a cellulose filter freshly underlaid with 1 ml of DMEM-
FTOC medium.
Hanging drop cultures were done by placing 5 # 104-1 # 105 donor
cells in 20 #l of DMEM-FTOC per Terasaki plate well. Deoxyguanosine-
depleted host thymic lobes were transferred to the wells, and the plates
were incubated at 37°C, 7% CO2 in a humidified container for 48 h. The
lobes were then transferred to cellulose six-well plate insert filters under-
laid by 1 ml of DMEM-FTOC medium. Medium for both reaggregates and
hanging drop lobes was changed every 7 days.
Enrichment of fetal liver donor cells for precursor cells
Cells were dissociated and washed in 5.5 mM KCl, 0.4 mM KH2PO4, 140
mM NaCl, 5 6 mM glucose, 0.3 mM Na2HPO4, 3.9 mM NaHCO3, 0.2%
BSA, 1 mM EDTA before incubation with biotinylated anti-Ter119, anti-
Gr-1, anti-CD19 (BD PharMingen, San Diego, CA), and anti-F4/80 (Caltag
Laboratories, Burlingame, CA). Cells were then incubated with strepavidin
microbeads and passed over a MACS column, as directed (Miltenyi Biotec,
Auburn, CA). The flow-through fraction was put into culture overnight in
six-well plates in DMEM-FTOC plus 50 ng/ml IL-7 and 10% baby hamster
kidney cells transduced with mouse kit ligand supernatant as a source of
c-kit ligand.
Retroviral constructs
Runx1 clones were inserted into the murine stem cell virus (MSCV) ret-
roviral vector and packaged, as previously described (14). Inserts were
generated by PCR with an editing DNA polymerase using 5$ primers de-
signed to generate a BglII restriction site and a consensus Kozak sequence
upstream of the initiation methionine. The isolated runt domain construct
starts at Runx1 methionine 51 and stops at arginine 178, with the in-frame
addition encoding SV40 nuclear localization domain EKKKRKVAIDQL
(from Stratagene (La Jolla, CA) vector CMV-AD). Internal deletion con-
structs were made by ligating the PCR-generated flanking regions via an
engineered in-frame EcoRI site, which encodes for the amino acids EF in
place of the indicated deletion. All amino acid numbering in this study
refers to the murine proximal Runx1 isoform. Truncation constructs are
named after the last Runx1 amino acid present internal deletion constructs
are named after the first and last amino acids deleted. Cells were infected
by centrifuging in six-well plates with 3 ml of retroviral supernatant plus
20 #g/ml lipofectamine (Life Technologies) at 1800 rpm for 1–2 h in a
Sorvall RT6000 centrifuge at 30oC or by drawing the supernatant plus
lipofectamine through the cells on a cellulose filter by gravity feed. The
retroviral supernatant was then replaced by DMEM-FTOC medium. Donor
thymocytes used in FTOC were infected once and incubated at 37°C, 7%
CO2 for %3 h before use in FTOC. Donor fetal liver cells were infected
with the Runx1 retroviral constructs at 24 h and again at 36 h postisolation.
They were then placed in hanging drop culture with host thymic lobes.
FACS analysis of FTOC
Cells were dissociated from lobes by a 2-h, 37°C treatment with 2 mg/ml
collagenase in RPMI 1640 medium plus 20 mM HEPES, pH 7.5. Cells
were washed with 5 5 mM KCl, 0.4 mM KH2PO4, 140 mM NaCl, 5 6 mM
glucose, 0.3 mM Na2HPO4, 3.9 mM NaHCO3, 0.2% BSA, 1 mM EDTA
and incubated with anti-CD4 PE, anti-CD8 CyChrome (BD PharMingen),
anti-TCR" allophycocyanin (H57-597 BD PharMingen), anti-TCR$% PE
Cy5 (GL3 Accurate Chemical and Scientific, Westbury, NY), anti-CD3
(500A2), anti-heat-stable Ag (CD24) PE, and anti-CD69 PE (BD PharM-
ingen). The 7-amino actinomycin D (Molecular Probes, Eugene, OR) was
used as a vital dye at 10 #g/ml in the final cell suspension buffer. Cells
were run on a FACSCalibur (BD Biosciences, San Diego, CA). FACS data
were analyzed using FlowJo (Tree Star, Ashland, OR) software.
The bcl-2 transgenic cell culture
Thymocytes were harvested from the E#-bcl-2-25 line of bcl-2 transgenic
mice (34) (The Jackson Laboratory, Bar Harbor, ME). They were enriched
for immature thymocytes by negative selection with anti-CD4 and anti-
CD8 Abs directly conjugated to microbeads and passage over a MACS
column, as directed (Miltenyi Biotec). Thymocytes were plated in six-well
cell culture plates in DMEM-FTOC at a density of 1.6–3.6 # 103 cells/
mm2. The thymocytes were infected with retroviral constructs, as described
above, and cultured in DMEM-FTOC at 37°C, 7% CO2.
Splenocytes from bcl-2 transgenic mice were enriched for T cells by
negative selection with anti-CD19 Ab conjugated to microbeads and pas-
sage over a MACS column, as directed (Miltenyi Biotec). Cells were stim-
ulated with plate-bound anti-CD3 and anti-CD28 (each 10 #g/ml) and
infected with retroviral constructs 48 h later.
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RT-PCR
RT-PCR was performed, as described (15), using the following PCR prim-
ers: ACGTCCCGGATGGCACTCTGGTCACC (forward primer exon 4),
GTCCTCATTCTGGGGTTGGTTCGCTCACTT (reverse primer "5 Runx1
3$ untranslated region), and GTACACCAGCCCAGACAGTTACCAGCCC
(reverse primer "6 Runx1 3$ untranslated region). Thymic subsets were
prepared, as described (35).
Results
Expression of either distal or proximal full-length Runx1 in fetal
thymocytes results in the suppression of CD4/CD8 DP
thymocytes and CD4 SP thymocytes, but spares CD8 SP
thymocytes
We have previously shown that the distal promoter of distal Runx1
mRNA is highly active in thymocytes and that both full-length and
truncated splicing isoforms of the mRNA are produced there (15).
Gene dosage is known to be important for the biological activities
of Runx1, but it has not been clear which isoforms are most im-
portant for the role of Runx1 in the thymus. Therefore, we sought
to investigate the functional effect on thymocyte development of
the enforced expression of distal or proximal full-length Runx1,
because the full-length form includes inhibitory, repressive, and
trans-activating domains not present in the alternatively spliced
shorter forms that are also naturally expressed in the thymus. To
determine the most direct effects of enforced expression of full-
length Runx1 at different, specific stages of thymocyte develop-
ment, we used a retroviral transduction strategy. Full-length Runx1
cDNAs with sequences encoding the distal or proximal promoter-
derived N termini were inserted upstream of the internal ribosome
entry site of the retroviral vector MSCV-internal ribosome entry
site-green fluorescent protein (GFP), resulting in a bicistronic tran-
script. The expression levels of Runx1 can thus be tracked by the
level of expression of GFP. Fetal thymocytes were harvested at a
stage when the majority of thymocytes are CD4&CD8&TCR"&/low
(data not shown), and thus not committed to either a
CD4!CD8&TCR!"! helper or CD4&CD8!TCR!"! cytotoxic T
cell fate. They were infected with the retroviral vectors encoding
full-length distal or proximal Runx1, as well as the control vector
encoding GFP alone. Infected fetal thymocytes were incorporated
into fetal thymic lobes depleted of endogenous thymocytes and
allowed to develop.
Thymocytes infected with the empty control vector expressing
only GFP reflect the CD4 and CD8 expression profile seen in GFP-
negative uninfected thymocytes (Fig. 1). Compared with these control
samples, there is an overall decrease in the number of thymocytes
expressing GFP after culture in fetal thymic lobes in those transduced
with distal or proximal full-length Runx1. Furthermore, thymocytes
FIGURE 1. Expression of either distal or proximal full-length Runx1 in fetal thymocytes suppresses CD4/CD8 DP and CD4 SP thymocytes. Donor
thymocytes were infected with MSCV retroviral constructs coding for control GFP alone (A, and lanes 2 and 7), distal (B, and lanes 4 and 8), or proximal
(C, and lanes 6 and 9) full-length Runx1 plus GFP. Cells were placed in FTOC, and resulting thymocytes were analyzed for maturation status 10 days later
by staining with anti-CD4 PE, anti-CD8 CyChrome, and anti-TCR" allophycocyanin. Cells were gated for viability based on forward and side scatter
profiles (data not shown) and then analyzed for GFP expression (A, B, and C left gate represents uninfected GFP-negative cells right gate represents
infected GFP-positive cells). Expression of CD4 and CD8 on all live uninfected GFP-negative cells is shown in lanes 1, 3, and 5 and on all infected
GFP-positive cells is shown in lanes 2, 4, and 6. Numbers and percentages of cells in each quadrant of the CD4 vs CD8 plots are indicated. GFP-positive
(lanes 7, 8, and 9) subpopulations were gated for TCR" negative, intermediate, and high expression. D, The percentage of CD8 SP thymocytes of total
live GFP-positive and subpopulations of live GFP-positive thymocytes based on the level of TCR" expression (negative, intermediate, and high, as
indicated in lanes 7, 8, and 9) are shown for thymocytes infected with control GFP only (filled bars), or with distal (gray bars), or with proximal (open
bars) full-length Runx1 plus GFP. The results shown are representative of four independent experiments, with two time points each.
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infected with vectors expressing distal or proximal full-length
Runx1 diverge markedly from the GFP-only control in their CD4
expression profiles. Thymocytes expressing either distal or prox-
imal full-length Runx1 show a profound decrease in the percent-
ages of both CD4/CD8 DP and CD4 SP thymocytes compared
with GFP-only controls. There is a corresponding increase in the
percentage of CD4/CD8 DN and CD8 SP thymocytes in popula-
tions of thymocytes expressing either distal or proximal full-length
Runx1 compared with GFP-only controls. However, absolute
numbers of DN or CD8 SP thymocytes are not greater in popula-
tions of cells expressing full-length Runx1 compared with GFP-
only controls.
Surprisingly, despite the much higher levels of distal Runx1
than proximal Runx1 naturally expressed in thymocytes (15), there
is no difference between the kind or severity of the phenotype
between the two isoforms. The phenotype is dose dependent: high
levels of GFP and, thus, high levels of distal or proximal Runx1,
are not seen in thymocytes expressing high levels of CD4, as com-
pared with thymocytes infected with the control empty vector (data
not shown). Only those cells expressing low levels of GFP and,
thus, low levels of distal or proximal Runx1, have high levels of
CD4 expression (data not shown). In contrast, high levels of GFP
and, thus, distal or proximal Runx1, are seen in thymocytes ex-
pressing high levels of CD8 (data not shown).
To gain insight into the developmental stage of the thymocytes,
we analyzed them for their level of TCR" expression, which in-
dicates level of maturity. Thymocytes committed to the !" T cell
lineage initially are negative for CD4, CD8, and TCR" surface
expression, then start up-regulating TCR" surface expression at
the DP thymocyte stage and become TCR" high as they mature to
the CD4 or CD8 SP thymocyte stage. Murine thymocytes that are
negative for TCR" expression, but positive for CD8 expression,
are called immature SPs, because CD8 surface expression may be
up-regulated before CD4 and TCR" surface expression. Also in-
cluded in the DN TCR"& and CD8!TCR"& populations are thy-
mocytes committed to the $% T cell lineage. Thymocytes trans-
duced with distal or proximal Runx1 have similar TCR"
expression profiles compared with thymocytes transduced with the
GFP-only control (Fig. 1) and uninfected thymocytes (data not
shown). The only difference seems to be a slight decrease in the
average intensity of TCR" staining within the TCR" intermediate
gate in the thymocytes transduced with distal or proximal Runx1
compared with GFP-only control-transduced thymocytes (Fig. 1).
However, the percentages of thymocytes in the TCR" negative,
intermediate, and high gates are similar whether the thymocytes
were infected with control GFP only or with full-length distal or
proximal Runx1. The increase in the percentage of CD8 SP cells
resulting from enforced expression of either distal or proximal
Runx1 does not appear to arise from a total block in the develop-
ment of the thymocytes at the immature SP stage (CD8!TCR"&),
because the percentage of CD8 SP thymocytes is increased over
control at all three levels of TCR" expression (Fig. 1D).
Expression of truncated isoforms of Runx1 conveys a growth
advantage to developing thymocytes; expression of full-length
Runx1 conveys a growth disadvantage to developing thymocytes
To dissect the mechanism of the effects of Runx1 on thymocyte
proliferation and development, we compared full-length Runx1
with naturally occurring truncated isoforms of Runx1 expressed in
the thymus (Fig. 2). We have cloned and designated two novel
Runx1 isoforms as "5 and "6 (15), which refers to truncation of
the open reading frame before exons 5 and 6, respectively (Fig. 2).
FIGURE 2. Expression of truncated isoforms of Runx1 conveys a growth or survival advantage to developing thymocytes expression of full-length
Runx1 conveys a growth or survival disadvantage to developing thymocytes. A, RT-PCR analysis of "5 and "6 Runx1 expression in recombination-
activating gene&/& thymocytes (lane 1), C57BL/6 thymocytes (lane 2), and C57BL/6 splenocytes (lane 3). The PCR products represent "5 Runx1 (top),
"6 Runx1 (middle), and control GAPDH mRNA transcripts. B, RT-PCR analysis of relative levels of "5 Runx1 mRNA transcripts in DN (lane 4), DP (lane
5), CD4 SP (lane 6), and CD8 SP (lane 7) thymocyte subsets and unfractionated splenocytes (lane 8). The levels of mRNA transcripts are graphed in
arbitrary units. C, Amino acid sequences of the C termini of "5 and "6, with novel sequences in bold type. D, Change in the percentage of GFP! cells
after 17 days of FTOC using fetal liver precursors as donor cells. The position of the conserved DNA binding domain is depicted as a gray box in the
schematics of the constructs used. The open bars indicate the initial percentages of GFP! cells at 48 h. The mean of the initial infection efficiency is 15%,
with an SD between constructs of 3%. The initially transduced populations were divided among fetal lobes and analyzed in duplicate (lanes 5–8) or in
quadruplicate (lanes 1–4). The filled bars indicate the mean percentages of GFP-positive cells after culture, with the SDs indicated by error bars.
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These clones represent use of alternative polyadenylation sites in
the introns downstream of exon 4 for "5 and downstream of exon
5 for "6. They lack DNA-binding and CBF"-binding capability,
nuclear localization sequences, a trans activation domain, a nu-
clear matrix attachment domain, and a Groucho/TLE repressor
binding domain. They are comprised of an N terminus of unknown
function plus two-thirds ("5) or the entire ("6) runt domain. It is
unknown whether they have the capacity to act as a naturally oc-
curring inhibitor of full-length Runx1 functions or whether they
have no activity.
As noted above, the yields of GFP! cells are much lower for the
full-length Runx1 retroviral constructs as compared with the con-
trol empty vector in fetal thymocyte donors after 10–15 days of
FTOC (Fig. 1). In contrast, both frequencies of GFP! cells and
levels of GFP expression per cell are higher for the "5 and "6
Runx1 constructs than for the control empty vector (data not
shown). We investigated whether this difference was actually due
to different infection efficiencies or whether it arose due to a
growth disadvantage or advantage. Because thymocyte donor cells
do not survive long enough in vitro to be used for this assay, fetal
liver cells enriched for precursor cells were used as donor cells.
The cells were infected, and a sample was analyzed for GFP ex-
pression after 48 h in culture, to elicit optimal fluorescence. The
remainder of the cells were placed in depleted fetal thymic lobes
and cultured for 17 days before FACS analysis. All of the con-
structs had similar infection efficiencies before FTOC incubation,
%15% of live cells for this experiment. After 17 days of incubation
in FTOC, the fraction of cells transduced with the control empty
vector is little changed. In contrast, expression of either distal or
proximal full-length Runx1 conveys a growth disadvantage to cells
in FTOC (Fig. 2D).
This growth disadvantage does not depend on recruitment of the
corepressor Groucho/TLE. Runx1 has been shown to act as a re-
pressor through its association with the corepressor Groucho/TLE
(20, 32, 33). The corepressor Groucho associates with Runx1
through the last 5 aa (VWRPY) of the C terminus of Runx1. We
manufactured a distal Runx1 construct deleted for the last 5 aa
(447–451), selectively ablating the Groucho interaction with
Runx1 (Dis.d446). The same growth disadvantage is imparted by
this Dis.d446 mutant form of distal Runx1, or even by a minimal
construct consisting of the DNA binding runt domain plus a nu-
clear localization sequence (Fig. 2D). This implies that Runx bind-
ing to Runx cognate sites in the genome is responsible for the
growth disadvantage phenotype.
In contrast, expression of the non-DNA-binding isoforms, prox-
imal or distal "5, conveys a growth advantage to cells in FTOC.
Surprisingly, even expression of the distal or proximal N-terminal
fragments up to the runt domain, especially at higher expression
levels, enhances growth in FTOC (Fig. 2D). This suggests that
despite the lack of known functional domains present in "5 and "6
Runx1, they may either interfere with the full-length form’s func-
tion or exercise independent functions. The growth advantage con-
veyed by the isolated N termini suggests that "5 and "6 derive
their growth advantage phenotype in part from the Runx1 N ter-
minus, with or without the runt domain.
The Runx1 C terminus is necessary for the suppression of CD4/
CD8 DP thymocytes and CD4 SP thymocytes by Runx1
The effect of Runx1 on the appearance of CD4! thymocyte subsets
is not simply a byproduct of its growth-inhibitory effect, as shown
by the comparison of the activities of different Runx mutant forms.
Expression of "5 or "6 has no appreciable effect on the percentage
of DP or CD4 SP thymocytes compared with control. However,
the runt DNA binding domain plus nuclear localization sequence
also cannot mediate the inhibitory effect on the production of
CD4! thymocytes seen with full-length Runx1 (Fig. 3), despite
having a growth-suppressive effect similar to that seen with ex-
pression of full-length Runx1 (Fig. 2D). This separates the two
phenotypes of growth disadvantage and CD4 repression: the
former requires only DNA binding and the latter requires the do-
mains downstream of the runt domain. These experiments dem-
onstrate that the Runx1 C terminus is necessary for the suppression
of DP thymocytes and CD4 SP thymocytes mediated by expres-
sion of full-length Runx1.
An obvious candidate mechanism for the repression of CD4
expression would be Groucho/TLE recruitment via aa 447–451.
FIGURE 3. The Runx1 C terminus
downstream of the runt domain and
upstream of the Groucho-binding mo-
tif is required for Runx1-mediated
suppression of DP and CD4 SP thy-
mocytes in FTOC. Fetal thymocytes
were infected with control retroviral
vector (A), distal (B) or proximal (C)
full-length Runx1, distal (D) or proxi-
mal (E) "5 Runx1, distal (F) or prox-
imal (G) "6 Runx1, the runt DNA
binding domain with nuclear localiza-
tion sequence (H), or distal Runx1
lacking the corepressor Groucho bind-
ing site (I). Thymocytes were placed
in FTOC and analyzed for their GFP,
CD4, CD8, and TCR" expression by
FACS at day 10 (A–I). Cells were
gated for their viability by forward and
side scatter profiles and then for GFP
positivity before generating CD4 vs
CD8 plots. Percentages are expressed
as a percentage of live GFP! thymo-
cytes. Results shown are representa-
tive of two independent experiments,
with two time points each.
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The Dis.d446 Runx1 mutant does not decrease the percentage of
CD4 SP thymocytes; however, the percentage of DP thymocytes is
still decreased and the percentage of DN and CD8 SP thymocytes
is increased, as occurs when full-length Runx1 is expressed (Fig.
3I). This intermediate phenotype implies that some C-terminal
functions of full-length Runx1 map to the Groucho interaction do-
main and others do not. However, the decrease in cell number
resulting from expression of Dis.d446 Runx1 (Figs. 2D and 3I)
makes it difficult to interpret these results.
Full-length distal and proximal Runx1 directly down-regulate
CD4 expression on DP thymocytes
Because SP thymocytes are normally generated by MHC-depen-
dent selection events, Runx1 could be perturbing the CD4/CD8
phenotype by affecting the selection process or by direct cell au-
tonomous effects. To examine the effect of Runx1 on CD4! thy-
mocytes independently of thymic negative and positive selection,
we used the E#-bcl-2-25 line of bcl-2 transgenic mice, in which
the antiapoptotic gene bcl-2 is constitutively expressed in thymo-
cytes (34). We incubate bcl-2 transgenic thymocytes, which are
resistant to death by neglect, in suspension culture. This allows us
to examine the effect of Runx1 expression with greatly diminished
influence from interactions with class I and class II MHC, which
normally skew the final readout by the selective proliferation (pos-
itive selection) or deletion (negative selection) of certain thymo-
cyte subsets. To be able to monitor the effect of distal and proximal
Runx1 on DP thymocytes, these constructs were transduced into
the immediate precursors of DP cells.
In suspension culture, bcl-2 transgenic thymocytes differentiate
from DN to TCR"-intermediate and TCR"-high stages in a few
days. The starting population was largely negative for CD4 and
CD8 (Fig. 4B) and had negative to low levels of expression of
TCR" (data not shown). Within 16 h of isolation and incubation in
a single-cell suspension, the majority of these cells have up-regu-
lated their expression of both CD4 and CD8 (Fig. 4C). At 40 h,
TCR" expression is up-regulated from negative to intermediate
levels (Fig. 4E). Subsequently, a few CD4 or CD8 SP thymocytes
appear, probably due to the stochastic down-regulation of either
CD8 or CD4, as seen in the thymuses of mice with null mutations
of class I and class II MHC molecules (36). Thymocytes without
the bcl-2 transgene that are cultured under the same conditions die
within 24 h (data not shown). The bcl-2 transgenic thymocytes
thus allow examination of the molecular events of thymocyte mat-
uration in a more physiologically relevant regulatory context than
a transformed thymocyte cell line.
Expression of full-length distal or proximal Runx1 in cells trans-
duced at the DN stage leads to the selective down-regulation of
surface CD4 expression in the DP thymocyte population, starting
at 16 h when all populations contain many DP thymocytes and
intensifying through the time course’s end at 88 h (Fig. 4D). As in
the fetal thymic organ cultures, the level of expression of CD8 is
unaffected, resulting in the generation of apparent CD8 SPs. GFP!
control and all GFP!Runx1! viable cell numbers increase from 0
to 66 h (data not shown). This can be explained by the fact that
retroviral vectors can stably infect only proliferating cells. Thus,
the disappearance of CD4! thymocytes from populations express-
ing full-length Runx1 is not due to the death of these cells, but
rather results from the selective down-regulation of CD4 in viable
cells.
The down-regulation of CD4 in these cultures is not associated
with conventional positive selection signals. Thymocytes under-
going positive selection are characterized by an up-regulation of
the activation Ag CD69, which is not seen in these cultures (data
not shown). In addition, the apparent CD8 SP thymocytes induced
by expression of distal or proximal full-length Runx1 do not show
the heat-stable Ag down-regulation characteristic of SP thymo-
cytes after they have passed through positive selection and are
ready to immigrate to the periphery (data not shown). This indi-
cates that these cells are not mature CD8 SP thymocytes and that
CD4 down-regulation by Runx1 is likely to be independent of
coreceptor/TCR-MHC interaction.
Expression of the Runx1 mutant incapable of associating with
the corepressor Groucho/TLE (Dis.d446) in bcl-2 transgenic thy-
mocytes also results in the down-regulation of surface CD4 ex-
pression (Fig. 4). This clarifies the result seen in FTOC, in which
the effect on CD4 expression was occluded by a loss of GFP! cells
(Fig. 3I). The C terminus, but not the Groucho interaction domain
per se, is necessary for the silencing of CD4 expression by Runx1,
confirming results from FTOC.
Full-length Runx1 expression does not down-regulate surface
CD4 expression in mature CD4!CD8& splenic T cells
To investigate the limit of the responsiveness of the CD4 locus to
Runx1-mediated CD4 silencing in development, mature splenic T
cells from bcl-2 transgenic mice were infected with control vector,
distal or proximal full-length Runx1, distal Runx1 lacking the
Groucho binding domain, and distal or proximal "5 Runx1 (Fig.
5). In stark contrast to the DP thymocytes in FTOC and in the bcl-2
transgenic suspension culture, CD4 expression was not down-reg-
ulated in these cells. Indeed, expression of distal or proximal full-
length Runx1 or distal Runx1 lacking the Groucho binding domain
in mature CD4! T cells isolated from the spleen actually slightly
up-regulated CD4 expression compared with CD4 expression in
uninfected T cells. In these cells, the distal N-terminal isoforms
caused stronger up-regulation, consistent with our previous evi-
dence that the distal N terminus enhances DNA binding by Runx1
(15). CD8 expression levels are not affected by the expression of
either distal or proximal full-length Runx1. In addition, there is no
increase in the small number of CD4!CD8! splenic T cells, in-
dicating that Runx1 does not trans activate CD4 in CD8! splenic
T cells (data not shown). Distal or proximal "5 Runx1 expression
in splenic T cells does not alter CD4 expression, suggesting that
the C terminus of Runx1 may trans activate, rather than silence,
CD4 in CD4! T cells. This suggests that the mechanism of turning
off CD4 expression in DP thymocytes and the mechanism of main-
taining the CD4 locus in an “off” configuration in mature CD8! T
cells are distinct. This is consistent with data from mice with a
conditional deletion of the CD4 silencer in CD8! T cells, in which
CD4 expression continues to be repressed, whereas deletion of the
CD4 silencer in DP thymocytes results in the expression of CD4
throughout thymocyte development and in CD8! T cells (37, 38).
Expression of either Runx1 or Runx3 results in the down-
regulation of CD4 expression in DP thymocytes: essential roles
of the nuclear matrix targeting sequence and aa 212–263 for
CD4 repression in thymocytes
Enforced expression of Runx1 or Runx2 in the thymus of trans-
genic mice results in an increase in the production of CD8 SP
thymocytes (9, 10). Our results suggest that the increase in CD8 SP
thymocytes in these mice results from CD4 silencing in DP thy-
mocytes. Expression of Runx3 has been reported to be required for
CD4 silencing (11, 12). This suggests that all three family mem-
bers have the capacity to silence CD4. In agreement with this
hypothesis, enforced expression of Runx3 in bcl-2! DP thymo-
cytes results in the down-regulation of CD4 expression (Fig. 6).
Because all three Runx family members are capable of silencing
CD4, we chose to target conserved regions for deletion, as indi-
cated in Fig. 7. We also deleted a region that is responsible for the
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association of Runx1 with the corepressor Sin3A (25), but which
is not highly conserved between Runx1, 2, and 3 (Fig. 7). Deletion
of the Sin3A association domain (aa 181–210) has no effect on the
Runx1-mediated silencing of CD4 in bcl-2! thymocytes (Fig. 6),
indicating that Sin3A interaction with Runx1 is not required to
silence CD4. This is in accord with the relative lack of conserva-
tion of this domain between the Runx family members. Deletion of
the conserved aa 361–451, downstream of the nuclear matrix tar-
geting sequence, also leaves Runx1-mediated CD4 silencing
largely intact (Fig. 6). In contrast, deletion of the region (aa 263–
360) containing the conserved nuclear matrix targeting sequence
(aa 318–358) virtually abrogates Runx1-mediated silencing of
CD4. It is unlikely that aa Runx1 263–301 are required for CD4
silencing, because the corresponding amino acids are absent in
murine Runx3 (Fig. 7). Deletion of a second region containing
conserved amino acid residues that leaves the nuclear matrix tar-
geting sequence intact (aa 212–262; Fig. 7) also decreases Runx1-
mediated silencing of CD4, although not to the same extent as
deletion of the region containing the nuclear matrix targeting se-
quence. Deletion of the C terminus while leaving intact the nuclear
localization sequences and DNA binding domain causes the Runx
protein to lose all activity as a silencer, reducing the effectiveness
of CD4 silencing below the level of control. This implies that
occupation of the Runx binding sites in the CD4 silencer by the
retrovirally expressed protein blocks CD4 silencing by endoge-
nous Runx proteins.
The Runx transcription factor family is highly conserved in ver-
tebrates, and an isoform of Runx3 recently cloned from an elas-
mobranch (Raja eglanteria, the clearnose skate) includes most, but
not all, homologous C-terminal domains of murine Runx3 (Fig. 7)
FIGURE 4. Runx1 down-regulates CD4 expression independently of positive selection, in a Groucho-independent manner. The bcl-2! transgenic
thymocytes (A, plotted to show CD4 and CD8 expression) were used as a starting population to enrich for CD4/CD8 DN thymocytes (B). CD4&CD8&
thymocytes were infected with GFP-alone control vector (C, 1–9 D, 1–4 E, 1–5), distal full-length Runx1 (D, 5–8 E, 6–10), proximal full-length Runx1
(D, 9–12 E, 11–15), distal.d446 Runx1 (D, 13–16 E, 16–20), distal "5 Runx1 (D, 17–20 E, 21–25), and proximal "5 Runx1 (D, 21–24 E, 26–30). The
GFP-positive and GFP-negative populations in the cells infected with the control vector are shown, plotted for CD4 vs CD8 expression at 16 h postinfection
(C, 2 and 6), 40 h postinfection (C, 3 and 7), 66 h postinfection (C, 4 and 8), and 88 h postinfection (C, 5 and 9). The GFP-negative (no fill) and GFP-positive
(green tint) populations are shown as overlaid histograms with the level of CD4 expression on the x-axis, at 16, 40, 66, and 88 h postinfection (D, 1–24).
An increase in TCR" expression of the GFP-positive populations over time (E, 16 h postinfection, 1, 6, 11, 16, 21, and 26 40 h postinfection, 2, 7, 12,
17, 22, and 27 88 h postinfection, 4, 9, 14, 19, 24, and 29) is shown, with TCR" positivity indicated by boxes. The level of CD4 expression in the
TCR"-positive subpopulations of the GFP-negative (no fill) and GFP-positive (green tint) populations is shown as overlaid histograms with the level of
CD4 expression on the x-axis, at 40 h postinfection (E, 3, 8, 13, 18, 23, and 28), and 88 h postinfection (E, 5, 10, 15, 20, 25, and 30).
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(M. K. Anderson, R. Pant, A. L. Miracle, X. J. Sun, C. A. Luer,
C. J. Walsh, J. C. Telfer, G. W. Litman, and E. V. Rothenberg,
manuscript in preparation). We did not see silencing of CD4 upon
expression of R. eglanteria Runx3 (Fig. 6), despite the substantial
conservation of the nuclear matrix targeting sequence in this mol-
ecule (Fig. 7). It is of note that this Runx3 isoform from R. eg-
lanteria lacks the amino acid residues corresponding to Runx1 aa
178–296, including a region between aa 222 and 235 (Fig. 7,
bolded) that is conserved between murine Runx3 and Runx1 and is
contained within the sequences deleted in the d212–262 Runx1
mutant, which does not silence CD4 effectively. This provides ad-
ditional support for the inference that mammalian Runx-mediated
silencing depends on conserved domains encompassed within aa
178–296, in addition to the runt DNA binding domain (aa 50–177)
and the nuclear matrix targeting sequence (aa 318–358).
Discussion
In this study, we demonstrate that enforced expression of Runx1
isoforms in thymocytes can have strongly isoform-dependent ef-
fects on CD4 expression and on proliferation and survival. Using
a retroviral transduction system, the effects of distinct isoforms on
specific target populations have been distinguished. Full-length
Runx1 inhibits CD4 expression in immature TCR"-low thymocyte
subsets as well as preventing the appearance of mature CD4!
TCR"-high thymocyte subsets, while sharply inhibiting prolifera-
tion or survival overall. Truncated, naturally expressed isoforms of
Runx1 with reduced DNA-binding activity enhance survival
and/or proliferation. In short-term culture of bcl-2-expressing thy-
mocytes, full-length Runx1 is shown to mediate some of its effects
in fetal thymic organ culture by silencing CD4 expression in DP
thymocytes. CD4 repression in this system does not depend on
previously described interactions between Runx1 and the corepres-
sors Groucho/TLE or Sin3A, because deletions that remove these
interaction domains do not affect repression. Instead, we show that
this repressive mechanism depends on the region containing the
nuclear matrix targeting sequence and on another region mapping
between aa 212 and 262.
These results are in good agreement with the evidence derived
from transgenic mice expressing Runx1 or Runx2 under the con-
trol of T cell lineage-specific promoters and from mice ablated for
one or both alleles of Runx1 or Runx3, or Runx target sites in the
CD4 gene (9–13). Our results extend in several ways the insights
obtained from these steady state analyses of mice with genetic
modifications affecting Runx expression. First, not only full-length
isoforms of Runx1 mRNA are produced by the intact Runx1 gene,
but also the truncated variants investigated in this study. As we
show, these appear to act in vivo as competitive inhibitors for the
full-length isoforms’ negative effect on thymocyte proliferation or
survival. A null mutation in a gene can preclude the ability to
express both kinds of forms. We would note that thymocyte pop-
ulation expansion generally, and accumulation of DP thymocytes
specifically, may depend in vivo on an adequate level of the trun-
cated isoforms. Thus, a Runx1 null mutation resulting in a lowered
thymocyte cell count in vivo does not necessarily imply a require-
ment for full-length Runx1 and its associated DNA binding, re-
pression, and trans activation domains. The phenotype might also
arise from an absence of the truncated Runx1 isoforms. Second,
our retroviral transduction system enables us to target specific
stages of development for perturbation from a known, normal
starting baseline. This is important because gene dosage of Runx
family members crucially affects hemopoietic differentiation
stages back to the hemangioblast and hemopoietic stem cell (39–
42). In mice with a constitutive null mutation or in transgenic
mice, the existence of any thymus-populating cells could depend
on unknown, compensatory alterations. Finally, this analysis has
enabled us to identify specific regions of the Runx1 transcription
factor that are most critical for the stage-specific repression of
CD4. The results argue against roles for the corepressors Groucho
and Sin3A and suggest that the nuclear matrix targeting sequence
is involved in this function.
The suspension culture system that we describe using bcl-2!
thymocytes clearly shows that Runx1 or Runx3 can act by specif-
ically down-regulating CD4 expression as soon as CD4 is ex-
pressed in DP thymocytes, with ersatz CD8 SP cells accumulating.
It remains to be seen whether such disguised DP cells are also the
source of the more mature, TCR"-high CD8 SP cells that can be
generated by Runx1-transduced cells in fetal thymic organ culture.
Positive selection signaling via MHC class I ligation of the CD8-
TCR!" complex has been postulated to deliver survival signals or
to send a signal to down-regulate CD4 expression in normal thy-
mocyte development. However, the short-term suspension culture
system shows that Runx1 or Runx3 can act on the CD4 locus
independently of positive selection, which does not occur in the
single-cell suspension culture. This suggests that Runx repression
of CD4 is downstream of signaling from the CD8-TCR!"
complex.
The CD4 locus is responsive to Runx-mediated repression as
soon as CD4 is up-regulated in the DP compartment, but loses this
responsiveness in CD4! splenic T cells, in agreement with in vivo
data using Runx site mutants of the CD4 silencer (13, 37, 38).
Runx family members are the first transcription factors described
as capable of down-regulating CD4 specifically in the DP com-
partment. The fact that cells can respond this way demonstrates
that DP cells contain the cofactors needed to carry out the repres-
sion. This implies that under normal conditions, the expression of
CD4 in DP cells depends on a mechanism that keeps the repressive
activity of full-length Runx proteins in check. It is tempting to
speculate that the truncated forms of Runx1 could play a role in
this antagonism. The DN to DP transition, when CD4 is normally
turned on in murine thymocytes, is also the phase of the most rapid
FIGURE 5. Full-length Runx1 or Runx1 lacking the Groucho binding
domain does not silence CD4 expression in mature CD4! T cells. The
bcl-2 transgenic splenic T cells were infected with control vector (A), distal
(B) and proximal (C) full-length Runx1, distal Runx1 truncated at aa 446
(D), and distal (E) and proximal (F) "5 Runx1. Cells were harvested at 24
and 48 h postinfection, with the two time points giving the same results.
Cells were analyzed by FACS by gating for viability, GFP expression, and
then for the CD4!CD8& population. CD4 expression profiles are shown
for uninfected GFP-negative cells (unfilled histograms) and GFP-positive
cells (green-tinted histograms).
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proliferation, in accord with the growth advantage seen with the
expression of the truncated isoforms.
A model in which DP thymocytes receive a signal instructing
them to down-regulate CD4 would require the cooperation of a
transcriptional repressor active only in those cells. However, in
vivo, CD4 expression is not down-regulated until positive
selection is well underway. Analyses of the timing of the shut-off
of de novo CD4 expression in positive selection (43, 44) imply
that the Runx-repressive complex would only be assembled in
CD4!CD8low DP intermediates. What role does TCR signaling
play in mobilizing CD4 repression by Runx factors? Runx3 has
been reported to be required for CD4 silencing during thymocyte
development into CD8! CTLs (11, 12). Both Runx1 and Runx3
are expressed in the thymus (9, 45). However, neither Runx3
mRNA nor Runx1 mRNA levels differ significantly between CD4
SP and CD8 SP thymocytes. Our finding that enforced expression
of either full-length Runx1 or Runx3 can silence CD4 in DP
thymocytes supports the hypothesis that signals leading to CD4
silencing in positive selection trigger increased Runx3-repressive
activity without an increase in Runx3 mRNA. This increase in
FIGURE 6. Either murine Runx1 or Runx3, but not Runx3 from the skate, can silence CD4 expression in thymocytes. The Runx1 nuclear matrix
targeting sequence and Runx1 aa 212–262 are required for complete Runx1-mediated CD4 repression in thymocytes. CD4&CD8& bcl-2! transgenic
thymocytes were infected by murine Runx1, murine Runx3, and R. eglanteria Runx3 retroviral constructs. Schematics of the constructs indicate the runt
DNA binding domain (red box) and nuclear matrix targeting sequence (blue box). Thymocytes were infected with retroviral constructs encoding GFP alone
(MSCV, 1), distal full-length Runx1 (Dis.full Runx1, 2), murine Runx3 (mRunx3, 3), distal Runx1 truncated at aa 190 (Dis.d190 Runx1, 4), distal Runx1
truncated at aa 211 (Dis d211 Runx1, 5), isolated runt DNA binding domain with an exogenous nuclear localization sequence (Runt NLS, 6), distal Runx1
truncated at aa 361 (Dis.d361 Runx1, 7), distal Runx1 with an internal deletion from aa 263–360 (Dis.d263–360 Runx1, 8), distal Runx1 with an internal
deletion from aa 212–262 (Disd.d212–262, 9), distal Runx1 with an internal deletion from aa 181–210 (Dis d181–210, 10), and R. eglanteria (clearnose
skate) Runx3 (R. eglanteria Runx3, 11). The GFP-negative (no fill) and GFP-positive (green tint) populations are shown as overlaid histograms with the
level of CD4 expression on the x-axis, at 60 h postinfection. Percentages in the overlaid histographs indicate the percentage of CD4 low (range indicated
by the horizontal bars) cells in the GFP-positive cell populations (green-tinted histograms). The geometric mean fluorescence intensities of CD4 staining
of the GFP-positive cell populations (green-tinted histograms) are indicated below the horizontal bars.
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activity could arise from either alternative splicing to include the
domains necessary for silencing, or increased translational effi-
ciency. Alternative splicing and regulation by translational effi-
ciency are bypassed by our retroviral constructs; posttranslational
modifications and differences in cofactor activity are not. In sup-
port of this hypothesis, two groups report that there is normally
more full-length Runx3 protein in CD8 SP thymocytes than CD4
SP thymocytes (9, 46), contrasting with the similarity in RNA
expression. We have found no difference in the CD4-silencing
activity of retrovirally expressed Runx1 and Runx3 in thymocytes
treated with mitogen-activated protein kinase inhibitors (data not
shown), showing that posttranslational modification of serines in
the region C-terminal to the runt domain (47) is not required for
Runx-mediated CD4 repression.
We demonstrate that CD4 down-regulation by Runx1 requires
the presence of the Runx1 C terminus downstream of aa 210, but
does not require the sequences thought to mediate Runx1 interac-
tion with the corepressors Groucho or Sin3A. It is intriguing that
deletion of the sequence containing the nuclear matrix targeting
sequence abrogates Runx1-mediated silencing of both CD4 in thy-
mocytes and p21Waf1/Cip1 in NIH3T3 cells (25). The Runx nuclear
matrix targeting sequence is responsible for the subnuclear local-
ization of this molecule and has been associated with increased
trans activation (48–51) or repression (25) of target genes. An
attractive possibility is that the nuclear matrix targeting sequence
stabilizes Runx binding to the CD4 silencer, and that, in the ab-
sence of the nuclear matrix targeting sequence, Runx rapidly dif-
fuses away from the CD4 locus and/or from corepressor molecules
associated with sites on the nuclear matrix.
Deletion of aa 212–263 from Runx1 also makes Runx1 less
effective as a repressor of CD4 repression, possibly by deleting a
site of interaction with an unknown corepressor or by interfering
with the recruitment of a histone deacetylase. Murine Runx3 does
not include regions corresponding to Runx1 aa 242–297, but re-
presses actively nonetheless, making aa 212–241 more likely to
play a critical role. The skate Runx3 isoform that has been cloned
to date cannot repress CD4. In addition to regions of Runx1 that
are absent in mouse Runx3, the skate isoform of Runx3 lacks an
FIGURE 7. Alignment of murine Runx1, murine Runx2, murine Runx3, and R. eglanteria Runx3 regions downstream of the runt domain. Amino acids
that are identical between the molecules are indicated by an asterisk those that are similar are indicated by a colon or period. Gaps to facilitate alignment
are indicated by dashes. Numbering of amino acids is taken from murine proximal Runx1. The C-terminal portion of the highly conserved runt domain
is highlighted in yellow. A putative nuclear localization signal (NLS) is boxed. Amino acids removed from the deletion constructs of distal Runx1 used
in Figs. 4 and 6 are highlighted (pink, deletion of aa 181–210 orange, deletion of aa 212–262 underlined, deletion of aa 263–360 and blue, the truncation
removing the site of corepressor Groucho/TLE association, aa 447–451). Residues that are conserved between murine Runx1, Runx2, and Runx3, but which
are not present in R. eglanteria Runx3 in the region from aa 212–262 (orange) are bolded. The nuclear matrix targeting sequence (NMTS) is highlighted
in green.
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additional region corresponding to Runx1 aa 178–241. Runx1 aa
residues 178–241 are encoded by Runx1 exon 6. In this region,
amino acids potentially required for CD4 silencing by mammalian
Runx1, 2, or 3 include Runx1 aa 178–180 (Fig. 7, RHR) and
conserved aa from 222–235 (Fig. 7, bolded). Taken together, these
results map one of the functions needed to repress CD4 to the part
of the protein encoded by Runx1 exon 6. Exon 6 is often spliced
out of Runx1 mRNA transcripts from the endogenous gene, and
the resulting proteins have been reported to be capable of trans
activation (31). Results obtained with deletion mutants of Runx2
and the exon 6-deficient splice isoforms of Runx1 conflict as to
whether the amino acids corresponding to Runx1 aa 178–180 are
necessary for nuclear localization (52, 53). However, amino acids
in the region corresponding to aa 222–235 are conspicuous for
their conservation among the mammalian Runx family members
and lie within the region corresponding to aa 212–244, which ap-
pears to be required for full Runx1-mediated silencing activity. We
are therefore investigating the possibility that these conserved
amino acids represent an interaction site for a novel corepressor.
We have shown that either Runx1 or Runx3 can down-regulate
CD4 expression specifically in DP thymocytes independent of pos-
itive selecting signals. Further studies will be necessary to under-
stand the relationship between Runx subnuclear localization and
the nature of the control of the switch between Runx-mediated
trans activation and repression.
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WC1 molecules are transmembrane glycoproteins belonging to the scavenger receptor cysteine-rich family and uniquely expressed
on !" T cells. Although participation of WC1# !" T cells in immune responses is well established, very little is understood
regarding the significance of expressing different forms of the WC1 molecule. Two forms previously identified by mAbs, i.e.,
WC1.1 and WC1.2, are expressed by largely nonoverlapping subpopulations of !" T cells. In this study it was shown that
expression of the WC1.1 coreceptor was the main indicator of proliferation and IFN-! production in response to autologous and
bacterial Ags as well as for IFN-! production without proliferation in Th1-polarizing, IL-12-containing cultures. Nevertheless,
after culture in either Th1-polarizing or neutral conditions, mRNA was present for both T-bet and GATA-3 as well as for
IL-12R$2 in WC1.1# and WC1.2# subpopulations, and neither produced IL-4 under any conditions. Although the steady decrease
in the proportion of WC1.1# cells, but not WC1.2# cells, within PBMC with animal aging suggested that the two subpopulations
may have different roles in immune regulation, cells bearing either WC1.1 or WC1.2 expressed mRNA for regulatory cytokines
IL-10 and TGF-$, with TGF-$ being constitutively expressed by ex vivo cells. Overall, the results demonstrate that the form of
the WC1 coreceptor expressed on !" T cells divides them into functional subsets according to IFN-! production and proliferative
capacity to specific stimuli as well as with regard to representation within PBMC. Finally, evidence is provided for minor
differences in the intracytoplasmic tail sequences of WC1.1 and WC1.2 that may affect signaling. The Journal of Immunology,
2005, 174: 3386–3393.
T he !" T cells bearing the lineage marker WC1 are asso-ciated with production of the proinflammatory cytokineIFN-! (1–3) and are among the earliest cells to accumu-
late upon intradermal injection of Mycobacterium bovis purified
protein derivative, preceding the arrival of #$ T cells and macro-
phages (4). The majority of !" T cells in the blood of young ru-
minants express WC1, whereas in other tissues, such as the spleen,
the !" T cells are WC1! (5). Serial analysis of gene expression
and microarray analyses suggest that the WC1" !" T cells of cattle
represent the inflammatory population, whereas the WC1! !" T
cells are regulatory cells and share characteristics with myeloid
lineage cells (6, 7). This is supported by the observation that an-
imals depleted of WC1" cells by anti-WC1 Abs show a decrease
in nonspecific production of IFN-! and a bias toward a Th2 re-
sponse, as evidenced by increased IL-4 and decreased IgG2 Abs
(8). Thus, WC1" !" T cells appear to be important mediators of
cell-mediated (type 1) immunity. Although a generalized role for
!" T lymphocytes is emerging from these and other studies in
ruminant systems (9) as well as nonruminant systems (10), the
significance of WC1 expression itself remains enigmatic.
WC1, also known as T19, is a large, type 1, integral mem-
brane glycoprotein belonging to the scavenger receptor cys-
teine-rich (SRCR)3 family. Although WC1 proteins have only
been found on !" T cells of ruminants, cDNA inferred to be the
murine WC1 homologue was recently identified (11). WC1
molecules are products of a multigene family (12–14), and bo-
vine !" T cells express three known variants, WC1.1, WC1.2,
and WC1.3 (15). WC1.1 and WC1.2 are expressed on predom-
inantly nonoverlapping subsets of bovine !" T cells, whereas
WC1.3 is expressed on a small subpopulation of WC1.1" cells
(15). Although only WC1.1 has been fully sequenced, limited
sequencing and restriction mapping indicates substantial differ-
ences among the three cloned WC1 forms in their extracellular
SRCR domains, of which there are 11 (15).
The amino acid sequence of archetypal WC1 (WC1.1) (14) sug-
gests a role in cellular activation based on the potential ITAM
[YEDALAEAVYEEL] in the cytoplasmic tail proximal to the
transmembrane region. A role in cellular activation is supported by
examples of other known SRCR family members present on T
cells, namely CD5 and CD6 (16), both of which have roles in
activation and regulation of T cell responses (17–20). There is
evidence that Ab-mediated signaling through WC1 increases cel-
lular activation (21) as well as cell cycle arrest (22). These differ-
ences in purported WC1 function may be the result of cross-link-
ing different forms of the molecule, given that different Abs and
cellular systems were used. It has been suggested that the signif-
icant extracellular variation in WC1 may represent a new mecha-
nism of pattern recognition and regulation of immune responses by
!" T cells (23). In this study we evaluated functional responses of
!" T cells expressing alternate forms of WC1, their proportional
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representation within the PBMC population of animals of varying
ages, and the potential signaling motifs of their intracytoplasmic
tails.
Materials and Methods
Animals and cells
Blood was obtained from female cattle, ages 1 day to 44 mo, via ve-
nipuncture of the jugular vein. Blood was either collected into a solu-
tion of heparin or defibrinated as indicated for the assay (24). PBMC
were isolated from blood via density gradient centrifugation over Fi-
coll-Hypaque (Ficoll-Paque; LKB-Pharmacia Biotechnology) by stan-
dard techniques. Culture medium consisted of RPMI 1640, 10% heat-
inactivated FBS, 2 %M L-glutamine, 60 %g/ml gentamicin, and 5 #
10!5 M 2-ME. PBMC cultured with sonicates of Leptospira borg-
petersenii serovar Hardjo were obtained from animals vaccinated with
Spirovac (Biocore), a whole cell vaccine containing aluminum hydrox-
ide administered in two s.c. doses, 4 wk apart (25).
In vitro cultures
PBMC were cultured at 2.5 # 106 cells/ml, except for Con A-stimulated
cultures, which were seeded at 6.25 # 105 cells/ml. All cultures were
conducted at 37°C in 5% CO2 in air. PBMC isolated from heparinized
blood were used in cultures stimulated with PMA and ionomycin (1 %g/ml
each; Sigma-Aldrich), Con A (5 %g/ml; Sigma-Aldrich), anti-CD3 mAb
(protein A-purified mAb Veterinary Medical Research & Development
(VMRD) at 10 %g/ml used to precoat plates as previously described by
Hanby-Flarida et al. (21)), IL-12 (250 U/ml human rIL-12) as described
previously (26) (BD Pharmingen), or a sonicate of leptospira (0.5 %g/ml
protein L. borgpetersenii serovar Hardjo-bovis clone RZ33) (25). PMA-,
ionomycin-, Con A-, and IL-12-stimulated cultures were incubated for 4
days, whereas the leptospira sonicate cultures were incubated for 6 days
before analysis unless indicated otherwise. For autologous MLR (AMLR)
cultures, PBMC were depleted of monocytes by isolation from defibrinated
blood and were seeded at 2.5 # 106 cells/ml. These monocyte-depleted
PBMC were stimulated with gamma-irradiated (5000 rad) monocyte-con-
taining PBMC at a density of 6.5 # 105 cells/ml for 6 days. For all test
cultures, control cultures were established that were identical except for
exclusion of the Ags, cytokine, mitogen, or gamma-irradiated stimulator
cells and are referred to as medium cultures. In some experiments, cells
were loaded with CFSE (Molecular Probes) before culture using 3 %M
CFSE and 1.2 %M Pluronic F127, as described previously (27), to assess
cell division. Cellular responses analyzed included assessment of cell di-
vision by CFSE intensity, enumeration of subpopulations, expression of
CD25, production of IFN-! by flow cytometry, and evaluation of mRNA
transcript production as described below.
Immunofluorescence and flow cytometric analyses
Cells in culture were stained for cell surface differentiation molecules,
fixed in 1% paraformaldehyde, and analyzed via flow cytometry for two-
or three-color fluorescence (FACSCalibur; BD Biosciences) using the fol-
lowing primary mAb: BAG25A and BAQ159A for WC1.1 (VMRD),
CACTB32A for WC1.2 (VMRD), CACT21A for WC1.3 (a gift from Dr.
W. C. Davis, Pullman, WA) (15), IL-A29 (28) and CC15, which are pan-
specific for all WC1 molecules (Serotec), GB21A for "-TCR (VMRD), and
UC-2C2 for CD25 (a gift from Dr. B. Taylor, Davis, CA) (29). Secondary
Abs used for indirect staining were isotype-specific polyclonal goat anti-
mouse Ig conjugated with PE or FITC (Southern Biotechnology Associ-
ates). In staining procedures that used secondary Abs, unrelated isotype-
matched primary mAb were used with matching secondary Abs and used
as negative controls (Southern Biotechnology Associates and BD Pharm-
ingen). Where indicated, analyses were conducted using CACTB32A di-
rectly labeled with zenon Alexa Fluor 488 (Molecular Probes). Biotinyl-
ated anti-IFN-! mAb 7B6 (a gift from J. J. Letesson, Leeven, Belgium)
(30) and streptavidin-PerCP were used for intracellular staining essentially
as previously described (25). Biotinylated isotype-matched (IgG1) mAb
was used as a control primary Ab in these experiments. Viable cells were
gated based on scattering characteristics. Proliferation of cells stained with
the phenotypic markers described above was assessed by logarithmic plots
of CFSE intensity. Analysis of flow cytometric data was conducted using
CellQuest (BD Biosciences).
Enumeration of cells within WC1 subpopulations in cultures
To assess a relative change in the proportion of cells expressing a particular
form of WC1 after culture, cells were stained for the expression of WC1.1
or WC1.2 by indirect immunofluorescence, and the percentage of each was
determined. The total percentage of WC1" cells was defined as the sum of
cells bearing either WC1.1 or WC1.2 based on pilot studies, confirming
this was the case using a pan-specific anti-WC1 mAb. Changes in repre-
sentation of WC1.1" or WC1.2" cells as a result of culture were calculated
as follows: % change ($) in WC1.1" cells % ([% WC1.1"/% total
WC1"]stimulated ! [%WC1.1"/% total WC1"]control) # 100%; % $
WC1.2" cells % ([% WC1.2"/% total WC1"]stimulated ! [% WC1.2"/%
total WC1"]control) # 100%.
Sorting of cells
Cells were sorted after 48 h in Con A- or IL-12-stimulated cultures using
magnetic bead cell sorting (Miltenyi Biotec). This was performed essen-
tially as previously described (31) in that cells were positively purified by
reacting PBMC with primary mAb, followed by goat anti-mouse IgG-con-
jugated magnetic microbeads in a suspension of PBS with 5% heat-inac-
tivated horse serum. The exception was that the entire isolation procedure
was conducted at 0–4°C, and cells were filtered through a 30-%m pore size
mesh (Miltenyi Biotec) immediately before application to the column. In
pilot experiments, cells that had been cultured with Con A for 48 h were
resuspended by pipetting, filtered, and then stained to assess the proportion
of cells in subpopulations with and without filtering. This ensured mesh
filtration removed cellular aggregates without biasing results. WC1.1"
cells were positively selected over magnetic bead columns after staining
with mAb BAQ159A and enriched to 97.3%, on the average, whereas
WC1.2" cells were positively selected after staining with mAb
CACTB32A and enriched, on the average, to 98.4%. Ex vivo PBMC were
stained in the same way, but were sorted via flow cytometry (FACSAria;
BD Biosciences) to 96.8% (WC1.1) and 98.3% (WC1.2) purity.
RNA isolation and PCR
RNA was isolated from either ex vivo PBMC or after 48 h of culture using
TRIzol (Invitrogen Life Technologies) according to the manufacturer’s in-
structions. Total RNA was subjected to DNase digestion and then used for
cDNA synthesis using a commercial RT kit (Promega). PCR was con-
ducted using primer pairs described below along with PCR reagents (Pro-
mega) to yield a final concentration of 2 mM MgCl2. Cycling conditions
were 30 s at 95°C, 1 min at 52°C, and 45 s at 72°C for 30 cycles. PCR
products were analyzed in 1.2% Tris-acetic acid-EDTA agarose gels,
cloned into the pCR2.1 vector (Invitrogen Life Technologies), and se-
quenced commercially. The following primers were used in semiquantitative
PCR with the PCR product length in parentheses and GenBank accession
numbers in brackets: bovine GAPDH [U85042]: sense primer, 5&-
GTCATCATCTCTGCACCTTCT-3&; antisense primer, 5&-ACCACCTTCT
TGATCTCATCAT-3& (430 bp); bovine GATA-3 [TC211018]: sense primer,
5&-CCAGACCAGAAACCGAAAAA-3&; antisense primer, 5&-ACCATACT
GGAAGGGTGGTG-3& (234 bp); bovine IFN-! [NM_174086]: sense primer,
5&-TAAGGGTGGGCCTCTCTTCT-3&; antisense primer, 5&-AAATATTG
CAGGCAGGAGGA-3& (387 bp); bovine IL-4 [NM_173921]: sense primer,
5&-CAGTGCTGGTCTGCTTACTG-3&; antisense primer, 5&-CAAGAG
GTCTTTCAGCGTAC-3& (338 bp); bovine IL-10 [U00799]: sense primer,
5&-GTGAACTCACTGGGGGAGAA-3&; antisense primer, 5&-CCCTCTCTT
GGAGCTCACTG-3& (112 bp); bovine IL-12R-$2: sense primer, 5&-
CTGGAATATGGTTAATGTCAC-3&; antisense primer, 5&-GAGTTAGCT
GCAGACACAG-3& (408 bp); bovine T-bet [TC216567]: sense primer, 5&-
CCTGGACCCAACTGTCAACT-3&; antisense primer, 5&-GAAA
CTCGGCCTCATAGCTG-3& (172 bp); bovine TGF-$1 [M36271]: sense
primer, 5&-CCTTACATCTGGAGCCTGGA-3&; antisense primer, 5&-
GTTGGACAACTGCTCCACCT-3& (165 bp); and bovine WC1 [X63723]:
sense primer, 5&-TTCTCTGCCTTATCCTGGGGT-3& or 5&-CGCTTCTCT
TCCTGGTCC-3&; antisense primer, 5&-GGCAGTTAGAATATCTGAG
GCTTCATCTC-3&. Bovine IL-12R-$2 primers were based on sequences from
White et al. (26), bovine T-bet was from the TIGR Bos taurus Gene Index
'http://tigrblast.tigr.org/tgi/(, and sequences coding for the transmembrane and
cytoplasmic tail of bovine WC1 were based on data from Wijngaard et al. (15)
and our pilot studies in this report. Analysis of sequences was performed using
BioEdit version 5.0.6 'http://www.mbio.ncsu.edu/BioEdit/bioedit.html(.
Statistical analyses
Statistical analyses were conducted using MINITAB (Minitab) and Mi-
crosoft Excel data analysis software. Where appropriate, the two-tailed
Student’s t test was used to detect significant differences.
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Results
Representation of WC1 variants on cells in animals of
various ages
It has been established that the proportion of !" TCR" cells bear-
ing the lineage-specific determinant WC1 decreases within the
PBMC population with age (32). In this study the relative propor-
tions of total !" T cells and those bearing variants of WC1 were
evaluated for animals in three age groups representing newborns
(0–2 mo), adolescents (15–21 mo), and adults (27–44 mo; Fig. 1).
The groupings were based on preliminary data analysis, which
indicated that large changes in the percentage of WC1" !" T cells
within PBMC occurred within the first few months of life, whereas
considerably less variation occurred after 6 mo, and only small
changes occurred in animals over 2 years of age. For all the lym-
phocyte populations represented in Fig. 1, the differences in per-
centages between the newborn and adult age groups were statisti-
cally significant ( p & 0.05, by t test), except for WC1.2" cells
( p % 0.058; Fig. 1D). When comparing the newborn and inter-
mediate age groups, the mean decreases in percentage of total !"
T cells, WC1" !" T cells, and WC1.1" !" T cells were very
similar (4.4, 4.7, and 4.2%, respectively), demonstrating that most
of the decrease in !" T cells during the first 2 years after birth was
due specifically to a decrease in the WC1.1" cells. In contrast, the
relative representative of WC1.2" cells did not decrease. Although
the difference was not significant, the mean representation of
WC1.2" cells was greater in the adolescent group compared with
the newborn group.
Proliferation of cells in response to stimulation varies according
to the form of WC1 expressed
Given that WC1.1 and WC1.2 are mainly expressed on nonover-
lapping subpopulations showing disparate patterns of change with
animal aging, we hypothesized that these cells also differed func-
tionally. Thus, their responses to several stimuli known to induce
proliferation of WC1" !" T cells were evaluated. Subsequent to
stimulation, the relative proportion of WC1.1" and WC1.2" cells
was compared with that in medium control cultures for multiple
experiments using PBMC from several different animals (Fig. 2).
This method of comparison represents the sum total of cells within
the WC1.1" and WC1.2" !" T cell subpopulations that prolifer-
ated or survived without proliferation and excluded changes by
other subpopulations of leukocytes found in the cultures. Com-
pared with their relative representation in medium control cultures,
representation of WC1.1" cells in AMLR cultures or those with
leptospira Ag was significantly greater than that of WC1.2" cells.
In contrast, Con A stimulation resulted in a greater relative repre-
sentation of WC1.2" cells. Plate-bound anti-CD3 stimulation,
which does not induce substantial proliferation of bovine !" T
cells (30), did not result in significant changes in the representation
of either population relative to the other, whereas PMA/ionomycin
favored only marginal increases in representation of WC1.2"
cells. The change in representation of WC1.3" cells, a form of
WC1 coexpressed on a subset of WC1.1" cells, followed the pat-
tern of WC1.1" cells (data not shown).
To more clearly resolve the reason for the changes in relative
representation of WC1.1" and WC1.2" cells in cultures with var-
ious stimuli, PBMC were loaded with CFSE and proliferation by
the subpopulations determined using two-color flow cytometric
analysis (Fig. 3). Although Con A stimulation induced prolifera-
tion of both WC1 subpopulations, the response by WC1.1" cells
was consistently less vigorous than that of the WC1.2" cells (Fig.
FIGURE 1. Analysis of various !" T cell populations within PBMC.
Indirect immunofluorescence staining for surface expression of TCR
"-chain (A; mAb GB21A), all WC1 molecules (B; mAb IL-A29), WC1.1
(C; mAb BAQ159A), WC1.2 (D; mAb CACTB32A), and WC1.3 (E; mAb
CACT21A) on PBMC from 30 animals is shown. Animals were subdivided
by age into three groups, with similar numbers of animals per group: group
1 (E), 1 day to 2 mo; group 2 (!), 15–21 mo; and group 3 (‚), 27–44 mo.
The mean and SE for each age group in order are as follows for data
represented in each panel: A) 22.0 ) 2.8, 17.6 ) 2.1, and 11.3 ) 1.1%; B)
13.3 ) 1.4, 8.6 ) 0.9, and 4.2 ) 0.5%; C) 9.0 ) 0.7, 4.8 ) 0.5, and 3.0 )
0.5%; D) 3.6 ) 0.5, 5.1 ) 0.7, and 2.1 ) 0.2%; and E) 2.0 ) 0.2, 1.7 )
0.1, and 1.1 ) 0.1%. Significant differences between groups 1 and 3 were
found for data in A, B, C, and E by Student’s t test (p & 0.05).
FIGURE 2. Proliferation of WC1" !" T cell subsets in response to
various stimuli. After culture of PBMC with the indicated stimuli, cells
were stained by indirect immunofluorescence, and the percentages of cells
bearing WC1.1 or WC1.2 relative to total WC1" cells were compared with
those percentages in the unstimulated medium controls (see Materials and
Methods for calculation). Bars represent results from separate experiments,
and each was assessed using PBMC from three to six different animals (u,
relative representational increases of WC1.1" cells; !, relative represen-
tational increases in WC1.2" cells in stimulated cultures compared with
unstimulated cultures). The mean and SEM of the relative increase in rep-
resentation are indicated for each culture condition, and significance (p &
0.05) indicated by an asterisk.
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3A). Even in cultures in which cells bearing WC1.1 were the ma-
jority of ex vivo WC1" cells, culture with Con A favored the
expansion of cells expressing WC1.2, so that by the end of the
culture period they predominated. In contrast, AMLR and lepto-
spira Ag stimulation resulted in almost exclusive proliferation by
WC1.1" cells (Fig. 3, B and C).
Because changes in the proportion of cells bearing either WC1.1
or WC1.2 could theoretically be due to changes in receptor ex-
pression, WC1.1" or WC1.2" cells were sorted by MACS and
evaluated ex vivo as well as after culture with Con A or medium
for 4 days. Although the cells responded to the Con A stimulations,
as assessed by CFSE-loading, there was no change in the ex-
pressed form of WC1 on the cells, i.e., WC1.1" cells did not
acquire WC1.2 expression and vice versa, as assessed by immu-
nofluorescence staining of the cells after culture (data not shown).
However, the sorted cells did have transcripts coding for the in-
tracytoplasmic tail sequences of both forms (data not shown), sug-
gesting that surface expression may be controlled at the level of
translation and not transcription.
Variant of WC1 expressed corresponds to IFN-! production
WC1" !" T cells separated into subpopulations according to the
variant of WC1 expressed reflected their relative abilities to pro-
liferate in response to various stimuli. This suggested that the sub-
populations might also differ in their cytokine profiles. Results of
previous studies showed that !" T cells in AMLR and leptospira
Ag-stimulated cultures produced IFN-!, and moreover, that almost
all bovine !" T cells producing IFN-! were WC1" (3, 33). Three-
color flow cytometry was used to evaluate IFN-! production
within the WC1.1" and WC1.2" populations (Fig. 4). After 6 days
of culture with leptospira Ag, both WC1.1" and WC1.2" cells
were present in the cultures in substantial proportions (Fig. 4A, left
panel). However, almost all the WC1" cells producing IFN-! ex-
pressed WC1.1 and not WC1.2 (Fig. 4A, right panel). The fre-
quencies of WC1.1 single-positive and WC1.1/WC1.2 double-pos-
itive cells among the IFN-!" population (Fig. 4A, right panel)
were the same as among the total cells in culture (Fig. 4A, left
panel). The potential for WC1.1" and WC1.2" cells to secrete
IFN-! was also evaluated using Th1-polarizing conditions. A pre-
vious study demonstrated that culture with IL-12 induced IFN-!
production in the absence of proliferation by bovine PBMC (26,
33). Again, the IFN-!-producing WC1" cells were largely
WC1.1", with a minor population of IFN-!-producing WC1.2"
cells (Fig. 4B, right panel). However, representation of WC1.2"
cells within the IFN-!" population was small, considering their
much larger representation within the culture (Fig. 4B, left panel).
Unlike in IL-12 cultures, where proliferation does not take place,
in all experiments performed with leptospira Ag-stimulated cul-
tures the intensity of WC1.1 staining on the IFN-!" cells was
intermediate to low, suggesting either that the level of WC1 may
decrease with cell division or that the WC1.1-highly expressingFIGURE 3. Proliferation of cultured WC1.1
" and WC1.2" !" T cells
analyzed by CFSE. CFSE-loaded PBMC stimulated with Con A (A),
AMLR (B), or leptospira Ag (C) and their accompanying medium control
cultures were stained for cell surface phenotype WC1.1 or WC1.2 by in-
direct immunofluorescence (ordinate) and analyzed for cell division (ab-
scissa) by flow cytometry. Results are presented as dot plots of 10,000 cells
in each panel and are representative of experiments performed with PBMC
from three different animals and typify responses represented by data re-
ported in Fig. 2. Cells above the horizontal line were positive for the cell
surface marker indicated, and dividing cells were those with decreased
CFSE intensity. The percentage of cells in various regions is indicated. In
some experiments CFSE loading resulted in greater fragility of the !" T
cells in medium cultures as culture time increased, as shown in C.
FIGURE 4. IFN-! production by WC1.1" and WC1.2" !" T cells in
response to various stimuli. PBMC in leptospira Ag-stimulated (A) and
IL-12-stimulated (B) cultures, stained via direct (zenon Alexa Fluor 499-
labeled anti-WC1.2 mAb CACTB32A) and indirect (anti-WC1.1 mAb
BAG25A with PE-conjugated isotype-specific secondary and biotin-la-
beled anti-IFN-! mAb with streptavidin-PerCP) immunofluorescence,
were analyzed via flow cytometry for the expression of WC1.1 and WC1.2
(50,000 events; left-most panels). The middle panels show IFN-! staining
vs WC1.1 (middle-left) or vs WC1.2 (middle-right). The right-most panels
show the same cells as in the left panels, except that they include only those
cells gated as IFN-!". The percentage of cells positive for WC1.1 or
WC1.2 is provided relative to the total number of cells for the panel. Insets
located in the upper right corner show the same plot without primary Abs
(controls) or, in the case of IFN-!, without staining for WC1. Results are
representative of three experiments performed for each culture condition.
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cells tend not to divide and produce IFN-! in response to
leptospira Ag.
CD25 expression on cells expressing different WC1 variants
IL-12-dependent and -independent IFN-! production is known to
be regulated in part by IL-2 (34), which is required for sustained
IFN-! production (35). Thus, cells from the various cultures were
evaluated for CD25 expression. The length of culture was varied
inversely according to the strength of the stimulus, except for me-
dium cultures that were evaluated along with Con A cultures. A
very low level of CD25 was constitutively expressed on cells cul-
tured in medium alone, with identical profiles found for WC1.1"
and WC1.2" cells (Fig. 5, column 1). CD25 expression substan-
tially increased on both WC1.1" and WC1.2" cells after only 1
day of culture with Con A relative to that on cells cultured with
medium (Fig. 5, column 2), with the mean fluorescence intensity of
CD25 being 2-fold greater on WC1.2" cells than on WC1.1" cells
in Con A cultures. This reflected their levels of proliferation (see
Fig. 3A), but not IFN-! production, because Con A does not induce
appreciable IFN-! in WC1" cells (33). IL-12-stimulated cultures
showed almost 3-fold more CD25 expression on WC1.1" cells
than on WC1.2" cells (Fig. 5, column 3), correlating with their
production of IFN-! (refer to Fig. 4) even in the absence of cell
division (*1% of CFSE-loaded WC1" cells divided after 3 days
of culture with IL-12; data not shown). In Ag-stimulated cultures,
the mean fluorescence intensity of CD25 staining was 2-fold
higher on WC1.1" cells compared with WC1.2" cells. Therefore,
IFN-! production or cell division positively correlated with CD25
expression, although the lack of IFN-! production could not be
attributed to the lack of CD25 as seen in Con A cultures.
Evaluation of mRNA expression in WC1 subpopulations
Additional analyses assessed whether IFN-! production correlated
with the level of expression of IL-12R$2, which codes for a sub-
unit of the high affinity IL-12R, or with transcription factors
known to regulate IFN-!. Cells were sorted without stimulation or
after 48 h of stimulation with Con A or IL-12 into WC1.1" or
WC1.2" populations, and transcription levels were evaluated us-
ing semiquantitative RT-PCR. In all three experiments conducted
using cells from two different animals, IFN-! expression was
higher in WC1.1" cells compared with WC1.2" cells (Fig. 6).
However, only marginally higher IL-12R$2 expression was found
in WC1.1" cells compared with WC1.2" cells. Similarly, although
neither WC1.1" nor WC1.2" populations had increased IFN-!
transcript levels when stimulated with Con A, both expressed tran-
scripts for IL-12R$2, indicating that gene expression for the high
affinity IL-12R subunit alone does not determine IFN-! production
by these cells. Because the transcription factor T-bet positively
regulates responses to IL-12 in CD4 T cells, whereas GATA-3
negatively regulates them and promotes Th2 cytokine production
(36, 37), sorted populations were analyzed for transcript expres-
sion of their genes. GATA-3 was constitutively transcribed at low
levels without activation as well as by both populations after ac-
tivation with IL-12 or Con A, although WC1.2" cells expressed
higher levels of GATA-3 in Con A cultures, probably due to higher
levels of activation of these cells compared with Con A-stimulated
WC1.1" cells (refer to Fig. 3A and Fig. 5, column 2). T-bet was
not expressed in resting cells, but was expressed at similar levels
in both populations after stimulation. Although T-bet and GATA-3
are generally associated with opposing cytokine responses, coex-
pression of T-bet and GATA-3 transcripts in activated !" T cells
has previously been demonstrated (38), consistent with the results
reported in this study. Moreover, GATA-3 expression was not ac-
companied by IL-4 expression, even though transcript expression
of IL-4 was present in the total PBMC population stimulated with
Con A (Fig. 6).
Due to the increase in the percentage of WC1.2" cells among
PBMC in animals 15–21 mo of age compared with that in new-
borns, we hypothesized that this subpopulation might have a reg-
ulatory function, perhaps responsible for the accompanying de-
crease in the inflammatory WC1.1" cells. To address this, sorted
WC1 populations were evaluated for the expression of genes cod-
ing for the regulatory cytokines IL-10 and TGF-$ (for review, see
Ref. 39). We found IL-10 expression in both WC1 subpopulations
when cultured with IL-12, but minimally or not at all when cul-
tured with Con A. Modestly higher IL-10 expression was seen in
WC1.1" cells cultured with IL-12 compared with WC1.2" cells,
correlating with the higher activation levels as assessed by IFN-!
FIGURE 5. CD25 expression on WC1 subsets after culture with various
stimuli. WC1" subsets within PBMC were stained for CD25 expression
after culture with medium or Con A (24 h), IL-12 (3 days), or leptospira Ag
(5 days). Culture times were different depending upon the strength of the
stimulus, except for medium control cultures, which were stained at 24 h
because thereafter the cells may begin to die due to lack of stimulus. The
top two rows represent the dot plots for two-color staining of CD25 vs
the indicated form of WC1, whereas the bottom panels are histograms of
the same cultures representing WC1.1" (top row) or WC1.2" (bottom row)
cells only, with mean fluorescence intensity (MFI) shown (isotype control
staining has an MFI of 2.9). Results are representative of three experiments
performed.
FIGURE 6. RT-PCR analysis of RNA from WC1.1" and WC1.2" cells.
WC1.1" and WC1.2" cells were purified from PBMC ex vivo or after 2
days of culture with IL-12 or Con A and analyzed by RT-PCR. Three-fold
serial dilutions of cDNA were used to PCR-amplify transcripts from stim-
ulated cells, whereas only the highest concentration of cDNA was used for
ex vivo cells.
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production (see Fig. 4B) and CD25 expression (see Fig. 5). Inter-
estingly, TGF-$ was constitutively expressed with no apparent dif-
ferences between the subpopulations whether stimulated or ex vivo
(Fig. 6), suggesting that both subpopulations may have a
regulatory role.
Evaluation of WC1 tail sequences
Although cDNA coding for the archetypal WC1 form, WC1.1, has
been completely sequenced (14), that for WC1.2 and WC1.3 has
not. Therefore, we cloned and sequenced cDNA derived from tran-
scripts corresponding to the cytoplasmic tails of WC1.2 and
WC1.3 (Fig. 7). The sequences were compared to determine
whether there was variation in or adjacent to potential phosphor-
ylation sites that might account for the differences in the responses
of WC1.1" and WC1.2" subpopulations. All three tail sequences
contained five tyrosines predicted from the cDNA sequence as
well as the YEEL motif associated with binding Src homology 2
(SH2) domain-containing proteins. Additionally, all forms con-
tained a proline-rich motif ([PXPXXPXP] in WC1.1 and WC1.2;
[PXPXXPP] in WC1.3), associated with binding 3 domain-con-
taining proteins and intracellular signaling (40). None of the tails
had sites of significant homology to the CD4 or CD8 CXC motif
necessary for Lck binding (41). Additionally, none of the se-
quences had a motif analogous to the VVYKKL of CD5, another
SRCR family member; this motif is purported to be the docking
motif for the second SH2 domain of SHP-1 in the killer inhibitory
receptor (20), providing a mechanism by which CD5 inhibits lym-
phocyte responses.
Sequence differences among WC1 forms were found in the pre-
dicted amino acids upstream of the fourth tyrosine residue. Trans-
lation of cDNA corresponding to WC1.1 had a [DENY] sequence,
whereas WC1.2 and WC1.3 contained [AENY] and [GEDY], re-
spectively. The presence of aspartic acid three nucleotides 5& to
those sequences in WC1.1, but not in WC1.2 or WC1.3, is remi-
niscent of the aspartic acid seen three nucleotides upstream of
tyrosines in CD5, the autophosphorylation sites of the tyrosine
kinases Lck and Fyn, and CD3!, -", -', and -(. Thus, differences
in the amino acids upstream could affect the efficiency and kinetics
of phosphorylation of this tyrosine and, hence, signaling events.
Discussion
Given that there are two major forms of WC1 expressed by largely
nonoverlapping populations of ex vivo !" T cells of ruminants, we
hypothesized that WC1" !" T cells are divided accordingly into
functional subsets. The expression of different WC1 forms may
serve to extend the repertoire of !" T cells, because the TCR of !"
T cells can be invariant within a tissue (10). If the hypothesis is
correct, it might also provide an explanation for the disparity in
results regarding the effect of modulation of WC1 on !" T cell
function using different cell systems (21, 22). The results presented
in this study support the hypothesis, in that three main differences
were found between WC1.1" and WC1.2" cells. They had differ-
ent proliferation potentials to various stimuli, only WC1.1" cells
showed a penchant for producing the inflammatory cytokine
IFN-!, and although WC1.2" cells initially increased in propor-
tion in PBMC of young animals, WC1.1" cells decreased steadily
with age. Although a previous study showed that IFN-!" !" T
cells in cultures stimulated with leptospira Ags were WC1", it did
not exclude the possibility that some WC1! !" T cells may also
produce IFN-! given the appropriate stimulus, although the find-
ings of Jutila et al. (6, 7) suggest that this is not likely to be
the case.
The question of how alternate WC1 expression is involved in
varying !" T cell responses, especially with regard to IFN-! pro-
duction, remains to be answered. Although extracellular differ-
ences in WC1.1 and WC1.2, shown previously (15), might result
in binding of alternate ligands on cells that direct immune re-
sponses, differences in cytoplasmic tail sequences may also affect
intracellular signaling. In this study it was shown that transcripts
corresponding to WC1 cytoplasmic tails showed potential SH2-
binding sites with subtle sequence variations that could affect sig-
naling. The alternative paradigm, that the binding of the different
WC1 molecules to ligands on other cell types, such as dendritic
cells or macrophages, results in differential functional develop-
ment of these WC1 subpopulations can be argued from evidence in
other systems. It has been established that both dendritic cells and
macrophages have subpopulations with different cytokine secre-
tion profiles that affect #$ T cell development into Th1 and Th2
functional subpopulations (42) as well as activation of human V"1
!" T cells (43). It is possible that these APCs or other functionally
differentiated cells also have different ligands for WC1 forms on
their surface. Although we do not know the ligand for WC1, nor
has a role for classical APCs been conclusively established for !"
T cells, it is reasonable to speculate that the ligand for WC1 may
be on such cells or on other cells, such as keratinocytes, that have
been shown to direct !" T cell responses (44).
It is particularly interesting that the WC1.1" cells are the major
IFN-! producers, because the two subpopulations do not differ in
many other characteristics that predict IFN-! production. That is,
they both have transcripts for the high affinity IL-12R, IL-12R$2,
as well as for T-bet and GATA-3, transcription factors that polar-
ize CD4 T cells into Th1 and Th2 functional subpopulations, re-
spectively (36, 37). Although IFN-! drives the initial development
of Th1 CD4 T cells before the expression of IL-12R$2 (45),
WC1.2" cells would have had access to IFN-! in the cultures
evaluated in this study because it is produced in high quantities in
IL-12-stimulated cultures of bovine PBMC (33). Although the si-
multaneous transcript expression of T-bet and GATA-3 is contrary
to that which occurs in CD4 T cells, simultaneous gene expression
has been reported previously for !" T cells (38). In that study both
T-bet and GATA-3 transcripts were made in activated murine !" T
cells, but only T-bet protein was found in Western blots of nuclear
extracts from the same cells. It was concluded that GATA-3 tran-
scription was not sufficient to cross-regulate T-bet-mediated IFN-!
production in activated !" T cells. A similar event may be occur-
ring in this study in WC1.1" cells. The regulatory mechanism for
IFN-! production in the WC1 subpopulations could also be related
to activation of signal transducing molecules, such as STAT4.
STAT4 is required for IFN-! production in response to IL-12 and
FIGURE 7. Sequence of cytoplasmic tails of WC1.1, WC1.2, and
WC1.3. More than 30 cDNA sequences corresponding to the intracyto-
plasmic tails of known forms of WC1 were generated from ex vivo and
cultured cells. Tail sequences were identified according to the partially
complete genetic analysis of cloned WC1 (14). A single amino acid dif-
ference from the putative Wijngaard clone (14) is noted for WC1.2 (V136
to S136). The locations of tyrosine residues and potential SH2-binding sites
are shown in bold. The sequence in italics shows the position of the po-
tential SH3-binding site [PVPGTPSP].
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presented Ags even when IL-12R$2 and T-bet are already ex-
pressed by the cell (46). Although speculative, WC1 cytoplasmic
tails may act as docking sites for the SH2 domains of STAT4.
Thus, subtle differences among these tail sequences could affect
the ability of STAT4 to dock and thereby regulate the production
of IFN-! by WC1" !" T cells.
Although our results indicate that IFN-! production potential is
correlated with WC1.1 expression among !" T cells, WC1.2"
cells were not found to be the Th2 counterpart, a logical prediction
from the data. WC1.2" cells did not express detectable IL-4
mRNA when stimulated with Con A, even though its expression
was detected in total PBMC in the same cultures. These transcripts
are presumably products of CD4 T cells, as has been shown in
previous studies in response to Con A stimulation (1). Although it
is, of course, possible that other conditions might induce the ex-
pression of IL-4 in WC1.2" cells, a Th1/Th2 functional polariza-
tion is also not supported by their different proportional represen-
tations in PBMC of animals in various age groups. That is, there is
no precedent for a rise in Th2 cytokine-producing #$ T cells with
age with a concomitant decrease in Th1 cells.
The increased representation of WC1.2" cells within the PBMC
population corresponded with a sharp decrease in WC1.1" cells as
well as with development of #$ T cell memory, as shown by an
increase in CD4" CD62Llow cells in bovine blood beginning by 2
mo of age.4,5 However, both WC1.1" and WC1.2" subsets con-
stitutively express high levels of CD62L while in circulation; thus,
the two populations are not readily distinguished as effector mem-
ory cells vs naive cells. Also both WC1.1 and WC1.2 constitu-
tively express CD45RO, and CTLA-4 is expressed, but only after
activation (see Footnote 4). Thus, these evaluations do not point to
obvious explanations regarding the roles of the two subpopula-
tions. However, because the decrease in WC1.1" cells correlated
with the acquisition of immunological experience by #$ T cells
and thus a diminished need for WC1.1" !" T cells, we postulated
that the rise in WC1.2" cells might be consistent with a regulatory
role akin to that which occurs for CD4"CD25" #$ T cells. !" T
cells have been shown to have regulatory roles (reviewed in Refs.
47 and 48). For example, the presence of regulatory !" T cells has
been shown to minimize inflammation-associated tissue damage
during infection (49, 50), and depletion of WC1" !" T cells from
cattle results in increased Ab responses (51), whereas depletion
from PBMC results in increased CD4 proliferation in response to
Ag in vitro (52).
Of the four categories of regulatory #$ T cells identified, all
produce IL-10 and TGF-$, with Th3 regulatory cells producing
low IL-10 and high TGF-$ (39). Both WC1" !" T cell sub-
populations most closely match the Th3 cells according to
mRNA transcript analyses, with no obvious difference in either
IL-10 or TGF-$ expression levels between WC1.1" and
WC1.2" cells. The simultaneous expression of IFN-! and IL-10
under Th1-polarizing conditions by WC1.1" cells is similar to
the results of Hseih et al. (50), who showed involvement of
IFN-!/IL-10-producing murine !" T cells in Listeria infections
and suggested that IL-10 is a regulator of Th1 responses re-
gardless of whether a humoral Th2 response occurs. Although
CD25, a marker for regulatory CD4 T cells, has been reported
to be constitutively expressed at low levels on resting ex vivo
!" T cells (53), higher constitutive expression was not detected
on WC1.2" cells compared with WC1.1" cells in the group of
animals examined in this study. Thus, although no striking dif-
ferences were observed with regard to regulatory cytokines or
constitutive CD25 expression, both WC1.1" and WC1.2" sub-
populations could have a regulatory role in cattle through
TGF-$ production. TGF-$ induces the conversion of naive
CD4" T cells into CD4"CD25" T regulatory cells upon simul-
taneous stimulation through the TCR (54), and TGF-$ produced
by !" T cells has been shown to inhibit CTL and NK tumori-
cidal activity (55).
In summary, WC1.1" cells were shown to be the primary source
of !"-derived IFN-!, consistent with previous, more general, re-
ports demonstrating the potential of murine and bovine !" T cells
to secrete IFN-! (25, 56). WC1.1" cells may foster inflammatory
responses in young animals by the direct effect of their IFN-! on
macrophages as well as the development of Th1 responses by Ag-
stimulated CD4" and CD8" #$ T cells. Selective activation of a
cell population prone to secrete IFN-! during vaccination may
provide a means to consistently stimulate type 1 immune responses
and would be especially useful in vaccine design for intracellular
bacterial and protozoan pathogens and viruses. To date, the induc-
tion of strong type 1 or cell-mediated responses usually requires
live attenuated vaccines. Although advances are being made in the
stimulation of dendritic cells and macrophages through TLRs to
direct the immune system toward such a response, stimulation
through appropriate WC1 coreceptors along with TCR may pro-
vide an alternative adjuvant effect.
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Abstract
WC1 is a transmembrane glycoprotein and member of the scavenger receptor cysteine rich (SRCR) family that is uniquely
expressed on gd T cells. The WC1 isoforms referred to as WC1.1, WC1.2, and WC1.3 are expressed on discrete subpopulations
of gd T cells with WC1.1 and WC1.2 expressed on mostly nonoverlapping gd T cell populations. Studies have demonstrated a
potential role for WC1 in modulating the response of gd T cells but have not converged into a single accepted paradigm. Recent
investigations that examined changing representation among mononuclear cells with age and patterns of proliferation and
cytokine production by subsets bearing one or more of the previously identified variants of the WC1 molecule are summarized
here. While the decrease in percentages within blood in the first year of life was found to be precipitous for WC1.1+ gd T cells it
was not for WC1.2+ cells. While both populations proliferated to mitogen stimulation there was a bias towards responses by
WC1.2+ cells. In leptospira antigen stimulated cultures and autologous mixed lymphocyte reaction (AMLR) cultures WC1.1+
cells proliferated and produced interferon g (IFN g) while WC1.2+ cells did to a much lower extent. This suggested functional
differences related to the isoform of WC1 expressed. Under Th1 polarizing conditions, the WC1.1+ cells also made IFN g
whereas the vast majority of cells expressing WC1.2 did not. Despite the difference in IFN g production, cells bearing either
WC1 isoform had similar transcription levels of the high affinity IL 12 receptor subunit (IL 12Rb2) as well as of the
transcription factors T bet and GATA 3 when cultured with IL 12. Both populations transcribed low levels of IL 10 mRNA
under Th1 polarizing conditions and TGF b transcripts were ubiquitously expressed by each of these cell types. Cloning and
sequencing of the cytoplasmic tails of the WC1 isoforms revealed a consensus ITAM in all three isoforms but a DENY sequence
adjacent to one of the SH 2 binding sites of WC1.1 only. The results suggest that WC1+ gd T cells differentiated on the basis of
WC1 isoform expression play distinct roles in immune responses that may be dictated by WC1 intracellular signaling.
# 2005 Elsevier B.V. All rights reserved.
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1. Introduction
WC1 is a transmembrane glycoprotein and member
of the scavenger receptor cysteine rich (SRCR) family
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that is uniquely expressed on gdT cells. Several studies
have demonstrated a potential role for this molecule in
modulating the response of gd T cells but have not
converged into a single accepted paradigm. This
manuscript reviews those finding as well as those of
a recently completed study that examined patterns of
proliferation and cytokine production by gd T cells
subsets bearing one or more previously identified
variants of theWC1molecule andwhich was presented
at the Seventh International Veterinary Immunology
Symposium in Quebec City, Quebec in July 2004.
2. Previous studies
A large proportion, and often the majority, of bovine
peripheral blood gd T cells in young animals express
WC1. In contrast, other tissues such as the spleen are
populated with gd T cells that do not express WC1
(MacHugh et al., 1997). The first sequence of a WC1
clone (Wijngaard et al., 1992) showed it was a type I
integral membrane protein with 11 extracellular SRCR
domains and contained a potential ITAM [YEEL] in the
cytoplasmic tail proximal to the predicted transmem
brane region. This suggested the molecule was
important in signal transduction in gd T cells. Others
studies of sequence analysis of WC1 protein revealed
that it does not contain any potential kinase or
phosphatase domains in the cytoplasmic region but
contains several potential serine/threonine phosphor
ylation sites and a potential tyrosine phosphorylation
sitewith an SH2 binding domain (Kirkham et al., 1997)
which would allow the recruitment of various kinases
and phosphatases.
WC1 has thus far only been identified in ruminants
and pigs. This is in contrast to other known SRCR
family members present on T cells including CD5 and
CD6 (see Resnick et al., 1994), both of which have
been shown to have a role in activation or regulation of
lymphocyte responses in many mammalian species in
addition to cattle (Baldwin et al., 1988; Morimoto
et al., 1988; Gangemi et al., 1989; Swack et al., 1989;
Ledbetter et al., 1989; Bott et al., 1993; Tarakhovsky
et al., 1995; Bikah et al., 1996; Sen et al., 1999).
Modulation of WC1 by anti WC1 monoclonal
antibodies (mAb) has been shown to inhibit gd T
cell responses when used at very high concentrations
(Kirkham et al., 1997) while we have found that at
lower concentrations anti WC1 mAb enhance cellular
proliferation (Hanby Flarida et al., 1996). Hence, like
anti CD5 treatment, it is possible to obtain both
stimulatory and inhibitory effects through anti WC1
stimulation.
Previous studies have shown a propensity of WC1+
gd T cells to respond to bacterial antigens and produce
IFN g, albeit at a lower level than CD4 T cells, when
donor cells were from mycobacterial infected or
leptopsira vaccinated cattle (Naiman et al., 2001,
2002; Smyth et al., 2001; for a review see Pollock and
Welsh, 2002). Based on data from serial analysis of
gene expression (SAGE) and microarray analyses,
Jutila and co workers have suggested that the WC1+
gd T cells of cattle represent the inflammatory
subpopulation characterized by production of IFN g
(Hedges et al., 2003; Meissner et al., 2003). In this
way WC1+ gd T cells may be important mediators of
cell mediated (type 1) immunity or establish a
cytokine milieu that promotes development of CD4
Th1 or CD8 Tc1 cells similar to roles proposed for
cells of the innate immune response (Medzhitov and
Janeway, 1997). gd T cells in other species have been
suggested to play such a role (Mak and Ferrick, 1998;
Bukowski et al., 1999). Supporting this hypothesis,
cattle depleted of WC1+ cells by anti WC1 antibodies
showed a decrease in non specific production of IFN
g and a bias towards a Th2 response as evidenced by
more IL 4 production and decreased IgG2 antibody
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Fig. 1. Regression analysis of PBMC expressing WC1.1 or WC1.2
isoforms. Regression analyses of isoform expression with age
normalized to total WC1 expression using PBMC from 30 cattle
of different ages. Variation in WC1.3 expression was given by a
linear regression fit. However, both WC1.1 and WC1.2 were
sequentially regressed with first and second-order polynomial
regression terms for best-fit analysis. Each line/curve accounts
for >95% of the variability among cattle with age.
(Kennedy et al., 2002). Also a decrease occurred in the
representation ofWC1+ cells in peripheral blood when
cattle were moved from grazing on the African plains
to BL2 housing and given sterile food (Baldwin et al.,
2000).
Despite the progress made toward a general
functional characterization of cells bearing the WC1
receptor, gd T cells expressing WC1 do not behave in
a clonotypic or homogeneous manner. This is
particularly interesting given the identification of
three discrete forms of WC1, referred to as WC1.1,
WC1.2, and WC1.3 (Wijngaard et al., 1994) that are
expressed by peripheral blood gd T cells. WC1.1 and
WC1.2 are expressed on mostly nonoverlapping gd
populations while WC1.3 is expressed on a small
subpopulation of gd T cells bearingWC1.1. Results of
recent studies attempting to understand the signifi
cance of their expression are described below.
3. Summary of recent findings
An analysis of WC1 subpopulations showed that
the overall decrease in representation within the
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Fig. 2. Proliferative response ofWC1.1+ andWC1.2+ gd T cells to various stimuli. PBMC loaded with carboxyfluorescein succinyl ester (CFSE)
and then stimulated as indicated. (A) Cells were stimulated with anti-CD3 mAb, PMA plus ionomycin or in medium for four days following
which they were stained for expression of WC1.1 or WC1.2 by indirect immunofluorescence (ordinate) and evaluated for cell division based on
the CFSE levels (abscissa). There was a greater tendency for WC1.2+ cells to proliferate to PMA/ionomycin whereas neither population
proliferated to anti-CD3 mAb stimulation during the time period of this culture. (B) CFSE-loaded PBMC were stimulated with Con A, in the
AMLR, or with leptospira antigen or with medium and then stained for cell surface WC1.1 or WC1.2 and analyzed by indirect immuno-
fluorescence (ordinate) and cell division (abscissa) by flow cytometry. Results are representative of experiments performed with PBMC from
three different animals. The percentage of cells in various regions is indicated. In some experiments CFSE-loading resulted in greater fragility of
the gd T cells in medium cultures as culture-time increased as can be seen in Panel C. Fig. 2B is Copyright 2005, The American Association of
Immunologists, reprinted with permission from Rogers et al. (2005).
peripheral blood mononuclear cell (PBMC) popula
tion commonly observed in the first year of life was
particularly precipitous for WC1.1+ gd T cells but not
for WC1.2+ cells (Rogers et al., 2005). That is, all the
decrease in circulating gd T cells in the first year of life
could be accounted for by the decrease in gd T cells
bearing WC1.1. Although WC1.1 was found to be the
predominant form expressed by cells in young cattle,
because of the early and rapid decline of cells
expressing WC1.1, the WC1.2+ cells were equally
represented by 1 2 years of age (Fig. 1).
Although previous reports demonstrated the poten
tial of gd T cells and particularly WC1+ gd T cells to
secrete IFN g as discussed above, the recent study
identified cells bearing WC1.1 as the primary source
of gd T cell derived IFN g. Populations of cells
bearing WC1.1 and WC1.2 proliferated to mitogen
stimulation, however only WC1.1+ cells proliferated
and produced IFN g in leptospira antigen stimulated
cultures established as described by Naiman et al.
(2001) and autologous mixed leukocyte reaction
(AMLR) cultures established as described by Sathiya
seelan et al. (2002) as reported in our recent
publication (Rogers et al., 2005) (Fig. 2). WC1.2+
cells did not, pointing to functional differences related
to the isoform of WC1 expressed. In addition, Th1
polarizing conditions, that is cultures containing
recombinant human IL 12 as described previously
by White et al. (2002), induced IFN g production
among WC1.1+ cells in the absence of proliferation
while the vast majority of cells expressing WC1.2 did
not produce IFN g (Fig. 3). Thus, specifically the
WC1.1 cells may serve as coordinators of inflamma
tory responses in young cattle, fostering an environ
ment that supports cell mediated activities with a Th 1
polarizing bias until antigen specific CD4+ and CD8+
effector and memory cells have time to expand and
develop.
Despite the difference in IFN g production, cells
bearing either WC1 isoform had similar transcription
levels of the high affinity IL 12 receptor subunit (IL
12Rb2) previously described for ruminants (White
et al., 2002) and both co expressed mRNA for
transcription factors T bet and GATA 3 when cultured
with IL 12 (Rogers et al., 2005). Thus, analysis of the
transcription factors T bet and GATA 3, which have
come to be associated with Th1 and Th2 polarization,
respectively, could not adequately resolve the differ
ences in WC1 subpopulation polarization. However,
the simultaneous transcript expression of T bet and
GATA 3 in both subpopulations matches that which
was found for gd T cells in a study by Yin et al. (2002).
They found that, although both T bet and GATA 3
transcripts were produced in activated gd T cells, only
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Fig. 2. (Continued ).
T bet protein was found in Western blots of nuclear
extracts from the same cells. They concluded that
GATA 3 transcription was not sufficient to cross
regulate T bet mediated IFN g production in activated
gd T cells. In agreement with T bet expression in both
WC1+ subpopulations there was also IL 12Rb2
transcript expression. Additional studies are needed
to determine the extent to which signaling is
modulated by the level of high affinity IL 12 receptor
expression at the surface of theseWC1 subpopulations
and subsequently by relevant transcription factors.
WC1.1+ cells also simultaneously expressed
transcripts for IFN g, TGF b, and IL 10 under Th1
polarizing conditions, potentially indicative of self
regulation when activated. Evidence supporting a
similar combination of IFN g and IL 10 production by
gd T cells in mice was demonstrated during Listeria
infections (Hsieh et al., 1996). Moreover, results of
other gd T cell studies (Skeen et al., 2001; O’Brien
et al., 2000) have contributed to a growing interest in
the possibility that murine gd T lymphocytes may be
regulatory in nature. Likewise, bovine gd T cell
subsets may have such a role, since both had TGF b
transcripts even ex vivo. At this time it seems the
proinflammatory cytokine profile of the WC1.1+ cells
is coincident with a regulatory cytokine profile and
further studies evaluating TGF b protein levels are
needed.
While we hypothesized that differences in extra
cellular domains of WC1 isoforms might direct the gd
T cells into different functional pathways as a result of
interaction with the cells expressing their respective
ligands and the cytokines those cells produced, we
also recognized that differences in the intracellular
signaling through WC1 could affect the outcome.
Analysis of transcripts corresponding to the three main
forms of WC1 cytoplasmic tails required sequencing
of WC1.2 and WC1.3 (Rogers et al., 2005) and
comparison with the previously published sequence of
WC1.1 and partial sequences of the other two forms
(Wijngaard et al., 1994). The results showed several
potential SH2 binding sites with subtle sequence
variations suggesting the potential for WC1 to play a
functional role that is different or otherwise altered
A.N. Rogers et al. / Veterinary Immunology and Immunopathology 108 (2005) 211–217 215
Fig. 3. IFN-g production by WC1.1+ and WC1.2+ gd T cells in response to various stimuli. PBMC in (A) leptospira antigen and (B) IL-12-
stimulated cultures, stained via direct (Zenon Alexa Fluor 499-labeled anti-WC1.2 mAb CACTB32A) and indirect (anti-WC1.1 mAb BAG25A
with PE-conjugated isotype-specific secondary and biotin-labeled anti-IFN-g mAb with streptavidin-PerCP) immunofluorescence, were
analyzed via flow cytometry for expression of WC1.1 and WC1.2 (50,000 events; left-most panels). The middle panels show IFN-g staining
vs.WC1.1 (middle-left) or vs.WC1.2 (middle-right). The right-most panels show the same cells as in the left panels except that they include only
those cells gated as IFN-g+. The percentage of cells positive for WC1.1 or WC1.2 is provided relative to the total number of cells for the panel.
Insets located in the upper right-hand corner show the same plot without primary antibodies (controls), or in the case of IFN-g, without staining
for WC1. Results are representative of three experiments performed for each culture condition. Fig. 3 is Copyright 2005, The American
Association of Immunologists, reprinted with permission from Rogers et al. (2005).
depending on the isoform expressed. This could
account for the discrepancy in previous studies
regarding the outcome of WC1 modulation. Our
unpublished data suggests that WC1 may bind to the
B cell kinases lyn and blk. This possibility is made all
the more interesting by studies showing transcription
of certain B cell factors by gd T cells (Hedges et al.,
2003; Meissner et al., 2003). There were also several
changes to serines and a threonine in the WC1.2 form.
The earlier studies by Parkhouse and colleagues which
used an ovine gd T cell line to evaluate the effects of
WC1 signaling and indicated that ligation with anti
WC1 mAb could induce reversible cell cycle arrest
(Takamatsu et al., 1997) showed that this effect was
associated with activation of tyrosine phosphatases
and dephosphorylation of erk2 (Kirkham et al., 1997),
a serine/threonine MAP kinase that is part of the MAP
kinase [mitogenic] signaling cascade. The direct role
of particular WC1 isoforms in this response will be of
interest for future studies.
4. Conclusions
The discovery of the SRCR molecule WC1
provided an important differentiation marker, allow
ing researchers a means of further separating or
distinguishing gd T lymphocyte subpopulations into
WC1+ or WC1! cells to ascertain their functions and
tissue localization. Our results showing proliferation
and cytokine production by gd T cells according to the
isoform of WC1 expressed indicates that WC1+ gd T
cells should not be considered as a single functional
population. Selective activation of WC1.1+ cells prone
to secrete IFN g during vaccination may provide a
means to consistently stimulate type 1 immune
responses and would be especially useful in vaccine
design for intracellular bacterial and protozoan
pathogens and viruses. Moreover, it may provide a
means to direct adaptive immune responses down this
pathway reliably even when subunit vaccines are used.
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